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Abstract 
 
Replication-selective oncolytic adenoviruses represent a promising anticancer approach with proven 
efficacy in cancer cell lines and tumour xenografts in vivo. Anti-tumour efficacy, both in preclinical 
studies and clinical trials, was significantly improved in combination with chemotherapeutics in 
numerous cancers, including prostate cancer. It has been established that expression of the viral E1A 
gene is essential for the enhancement of cell killing in combination with cytotoxic drugs.  
The overall goal of this project is to identify specific E1A gene regions involved in the sensitization to 
the cytotoxic drugs mitoxantrone and docetaxel, the current standard of care for late stage prostate 
cancers, to enable the development of improved anti-cancer therapies. Specific regions in the E1A 
proteins bind to numerous cellular factors to regulate the host cell function and the viral life cycle, 
including the p300, p400 and pRb family proteins. This work was aimed at determining the 
mechanisms involved in the synergistic cell killing in prostate cancer cells in response to the 
combination of the replication-selective (oncolytic) mutant Ad∆∆ with cytotoxic drugs. Previous 
findings suggested an enhancement of drug-induced apoptosis. I found that the small E1A12S protein, 
unable to induce viral replication, is sufficient to sensitize the prostate cancer cells, 22Rv-1 (AR+), and 
PC-3 and DU145 (AR-), to drugs. The non-replicating AdE1A12S-mutant AdE1A1104 (defective in p300-
binding) could not sensitize the cells while mutants with intact E1A-p300 binding (AdE1A12S, 
AdE1A1102, AdE1A1108) and defective in p400- (AdE1A1102) or pRb-binding (AdE1A1108) potently 
sensitized all tested cell lines. In fact, all mutants except AdE1A1104 potently synergised with 
mitoxantrone and docetaxel to kill the prostate cancer cells. When comparing the non-replicating 
E1A12S mutants with the corresponding replicating E1A-deletion mutants (expressing E1A12S and 
13S) synergy was demonstrated with all replicating mutants except dl1104, which caused an additive 
effect with mitoxantrone. We hypothesised that the synergistic cell killing is the result of pathway 
convergence through E1A-p300 and mitoxantrone-activated DNA-damage/apoptosis events. To 
address this I employed an extensive miRNA array screen to identify potential pathways. Several 
miRNAs were found to be differentially regulated in response to the combination of AdE1A12S with 
mitoxantrone compared to each single agent treatment. The majority of these miRNAs are reported 
to be part of cell death and survival pathways (e.g. apoptosis and autophagy) and to be differentially 
regulated in prostate cancer. To further investigate the role of these pathways, I determined changes 
in expression levels of key proteins that had previously been suggested to be targeted by the 
identified miRNAs, thereby preventing translation of the respective mRNAs. The greatest changes in 
protein levels in response to AdE1A12S and mitoxantrone were observed for Bcl-2, p-Akt, LC3BII and 
p62. Finally, I verified similar mechanisms of action when the oncolytic Ad∆∆ was combined with 
mitoxantrone under synergistic conditions. These findings will direct future investigations aimed at 
dissecting the mechanisms of action for virus-induced sensitization to cytotoxic drugs and may aid in 
the development of improved therapies for prostate cancer by design of novel oncolytic mutants and 
combination strategies and/or identification of targets for small molecules inhibitors. 
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1. Introduction 
1.1  Prostate cancer 
Prostate cancer (PCa) is a major public health problem in Western industrialized 
countries and is the third most common cause (after lung cancer) of cancer-related 
deaths in men.1 The initial treatment of advanced metastatic PCa is to deprive 
tumours of androgens by chemical castration, achieved by the use of Gonadotropin-
releasing hormone (GnRH) agonists or antagonists; inhibition of steroidogenic 
enzymes; and the use of anti-androgens that block the binding of androgens to the 
androgen receptor (AR).2 For most patients, the cancer becomes insensitive to 
androgen ablation therapy, spreads further, and ultimately patients will die from 
hormone-refractory metastatic PCa (HRPC).3 The development of PCa to a hormone-
independent stage invariably results in advanced disease, with limited therapeutic 
options, poor prognosis and death.4,5 HRPC frequently displays alterations in AR 
signalling, cell cycle and apoptosis pathways or neuroendocrine differentiation.6 No 
effective treatment is yet available for HRPC with radiation and chemotherapy (e.g. 
mitoxantrone and docetaxel) mainly being palliative.7 Therefore, novel therapeutic 
strategies that target treatment-resistant PCa are needed.8 The key goal when 
developing new, targeted cancer treatments is to disable signalling mechanisms that 
are essential for tumour maintenance without affecting normal tissue.9,10 
Development of novel drugs is urgently needed because the current standard of care 
such as cytotoxic drugs 11 and radiation therapy 12 are not curative in the majority of 
cases, and efficacy is invariably reduced by side effects and treatment resistance.13  
 
1.1.1 Epidemiology and Risk Factors 
 
With the advent of prostate-specific antigen (PSA) testing, one in six men in the 
United States will be diagnosed with prostate cancer at some point in their life.14 In 
2008, PCa was the second most frequently diagnosed cancer and the sixth highest 
cause of all cancer-related death in men worldwide.1 In the United Kingdom, the 
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incidence rate of PCa is the highest of all cancers in men and is the second leading 
cause of cancer-related deaths in men.15  
Age is considered to be the most important risk factor, with increasing incidence in 
men of advanced age, being 15-30% by the age of 50, and up to 60-80% by the age of 
80.16 Cultural origin and environmental factors can also increase the risk of 
developing the disease. North America has the highest incidence of PCa (92 cases per 
100,000 men),16 however men of African descent in the Caribbean have the highest 
mortality rate in the world.1 In contrast, in East Asia, the rates remain below those of 
western countries. For example, Chinese men have the lowest incidence (1 case per 
100,000 men).16 However, both incidence and mortality has increased in the last 20 
years in Asian countries.17 Asian immigrants in the United States have a higher 
incidence of PCa compared to the incidence in their own countries, suggesting that 
environmental and dietary factors play a role.18 Studies have suggested that first 
degree male relatives of men with PCa have a 2- to 3-fold higher risk of developing 
PCa, and up to 10-fold if three or more relatives are affected, implying a hereditary 
and genetic link.16  
Diet has been strongly implicated as a risk factor for PCa. A Health Professionals 
Follow up study of 51,000 men suggested a positive correlation between PCa 
incidence and the intake of red meat and a diet high in fat.16 In contrast, the 
consumption of a diet rich in fatty fish, isoflavones, lycopenes and high systemic 
levels of vitamin D, showed an inverse correlation with the incidence of PCa.16  Also, 
reduction of cholesterol levels in the blood decreases the incidence of PCa by 50%.17 
Inflammation is another possible risk factor for PCa. Although the reasons for the 
inflammatory responses are unclear, there are many potential sources, including 
direct infection, urine-reflux-induced chemical and physical trauma, dietary factors, 
oestrogens, or a combination of two or more of these factors (Fig. 1).18  
15 
 
 
Figure 1. Potential sources of prostate inflammation. Factors that could trigger an 
inflammatory response within the prostate and induce PCa, adapted from 18. 
 
Another potential source of inflammation is pathogens such as virus and bacteria. 
The induction of PCa by bacteria has not been proven definitively, but there is strong 
evidence connecting bacterial infection with chronic inflammation of the prostate 
tissue.19 Moreover, bacteria responsible for the inflammation of the prostate can be 
divided into sexually transmitted and non-sexually transmitted pathogens, and 
among the sexually transmitted Neisseria gonorrhoea, Chlamydia trachomatis, 
Trichomonas vaginalis and Treponema pallidum have been associated with PCa.18 
The non-sexually transmitted bacteria include Propionibacterium acnes that is also 
found in the skin and is associated with acne. These bacteria have a high prevalence 
in prostate cancer tissue (35%) and show a strong correlation with inflammation in 
16 
 
PCa tissue.20 Propionibacterium acnes in a mouse model was found to induce acute 
chronic inflammation of prostate tissue and favour cell proliferation, although the 
induction of PCa by these bacteria remains to be elucidated.21 Other pathogens such 
as human papillomavirus (HPV), human herpes simplex virus type 2 (HSV2), 
cytomegalovirus (CMV) and human herpes virus type 8 (HHV8) are known to infect 
the prostate tissue, although a correlation between virus-induced inflammation of 
the prostate and the induction of PCa has not been proved definitively.18 In 2006, 
Urisman and colleagues22 reported that the xenotropic murine leukaemia virus-
related virus (XMRV) was associated with prostate cancer. However, this finding was 
not verified and has been dismissed since the identification of the virus in prostate 
tissue has been shown to be related to a contamination of the samples rather than 
the result of an infection.19 In contrast, both HPV and Epstein Barr virus (EBV) 
sequences have been identified simultaneously in 55% of human prostate cancer 
samples, indicating a strong correlation of HPV and EBV with prostate cancer.23 
Although the results indicated a correlation between HPV and EBV and prostate 
cancer, the number of samples were low (n=40) and a direct link between viral 
infection and prostate cancer was not shown. Thus, the implications of viral 
infections as inducers of prostate cancer remain unclear. However, despite the facts 
mentioned above the only risk factors that have been established are old age, 
ethnicity (African descent), familial history and dietary habits.1,19 
 
1.1.2 Biology of prostate cancer 
 
The prostate is a gland that reaches maturity in an androgen-dependent manner 
after puberty. The mature prostate is the size and shape of a walnut (20g and 4cm × 
2.5cm) in an adult man.24 It is localized in the pelvis, anterior to the rectum 
surrounding the urethra at the base of the bladder.16 The human prostate has a zonal 
architecture, corresponding to central, periurethral, transitional, and peripheral 
zones, together with an anterior fibromuscular stroma (Fig. 2).25,26 The gland 
produces part of the seminal fluid and may facilitate sperm motility. The prostate is 
composed of branching glands with ducts that are lined by luminal secretory and 
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basal epithelial cells.16 Most tumours initially develop gradually from the luminal 
secretory epithelial cells (Fig. 3).27,28 The prostate tissue is mainly composed of 
glandular tissue and growth is androgen-dependent. Luminal secretory epithelial 
cells represent the major cell type in the gland and produce PSA and prostatic acid 
phosphatase.29 PCa is a multifocal disease that develops from multiple histological 
foci of cancer cells that are often genetically heterogeneous.30 Over 95% of PCas are 
adenocarcinomas with a luminal phenotype; of these, the vast majority are acinar 
adenocarcinomas (Fig. 3).28 Androgen deprivation results in apoptosis of the luminal 
epithelium.31  
 
 
Figure 2. Predisposition to prostate diseases and association with specific zones in the 
gland. Zones of the prostate that are susceptible to chronic illnesses that could result in 
cancer development, adapted from.18 
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 Other subtypes of PCa such as ductal adenocarcinoma, mucinous carcinoma, signet 
carcinoma and neuroendocrine PCa can be defined molecularly and genetically, 
however, they are uncommon and have similar prognosis.28 Neuroendocrine PCa 
shows the most differentiated histological pattern of all, and is generally classified as 
small cell carcinoma or a carcinoid tumour.28 The peripheral zone occupies the 
largest volume (Fig. 2), and harbours the majority of prostate carcinomas. In 
contrast, benign prostatic hyperplasia (BPH), a common non-malignant condition 
found in older men, arises from the transition zone (Fig. 2).16   
1.1.3 Development of prostate cancer 
1.1.3.a Molecular Pathogenesis 
 
It is well known that PCa cells have numerous mutations, but the development of its 
molecular pathogenesis is still unclear. The disruption of the prostate homeostasis, 
due to genetic and molecular alterations, leads to the dedifferentiation of prostatic 
smooth muscle and enhanced proliferation of vascular endothelial and epithelial cells 
during the transition from low to high grade PCa.27 Molecular mechanisms triggered 
by inflammatory events induced by highly reactive chemical compounds can also 
affect prostate epithelial cells undergoing DNA synthesis, increasing the risk of PCa 
development.18 
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Figure 3. Prostate Cancer progression. Histology of the normal prostate epithelium and the 
genetic events altered within the progression from a normal to a metastatic prostate 
phenotype. The luminal secretory cells that attach to the basal cells and extend to the acinar 
lumen express the androgen receptor and synthesize and secrete distinct prostate 
differentiation markers (e.g. PSA) into the acinar lumen.16 EMT; epithelial to mesenchymal 
transition, NKX3.1; transcription factor NK (named after Niremberg and Kim),32 homeobox 
family 3 locus-1, MYC; myelocytomatosis viral oncogene homologue, TMPRSS2-ERG; trans-
membrane protease serine 2-Ets-related-gene, PTEN; phosphatase and tensin homolog, 
ERK/MAPK; mitogen-activated protein kinase and EZH2; enhancer of zeste homolog 2 
(Drosophila). Figure modified from.28 
 
Inflammation can contribute to PCa progression and the development of high 
prostatic intraepithelial neoplasia (PIN) that is considered as the only clearly defined 
precursor of prostatic adenocarcinoma (Fig. 2-3). PIN has an intermediate phenotype 
and genotype between benign prostatic epithelium and cancer, and is histologically 
characterized by the enlargement of nuclei and nucleoli, appearance of luminal 
epithelial hyperplasia, cytoplasmic hyperchromasia, reduction in basal cells and 
nuclear atypia. In addition, PIN is confirmed in biopsies by the elevation of cellular 
proliferation markers, the absence of p63 and cytokeratin 5/14 immunostaining and 
elevated immunostaining of the luminal marker α-methylacyl-CoA-race-mase 
(AMACR).28,33 
 
1.1.3.a.I Gene alterations in Prostate Cancer 
 
Genetic alterations (Fig. 3) in the normal prostate glandular epithelium induce 
gradual alterations leading to an oncogenic phenotype, initially as a localized 
androgen-dependent disease.27 Many phenotypic modifications in PCa are due to 
enhanced expression of several oncogenes and a decreased expression of tumour 
suppressor genes induced through gene amplification, somatic mutations, 
chromosomal aberrations and deletions.34 27 
Several chromosomal abnormalities have been reported in prostate cancer patients 
such as the insertion of genetic material in the chromosomes 7p, 7q, 8q and IX or 
deletions such as in chromosomes 10q, 13q and 16q.34,35 Other chromosomal 
alterations include the translocation of the TMPRSS2 and members of the E-twenty-
six (ETS) family of transcription factors (ERG and ETS-translocation variant1-4-ETV1, 
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ETV4, or ETV5) mainly ERG (Fig. 3). The translocation and fusion (by an interstitial 
deletion) of the TMPRSS2 promoter/enhancer and the coding region of ERG has been 
identified in 60% of prostate cancer tissue in almost seventeen regions within the 
chromosome 21q22 where both are localized, and has been shown to be promoted 
by androgens.34,36 Of the identified fusions, nine code for functional products (two 
ERG or six truncated ERG or a new protein combining TMPRSS2 and ERG), and eight 
do not encode functional proteins because of a premature stop codon.34 Other 
common chromosomal alterations present on prostate cancer include the loss of 
heterozygosity of 8p21.2 in nearly 85% of PCa and of chromosome 12q12-13 in 20% 
of localized and 50% of metastatic prostate cancer, additionally chromosome 8q24 
shows amplifications.34  
Several genes such as ribonuclease-L (2',5'-oligoisoadenylate synthetase-dependent) 
(RNASEL), hereditary prostate cancer protein-2 (ELAC2/HPC2), macrophage 
scavenger receptor-1 (MSR1), androgen receptor (AR), cytochrome P450 17( CYP17) 
and steroid 5-α-reductase type-2 (SRD5A2), have being identified as susceptibility 
genes in PCa (Fig. 3).16 Furthermore, oncogenes and tumour suppressors that 
regulate cell cycle and apoptosis pathways, such as p53, p21, Rb, also have been 
implicated in the pathogenesis of PCa.16 Other genes that have been observed to be 
deregulated in PCa progression are NKX3.1 (8p21.2), PTEN (10q23.31), c-MYC (8q24), 
and p27 (Fig. 3).34 The transcription factor NKX3.1, regulated by AR is involved in the 
terminal differentiation of prostate epithelial cells, and when downregulated by loss 
of heterozygosity, tumour progression is facilitated.34 In contrast, the amplification of 
MYC by amplification of chromosome 8q24 results in tumour progression and is 
frequently observed in localized and metastatic PCa.34 The downregulation of the cell 
cycle inhibitor p27 has been associated with poor prognosis.34 In addition, the 
tumour suppressor gene TP53 (17p13.1) involved in the regulation of apoptosis, cell 
cycle arrest and senescence has been found to be mutated or downregulated in 
around 50% of advanced PCa.18 Moreover, single nucleotide polymorphisms (SNP) in 
key genes have been suggested to be associated with PCa risk such as the 
cytochrome P450 17 (CYP17) gene where the SNP rs743572 has been associated with 
high risk of prostate cancer.34 PTEN, an inhibitor of the PI3K/Akt/mTOR pathway has 
been shown to be downregulated in 23-52% of PCas depending on the stage of 
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cancer progression. The lack of PTEN results in activation of the Akt/mTOR 
pathway.34,37 The stimulation of Akt can also be induced by NF-kB through IKK and by 
cholesterol28. The activation of Akt1 or the isoform p110β of PI3K cause activation of 
the PI3K/Akt/mTOR pathway, inducing tumour progression and resistance to 
hormone depletion.28 Other mutations that have been identified in PCa include the 
genes Forkhead box protein A1/O3 (FOXA1/O3; 6q21)) affecting cell proliferation and 
accumulation of DNA damage inducing cancer development and progression. In 
addition, other mutations include the mediator complex subunit 12 (MED12), 
thrombospondin, type-I, domain containing 7B (THSD7B), sodium channel, voltage-
gated, type XI, α subunit (SCN11A), speckle-type POZ protein (SPOP) that increases 
invasion and zinc finger protein 595 (ZNF595)38. Mutations and loss of heterozygosity 
that leads to pRb inactivation have been linked to the development and progression 
of PCa in clinical samples and in a mouse model39.  
 
1.1.3.a.II Hormonal and growth factors 
 
Evidence suggest that hormones and growth factors are implicated in PCa 
development; high levels of testosterone and Insulin like Growth Factor (IGF-1) are 
associated with higher incidence and early development.16 Other growth factors, for 
example Epidermal Growth Factor (EGF), Fibroblast Growth Factor (FGF), Hepatocyte 
Growth Factor (HGF), Vascular Endothelial Growth Factor (VEGF) and Transforming 
Growth Factor Beta (TFG-β) also have been reported to be involved.16,27 Several 
hormone and growth factor receptors are also altered in PCa, perhaps the best 
known is the androgen receptor (AR). AR is a nuclear receptor of 120kDa,27 and a 
member of the steroid-thyroid-retinoid superfamily of nuclear receptors, and it is 
localized on chromosome X and contains eight exons.29,34 When the AR is activated 
by ligand-binding, the receptor acts as a transcription factor by inducing the 
expression of gene products involved in proliferation and development of normal 
and neoplastic tissue in the prostate.27 AR is composed of the N-terminal domain 
(NTD), a carboxy-terminal ligand binding domain (LBD), a DNA-binding domain (DBD) 
in the mid region and a hinge region (Fig.4).29,40 There are two activating functions 
22 
 
(AF1 and AF2) localized in NTD and LBD (Fig. 4).41 Inactive AR is bound to heat-shock 
proteins and other proteins in the cytoplasm to prevent DNA transcription, while 
binding of ligand to AR activates the receptor through conformational changes that 
releases the bound proteins and enables AR phosphorylation, followed by nuclear 
translocation and binding to androgen response elements (AREs) in target genes.29  
 
   
Figure 4. The human androgen receptor (AR). AR contains ~ 919 amino acids. NTD – N-
terminal domain; DBD – DNA binding domain; LBD – ligand binding domain; Hinge – hinge 
region between the DBD and LBD. The activation function 1 (AF1) within the NTD and 
activation function 2(AF2) resides within the LBD. N; amino terminal end and C; carboxy 
terminal end.  
 
Activation of AR signalling pathways has been demonstrated to play an essential role 
in the development of HRPC.42 Germline variations in the AR gene have been 
demonstrated as a predictor of cancer aggressiveness.16 There are 1029 different 
mutations reported for the AR with most of them not causing malignancy, while 159 
mutations, most of which have single base substitutions due to somatic mutations 
have been associated with PCa.43 Genetic modifications within the AR coding region 
include point mutations, gene amplification and deletions which, can lead to AR 
overexpression, androgen hypersensitivity, AR-polymorphism and promiscuous 
binding to non-androgens (Table 1).29 Cancer related mutations in AR are more 
common in androgen independent PCa, most of which occur in the conserved 
domains (DBD and LBD) (Fig. 4).44 Mutations can also generate an AR that is 
hypersensitive to androgenic hormones, for example products of the 
dihydrotestosterone (DHT) metabolism. The mutations Val715Met and Val730Met in 
the AR-LBD are examples of substitutions that were identified in a metastatic tumour 
and a confined tumour respectively.44 Other examples of AR-LBD include the somatic 
mutations  Leu701His and in LNCaP cells Thr778Ala which induce prostate cancer cell 
growth and cell survival.34  
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Table 1. Mechanisms for development of hormone-refractory metastatic prostate 
cancer.  
 
Modified from 29. 
 
1.1.3.b Prostate Cancer metastasis 
 
Advanced PCa shows bone and lymph node metastasis in almost 80% of cases. 
Osteoblastic lesions occur in vertebral bodies, pelvic bones, sternum, ribs, and the 
femurs.16 These lesions are the main cause of death in most patients, however the 
cancer cell tropism is not well understood.28 Metastatic prostate tumour cells in the 
circulation show multiple chromosomal rearrangements and typical genomic 
instability.28 Findings suggest that metastatic PCa arises from a monoclonal cell 
source, selected as a result of treatment with chemo- or radiation-therapy killing 
most cancer cells, but not prostate cancer stem cells that have accumulated multiple 
mutations and epigenetic changes.45 Inflammation also creates a selective 
environment that triggers this carcinogenic progression.45  
 
1.1.4 Diagnosis of Prostate Cancer 
 
During the last 20 years more patients have been diagnosed at earlier stages, mainly 
because of increased screening in men. Screening is aimed at reducing PCa mortality. 
The choice of screening method is dependent on local health care regulations. To 
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increase the rate and accuracy of PCa detection it is necessary to combine different 
screening methods such as digital rectal examination (DRE), prostate specific antigen 
(PSA), and transrectal ultrasound (TRUS). However, to confirm PCa histological 
evidence is also needed in all cases and is obtained by biopsy sampling.  
 
1.1.4.a Digital rectal exam (DRE) 
 
The DRE has the potential advantage of detecting abnormal growth of the prostate 
and consequently both benign and malignant tumours and to limit overdiagnosis.46 
DRE has a 50% predictive accuracy, although it is only accurate and reproducible if 
executed by an expert.47 A disadvantage of DRE is that it is relatively insensitive and 
several cancers are not detected due to the inability to palpate the entire prostate 
gland and to detect tumours elsewhere in the prostatic capsule or at a more 
advanced pathological stage.46 Patients diagnosed by DRE alone have a poor survival 
rate, in which 75% of the patients eventually die.47 The effectiveness of DRE 
increases if used in combination with other diagnostic methods. 
1.1.4.b Prostate-specific antigen (PSA) 
 
PSA is a serine protease produced by the prostatic epithelium and periurethral 
glands.47 Although elevated PSA levels are a good diagnostic factor for PCa, changes 
in PSA levels could also be caused by other events such as prostate infection, 
prostatitis, urinary tract infection or recent ejaculation. In addition, PSA is not 
elevated in some patients with PCa.48 The PSA values recommended for use for 
diagnosis are determined by age range and ethnicity (Table 2).49 The widespread use 
of PSA testing has increased the diagnosis of patients with clinically localized low-
grade carcinomas that may not require treatment and could be managed by watchful 
waiting.28 The absence of a non-invasive prognostic method that distinguishes 
between a low-grade and an aggressive tumour has led to overtreatment of patients 
that otherwise would not require active treatment. The over-diagnosis and 
treatment of PCa reduces the overall impact and benefits in survival rates.28 Recent 
studies have revealed that PSA doubling time (PSADT) rather than absolute PSA 
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levels is a better predictor to determine the risk of metastatic disease and further 
progression of PCa.48 In a multi-ethnic older-men study a PSADT of less than 9 
months was associated with poorer overall survival and a worse prognosis than 
PSADT of more than 9 months after radical prostatectomy.50  
 
Table 2. Recommended age-specific PSA reference ranges for diagnosis among different 
ethnicities. PSA values above the indicated ranges suggest potential higher risk for 
developing PCa.  
 
Modified from 49. 
1.1.4.c Transrectal ultrasound (TRUS) 
 
TRUS is currently the most common imaging tool for PCa and is used as a guide for 
needle biopsies.51 TRUS gives an image of the prostate and seminal vesicles by using 
a biplane intra rectal probe.47 By convention TRUS is not considered a suitable single 
diagnostic and staging tool for PCa, due to low sensitivity and accuracy of non-
palpable cancers where 50% are missed.47,51 In addition, during TRUS-guided biopsies 
events such as infection, bleeding and pain can appear during the procedure.46 
However, TRUS is a reliable method to identify cyst, abscesses and calcifications 
within the prostate, and can be used to measure the volume of the prostate.16 A 
method derived from TRUS termed transrectal elastosonography (TRES) appears as a 
better diagnostic tool in terms of accuracy, however current analysis evaluating the 
efficacy of TRES are not conclusive since the studies did not use a standardized 
procedure that could be comparable.52    
 
1.1.4.d Biopsies 
 
A biopsy comprises the collection of 10 to 12 needle core samples for mapping the 
prostate, and involves taking samples from the parasagittal base, the mid-gland, the 
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apex from each side and from the far lateral peripheral zones.47 In biopsies, diagnosis 
of prostate adenocarcinoma can be confirmed by the absence of immunostaining 
using p63 and cytokeratin 5/14 antibodies and an elevated  immunostaining of a-
mehtylacyl-CoA racemase (AMACR), a luminal marker overexpressed in carcinomas.28 
Common complications of this invasive procedure include urinary tract infections, 
bleeding, haemospermia and pain in some cases requiring hospitalization. 
Unfortunately, a negative biopsy does not exclude the possibility of prostate 
cancer.47 In summary, currently there is no single diagnostic method that could be 
considered as 100% accurate, thus it is recommended to be evaluated with more 
than one diagnostic tool is in all cases. 
1.1.5 Grading and Staging of PCa 
1.1.5.a Gleason grade 
 
According to the degree of histological differentiation, prostate adenocarcinomas are 
classified based on the patterns of gland formation. The most accepted grading 
system was developed in 1966 by Gleason.53 This system is based on two levels of 
scoring due to heterogeneous differentiation patterns and determines the 
aggressiveness of the tumour.  
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Figure 5. Gleason Grading System. Histological grading for adenocarcinomas of the prostate. 
The main pattern in the glands is graded on a score from 1 (least aggressive) to 5 (most 
aggressive) on the largest available histological specimen. The two most common Gleason 
patterns are added to give a total score ranging from 2 (1 + 1) to 10 (5 + 5). Where there is 
no secondary grade, the primary grade is designated as both the primary and the secondary 
grade (e.g., 3 + 3),47 modified from .16,54 
 
The primary pattern is assigned with a Gleason grade of 1 (less aggressive) to 5 (more 
aggressive) based on morphology and its differentiated progression from normal 
appearance (Fig. 5). The second pattern is also assigned with a score resulting in a 
two digit scores i.e. 3 + 4 = 7.47 This scoring has been criticized for the complexity in 
determining the secondary pattern and an adequate distinction between good and 
poor prognosis in the majority of patients with scores from 5 to 7.16 However, the 
Gleason grading is highly reliable and reproducible, and it has been demonstrated 
that a higher Gleason score is a marker for higher mortality.16 
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1.1.6.b Tumour, Nodes and Metastases Staging System (TNM) 
 
The TNM system according to the Classification for Adenocarcinoma of the Prostate 
is the predominant method for staging PCa.47 According to the TNM categories, the T 
category refers to the primary tumour and is based on clinical examination, imaging, 
endoscopy, biopsy and biochemical tests (Fig. 6).  
 
Figure 6. Staging of prostate cancer according to the TNM system. The TNM system 
evaluates the location and size of a tumour in the prostate. T= local tumour growth, 
N= the lymph nodes, M= distant metastases,55 adapted from.15 
 
The grading and staging of PCa are important in determining which treatment is the 
most adequate for the patient. Therefore the combination of Gleason score, the 
TNM system and the PSA levels (Table 2) are determinants for the prognosis and 
treatment procedure. PCa can be divided in four stages where stage 1 is considered 
as low risk prognosis and stage 4 high risk with poor prognosis (Table 3).15  
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Table 3. Prostate cancer staging for prognosis.  
M, Metastasis; N, node; PSA, prostate-specific antigen; T, tumour; X, unknown, modified from 56. 
 
1.1.6 Treatment 
1.1.6.a Surgery and radiation therapy 
 
Radical prostatectomy (RP) is surgical removal of the prostate for patients with 
localized PCa, however it is not the preferred option for most patients.57 This 
procedure removes the prostate gland and some surrounding tissue.27 The survival 
rate for patients with favourable preoperative characteristics treated by RP is 5 to 9 
years without biochemical relapse.27 Recent studies have shown that RP is associated 
with a reduction in the rate of death from PCa.58 Radiation therapy by external beam 
radiation or brachytherapy (internal radiation) is used to treat localized PCa at early 
stages, low grade and low volume or with localized metastasis (when metastasis are 
close to normal tissues).27 
Radiation doses for cancer treatment are measured in Gray units (Gy), which 
measures the amount of radiation energy absorbed by 1kg of human tissue, thus 
different doses of radiation are needed to kill different types of cancer cells.59 The 
standard of care for patients in most countries is of 1.8-2.2Gy administered in 16-20 
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fractions.60 Studies have shown that biochemical progression-free survival and local 
control can be significantly improved with post-operative radiation therapy using 
60Gy.61 However, there is no clinical evidence that doses above 70Gy are beneficial 
for patients with previous long-term hormonal therapy.60 Radiotherapy, on average, 
results in 12 years of survival before recurrence.27  
 
1.1.6.b Hormonal therapy 
 
Androgen deprivation therapy is accepted as a standard treatment for advanced 
PCa.57 The most used current treatment comprises luteinizing hormone-releasing 
hormone (LHRH) agonist drugs (e.g. buserelin, goserelin, histrelin, leuprorelin and 
triptorelin) where testosterone production is ultimately inhibited by suppression of 
luteinizing hormone (LH) secretion. Alternatively LHRH antagonists drugs including 
abarelix, cetrorelix and degarelix directly inhibit LHRH with no agonist properties.62 
Other current treatments include steroidal antiandrogen monotherapy (e.g. 
megesterol acetate, medroxyprogesterone and cyproterone acetate) where the 
pituitary and hypothalamus are inhibited, supressing testosterone production.62 In 
addition, non-steroidal anti-androgens such as bicatulamide, flutamide and 
nilutamide where androgen binding to the AR is inhibited in target tissues.62 The aim 
of anti-androgen therapy is to block androgen effects within or beyond the prostate 
tissue; it is often used in combination with surgery. After a few years of successful 
treatment, patients develop resistance to the treatment and acquire an androgen 
independent state with poor prognosis.27 Other androgen antagonists (e.g. 
ketoconazole and dilutamideor) target the cytochrome P450 hydroxylase and an 
anti-androgen in combination with the 5-α-reductase inhibitor finasteride prevents 
synthesis of androgens.62,63 Abiraterone acetate, a pro-drug of abiraterone, is a 
selective inhibitor of androgen biosynthesis that potently blocks cytochrome P450 
c17 (CYP17), an enzyme in testosterone synthesis, thereby blocking androgen 
synthesis by the adrenal glands and testes and within the prostate tumour.64 Recent 
studies have shown that the inhibition of androgen biosynthesis by abiraterone 
acetate prolonged overall survival among patients with metastatic castration-
resistant PCa who previously received chemotherapy and was approved for 
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treatment by the FDA, in April 2011.64,65 Currently, there are several new drugs in 
clinical trials and on the market with similar mechanism of action.59 
1.1.6.c Chemotherapy 
 
Chemotherapy is the preferred treatment for some patients that do not respond to 
androgen ablation and is also used as an alternative for patients with HRPC.27 
However, the overall survival benefits are low, while chemodrug combinations have 
shown a palliative response to improve the quality of life for patients with pain.66 
Clinical trials data suggest that for locally advanced PCa the administration of 
cytotoxic drugs before surgery or as an adjuvant therapy is helpful in combination 
with anti-androgen therapy after surgery.27 Current chemotherapeutic regimes 
include the combination of agents such as mitoxantrone, taxols (docetaxel or 
paclitaxel), prednisone, estramustine, suramin, etoposide, vinblastine and platinum 
compounds (satraplatin, platinum IV, cisplatin or carboplatin).27 The 
chemotherapeutic regimes are effective in early stages of PCa but ineffective in most 
advanced hormone refractory and metastatic PCas, due to dose-limiting toxicities 
and treatment resistance.27 Therefore, it is essential to improve current treatment 
regimens and improve the development of alternative treatments that could be used 
in combination with conventional chemotherapeutic drugs. 
1.1.6.c.I Mitoxantrone  
 
Mitoxantrone is the most active compound in the anthracenedione series, and is an 
amino anthracenedione (Fig. 7)16 that induces inter- and intra-strand crosslinking and 
double-strand DNA breaks by inhibition of topoisomerase II ultimately resulting in 
apoptotic cell death.67 Mitoxantrone in combination with prednisone was considered 
as the gold standard for HRPC treatment before the introduction of docetaxel.16 
Mitoxantrone is administered intravenously at a dose of 12 - 14 mg/m2 once every 3 
weeks in patients with solid tumours, and is rapidly cleared from plasma.16 The drug 
binds tightly to DNA and resistance develops through alterations in topoisomerase II. 
Mitoxantrone is not specific for any phase of the cell cycle.67 The limiting factors for 
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mitoxantrone treatment are neutropenia, nausea, vomiting, alopecia and cardiac 
toxicity, at cumulative doses above 160 mg/m2.16 
 
Figure 7. Structure of mitoxantrone, adapted from.16 
1.1.6.c.II Docetaxel 
 
The taxane docetaxel is the current therapy of choice for HRPC in the UK. It is a 
semisynthetic analogue of paclitaxel with antimitotic activities and inhibits 
microtubule depolymerisation resulting in cell cycle arrest (Fig. 8).66 In phase III 
clinical trials docetaxel was shown to significantly decrease disease progression, 
decrease/stabilize PSA, prolong survival and to have palliative effects in patients with 
HRCP.66 Docetaxel is administered every 21 days at a dose of 75mg/m2 
intravenously.68 Prolonged treatment with taxanes such as docetaxel can result in 
resistance and induce neutropenia as the main toxic side effect. Docetaxel is a wide 
spectrum drug that binds to the N-terminal 31 amino acids of the β-tubulin subunit 
of tubulin polymers and has a 1.9-fold higher affinity than paclitaxel.16  
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Figure 8. Structure of docetaxel, adapted from 16. 
 
Docetaxel, like other taxanes alters the tubulin dissociation rate at both ends of the 
microtubules by reducing the tubulin concentration required for microtubule 
assembly, promoting nucleation and elongation phases of the polymerization 
reaction.16 Thus, stabilizing the microtubules against depolymerisation and 
enhancing polymerization thereby increasing the levels of microtubules and their 
stability in turn preventing cell cycle progression and inhibiting cell proliferation by 
sustained mitotic block at the metaphase/anaphase boundary. Moreover, it is known 
that disruption of microtubule reorganization induces the tumour suppressor gene 
p53 and inhibits the cyclin dependant kinase inhibitor 1a Cdkn1a (p21/Waf-1) and 
several protein kinases inducing G2/M-phase arrest and apoptosis. However, the 
exact taxane-dependent cell killing mechanisms are still not completely 
understood.16 
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1.2 Adenovirus 
1.2.1 Types of human Adenoviruses 
 
Adenoviruses were first identified during the 1950’s in tonsils and adenoid tissue, 
and were named according to the original tissue in which they were discovered 
(Adenoid) and are classified under Adenoviridae family.69 The strains infecting 
humans belong to the Mastadenovirus genera. Human adenoviruses are grouped in 
56 serotypes and seven species (A-G) (Table 4).70,71 The classification is based on 
their ability to agglutinate red blood cells, the genome sequences and 
phylogenomics, protein characteristics and biological properties (Table 4).69,71,72 
Adenoviruses can cause genitourinary infections, epidemic conjunctivitis and acute 
respiratory tract infections, being responsible for up to 5 to 10% of respiratory illness 
in children. In addition, adenoviruses are associated with a wide variety of clinical 
syndromes, with infantile gastroenteritis as the most common disease. 69,70 
 
Table. 4. Human Adenoviruses.  
 
CAR; Coxsackie virus and adenovirus receptor, HSPG; Cell surface heparan sulfates 
proteoglycans, VCAM-I; vascular cell adhesion molecule 1, MHC-I; major histocompatibility 
complex 1. Table generated from published information in 70-72.  
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1.2.2  Adenovirus Structure 
 
Adenoviruses are non-enveloped viruses and have a linear double-stranded DNA 
genome encapsulated in an icosahedral protein shell of about 70 to 100nm in 
diameter called the capsid.69 Structurally the capsid consists of seven polypeptides; 
hexon (protein II), penton base (protein III), fibre (protein IV), proteins IIIa, VI, VIII, 
and IX.73 The main components of the capsid are 252 subunits called capsomeres, of 
which 240 are homotrimeric hexons of 105 kDa localized on each face of the capsid 
and 12 pentones of 63 kDa (Fig.9).73,74 Each pentameric pentone is associated with a 
trimeric fibre of 62 kDa forming a complex of 12 vertices extending from the 
icosahedrons.73,74 Minor components of the capsid comprise protein IIIa (63 kDa) 
that is associated with the hexons and protein VI that is localized below the penton 
base (Fig. 9).74 The polypeptide VI (23 kDa) is also associated with the hexons and is 
thought to be involved in the early stages of infection as a lytic factor.73 Protein VIII 
(15 kDa) binds hexons and the rest of the capsid.73,74  
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Figure 9. Adenoviral structure. Representation of the proteins involved in the adenoviral 
structure and function.74  
 
Protein IX (14 kDa) is a structural protein that stabilises the capsid by interacting with  
hexon.73 Other structural proteins of adenovirus are localized in the virus core and 
are associated with the viral genome. These proteins named V, VII, X (Mu), terminal 
protein (TP), form nucleosome-like structures protecting the genome. Other proteins 
that are also located in the core are IVa2 and the viral protease (Fig. 9).73,74  
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1.2.3 Genome Organization 
 
The linear genome of 34-36 kb for human adenoviruses contains two origins for DNA 
replication.75 The genome also includes a cis-acting packaging sequence that drives 
the interaction between the viral DNA and the proteins of the capsid.69 The viral 
genome has five early transcription units (E1A, E1B, E2, E3 and E4) (Fig.10), involved 
in the regulation of viral gene expression and DNA replication; two delayed early 
units (IX and IVa2), and one late unit (major late) that is processed to generate five 
families of late mRNAs (L1-L5) (Fig.10), all viral genes are transcribed by the host cell 
RNA polymerase II.69 The viral genome also carries two virus associated (VA) RNAs 
transcribed by RNA polymerase III.69 The adenoviral genome has two reading strands, 
the transcription of the rightward strand codes for  E1B, IX, major late, VA, E3 and 
E1A that is drawn by convention at the left end; the leftward codes for the E4 gene 
localised at the right extreme, before E2, and IVa2 genes.69,75 The E1A gene encodes 
proteins that activate transcription and induce the host cell to enter the S-phase of 
the cell cycle (described in section 1.2.4).69 
 
Figure 10. Genomic organization and protein products of the serotype 5 adenoviral 
genome (Ad5). Ad5 genome structure indicating location of viral genes and the 
respective proteins expressed that are involved in the viral replication machinery. 
Splice variants are also indicated. The central genome is presented in both map units 
and kilobase pairs (Kbp) bottom. Coding regions are shown as shaded boxes and 
RNAs are represented by single lines with small arrowheads and base pairs indicated. 
The direction of the transcription is shown by arrows.75 
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1.2.3.a Early region genes 
 
The early region 1B (E1B) is located on the right of E1A within the viral genome. The 
E1B gene encodes 5 mRNAs that are processed by alternative splicing (Fig. 10).75 The 
most abundantly expressed are E1B19kD and E1B55kD which both block apoptosis.69 
E1B19kD is a member of the Bcl-2 anti-apoptotic family of proteins  and is a 
functional Bcl-2 homologue.75 The E1B19kD protein inhibits apoptosis by 
sequestering the Bcl-2 homologous antagonist killer (BAK) and Bcl-2 associated X 
protein (Bax).76 The E1B55kD protein forms a complex with the E4ORF6 product and 
inhibits p53 activity by direct binding and facilitates the transport of late viral RNAs 
for translation from the nucleus to the ribosomes.75,76 The E2 gene encodes three 
proteins that function directly in viral DNA replication.69 The gene is divided in two 
regions; E2A that transcribes a 59 kDa DNA-binding protein, E2B expressing a 135.6 
kDa DNA polymerase and a 74.5 kDa terminal protein precursor.77 The E3 genes 
encode nine proteins with nine open reading frames (ORFs), 12.5, 14.7, the 
heterodimer 10.4/14.5, 3.6, 7.1, 11.6, 7.5kDa and the glycosylated gp19kDa proteins 
(Fig. 10) that modulate the immune response of the host to the viral infection.75 The 
E314.7 kDa can also inhibit apoptosis induced by TNF-α. The three E3-proteins 14.7, 
10.4 and 14.5kDa forms the E3B region that is essential to avoid rapid immune 
system-mediated clearance of the virus during infection, two of the genes 10.4kDa 
and 14.5kDa form the receptor internalization and degradation (RID) complex.78,79 
The E4 region has seven open reading frames (ORFs) that are transcribed leftward 
with five of the ORFs having their own start codons (Fig. 10).75 Each reading frame 
gives specific products due to alternative splicing of mRNA; these products are 
involved in mRNA transport, in the modulation of viral DNA synthesis, in inhibiting 
cellular protein synthesis, cell death and inhibition of cellular DNA-damage 
repair.69,75 E4ORF4 regulates protein phosphorylation in infected cells, down-
regulates genes activated by E1A and cyclic adenosine monophosphate (cAMP) and 
regulates alternative splicing of adenoviral mRNAs.75,77 In addition, E4ORF4 can cause 
cell death mediated through binding to protein phosphatase 2A (PP2A).75 E4ORF6 
regulates late viral gene expression, viral DNA replication and transformation (Fig. 
11), can form a complex with E1B55kD to target p53 for degradation by 
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ubiquitination thereby inhibiting p53-dependent cell death.75 The E4orf6 protein can 
also bind to p53 in the carboxy-terminal region and block its transcriptional 
activation function, inhibiting its interaction with a subunit of TFIID called TAF31.69 
E4orf6 also inhibits the translocation of cytochrome c from the mitochondria to the 
cytoplasm.69 E4ORF6/7 enhances E2 transcription thus inducing cell growth arrest 
and cell death (Fig. 11).75 
The proteins IX and IVa2 are transcribed by gene products expressed from the 
delayed early region or intermediate region. Protein IX is a structural protein 
involved in DNA packaging and a transcriptional activator for the major late 
promoter (MLP). The IVa2 protein is also a transcription factor for the major late 
genes.77 
 
A) 
 
 
 
 
 
 
 
 
 
40 
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C) 
 
Figure 11. Sequential expression of genes during infection with Ad5. A) Early gene 
expression. B) Late gene expression. C) Sequential events during viral infection and the time 
lapse of the process. (A and B) Green Boxes represent genes expressed by the virus, yellow 
boxes represent cellular genes, and white boxes indicate genes that are not active at that 
moment. Modified from 75 and IMGT® The International imMunoGeneTics information 
system; http://www.imgt.org, Gamrot, E, 2009.80 
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1.2.3.b Late region genes 
 
The late family genes are involved in the production and assembly of components of 
the capsid and are named in sequence from II to IX (Fig. 9).69 They are transcribed 
from the major late promoter (MLP) as a single primary transcript (Fig. 10). The late 
genes are grouped in five families (L1-L5), each one with a distinct polyA signal.77 The 
L1 gene codes for two proteins, the 52 kDa protein that acts as a scaffold for capsid 
assembly and protein IIIa located in the outer surface of the capsid for structural 
support.77 The L2 sequence codes for four polypeptides, including the penton base 
protein that is part of the 12 pentagonal vertices protruding from the capsid. These 
vertices facilitate the viral internalization via integrins, in particular αvβ5 and αvβ3 
mediated by the amino acid sequence arg-gly-asp (RGD) in the penton (Fig.12).69,77 
  
 
Figure 12. The Adenoviral infectious cycle. 1) There are two steps for viral entry into 
the cells, mainly triggered by fiber knob attachment to CAR and endocytosis through 
clathrin and caveolae/lipid raft-mediated internalization.73 The clathrin-mediated 
classical model of virus uptake is induced by interactions between arginine-glycin-
aspartic acid (RGD) motifs present within the surface loops of penton base and cell 
surface αvβ1, αvβ3, αvβ5, or α3β1 integrins.73 In addition to endocytosis another 
mechanism utilised by the virus might be micropinocytosis.73 2) The internalization 
triggers the activation of dynamin and phosphatidylinositide-3 OH kinase (PI3K),73,81 
which can then activate downstream targets like protein kinase C (PKC) and the Rab5 
GTPase. PKC activation induces the reorganization of actin filaments and Rab5, a 
marker and determinant of the endosomal vesicular trafficking and maturation.73,81 
Disassembly begins with the release of fibres during the early stages of entry. 
Endosomal acidification triggers a conformational change in the viral capsid resulting 
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in endosomolysis and release of the virion into the cytoplasm.73 Protein VI contains a 
N-terminal amphipathic α-helical lytic domain that is responsible for the disruption of 
the endosomal membrane and escape.73 Free in the cytoplasm the partially 
dismantled capsid interacts with dynein, in a process facilitated by the hexons and 
the virions translocate along microtubules towards the microtubule organizing 
centre (MTOC) near the nucleus.73,81 The cellular nuclear export factor CRM1 has 
recently been implicated in the release of virions from the MTOC to the host cell 
nucleus.73 3) The virus binds to the CAN/Nup214 protein of the nuclear pore complex 
(NPC), this association and interactions between virions and the histone H1, leads to 
further disassembly and eventual import of adenoviral genome in the nucleus.73 4-5) 
The replication cycle can be divided into two phases, an early phase that starts as 
soon as the viral genome is transported to the nucleus, followed by the transcription 
and translation of early viral genes. 6-7) These events modulate the functions of the 
host cell to facilitate the replication of the late genes. 8-10) The second phase starts 
with expression of the late genes, leading to the assembly in the nucleus of the 
structural proteins and the maturation of infectious viruses.82 Modified from IMGT® 
The International imMunoGeneTics information system; http://www.imgt.org, Gamrot, E, 
2009.80 
    
 
Protein X (mu) and the viral core proteins VII and V are also located within the L2 
gene.77 L3 transcribes the capsid proteins VI, the major structural component of the 
capsid hexon, and a viral protease.77 L4 codes for protein VIII and L5 the fibre protein 
that binds via the knob domain to the coxsackievirus and adenovirus receptor (CAR), 
a member of the immunoglobulin superfamily (Fig. 12).77,81 CAR is a high affinity 
receptor for human adenoviruses from subgroups A, C, D, E and F, but not for 
subgroup B.81 The class I major histocompatibility complex (MHC) α2 domain has also 
been reported to serve as a receptor for Ad5.81  Additional receptors that have been 
suggested to bind adenoviruses are listed in Table 4. 
 
1.2.4. E1A 
1.2.4.a  Structure and functions 
 
The first viral transcription unit to be expressed in the nucleus after viral infection is 
the early region 1A (E1A) gene.81 E1A has a high amount of proline residues within its 
sequence and is phosphorylated at serine residues 89, 96, 132 and 219.83 E1A 
expression is under control of a constitutively active promoter81 and is required for 
expression of other viral genes to promote virus replication and regulate cellular 
43 
 
gene expression.77 E1A can bind to transcription factors such as TATA-binding protein 
(TBP), TBP-associated factors (TAF), ATF-2, c-Jun, CBP/p300, YY1 and CDK8 and the 
nuclear receptors for thyroid hormone and retinoic acid (Fig. 13).83,84 In the 
cytoplasm E1A targets Sug1 and S4 components of the proteasome, and RACK1.83 
E1A also binds to P300/CBP-associated factor (PCAF) that can acetylate p53 in 
response to DNA-damage inducing the transcription of p53 target genes including 
p21, however, E1A can also inhibit p53-dependent activation of p21 and G1 arrest 
independently of its interaction with pRb.76 
The E1A gene encodes five proteins generated by alternative splicing; a protein of 
243 amino acids termed 12S, a 289 amino acids protein termed 13S, 11S, 10S and the 
9S proteins (Fig. 13B). During replication E1A13S is the first protein to be produced 
and is essential for viral replication due to its trans-activating activity; subsequently 
E1A12S is generated inducing cell to progress through s-phase.85 Moreover, 9S is 
expressed late and is able to induce the expression of viral genes during infection in a 
process that requires the S8 component of the proteasome.85 The 11S and 10S are 
similar to the 13S and 12S proteins respectively but lack the amino acid sequence 27-
98 and are expressed late, there are no known specific functions identified for this 
proteins (Fig. 13B).75,85 The E1A gene is located at the left end of the viral genome 
and has four highly conserved regions (CR1-CR4) (Fig. 13B).84 CR1 and CR2 are 
essential for S-phase induction by E1A.83 Either CR1 and CR2 can stimulate cell cycle 
progression from G0 to S-phase, while both CR1 and 2 are essential for progression 
into mitosis.76  
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A) 
 
B) 
 
Figure 13. E1A gene structure with cellular proteins indicated at the specific E1A-binding 
regions. A) Cellular E1A-binding proteins and their binding region within the E1A gene. B) 
E1A proteins derived from alternative splicing of the E1A gene. The names are indicated at 
the left of each transcript. The numbers above refer to the respective amino acid at the 
beginning and end of each constant region (CR). The carboxy-terminal and amino-terminal 
are indicated with C and N respectively.83,84  
 
The E1ACR1 region can bind and inhibit the transcriptional co-activator p300/CREB 
binding protein (CBP).76 Previous work demonstrated that the deletion of the pRb or 
p300-binding domains within the E1A gene preferentially induced selective 
cytopathic effects in tumour cells in vitro and inhibited tumour growth in vivo.86-88 
Furthermore, p300 was originally identified using protein-interaction assays with the 
adenoviral E1A.89 p300 has been implicated in a number of diverse biological 
functions including cell proliferation, cell cycle regulation, apoptosis, cell 
differentiation and DNA damage response.89-91 p300 is highly homologous to the 
cyclic AMP response element-binding (CREB) protein (CBP), and transcriptional co-
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activation is mediated by p300/CBP acting as a bridge linking DNA-binding 
transcription factors to the basal transcriptional machinery.76    
The protein complex p300/CBP has acetyltransferase activity, that induces the 
acetylation of histone tails and lysines of transcription factors.76 The binding of E1A 
with p300/CBP blocks its acetyltransferase activity inducing S-phase through Myc 
activation antagonizing the inhibitory activity of p27kip1 preventing G1 arrest that can 
be induced by the transforming growth factor-β (TGF- β).76,81,92 In PCa, p300 is 
essential for regulating androgen-induced genes required for PCa progression.93 The 
binding of E1A to p300 promotes apoptosis induction, although the exact mechanism 
remains unknown, p53 can be stabilized and its degradation impaired through the 
binding of E1A and p300, therefore contributing to apoptosis induction.76,94,95 
E1ACR1 can interact with components of the proteasome to stabilize p53, unless it is 
blocked by E1B55K or E1B19K.76 E1ACR1 also binds to proteins involved in chromatin 
structure control, and binds to p400, TRAPP, HAT PCAF, TIP60, hGcn5 and p21 also 
inducing cell cycle progression (Fig. 13A).76 The 400kDa protein doublet p400 is part 
of the nucleosome acetyltransferase of H4 (NuA4) complex that is involved in 
transcriptional activation by acetylation of the nucleosomal histones H2A and H4.76 
E1A binds p400 in a region overlapping p300-binding-region inducing ATP-dependent 
chromatin remodelling and cell cycle regulation and promotes cell death in fibroblast 
cells, although requiring pRb simultaneous association.92,96 The E1ACR2 region binds 
to retinoblastoma proteins (Rb) and p107 and p130 Rb-related proteins that regulate 
the E2F family of transcriptional factors.76 The physical interaction of E1A with pRb 
displaces E2F from the pRb–E2F complex, through binding of its high affinity motif 
LxCxE to the Rb proteins, thus increasing the cellular concentration of free E2F.76,97 
Free E2F then activates both the Ad5 E2 gene (viral polymerase) promoter and cell 
cycle regulatory genes such as cyclin E, cyclin A, cdc2, cdk2, cdc6, orc1, Mcm 2-6, and 
DNA polymerase,76,86,97,98 inducing cell cycle progression to S-phase and preventing 
senescence.76 In a variety of human cancers, however, the Rb gene is inactivated or 
the pRb pathway is deregulated such that E1ACR2 deletion mutants can readily 
replicate and lyse cells as efficiently as wild-type Ad (Adwt). E1ACR3 is the most 
conserved region of the E1A gene and is a globular protein domain.76,99 The E1ACR3 
region is only present in the 13S protein.76 E1ACR3 functions as an activation domain 
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that is essential for early viral promoters; this region can bind to MED23 that leads to 
the stimulation of viral transcription initiation and re-initiation.76  E1ACR3 can induce 
transcriptional activation by binding p300 independently of the CR1 binding site.100 
E1ACR4 is a nuclear localization signal and a transcriptional regulatory region. 
E1ACR4 is the C-terminal region of E1A that binds to the cellular E1A C-terminal 
binding protein (CtBP), a transcriptional regulatory protein that inhibits transcription 
through histone deacetylases. In addition, the only known target genes of CtBP 
include CDH1 (E-Cadherin), CDKN2A (p16), Sirtuin 1 and BRCA1.76,101 E1A inhibits 
CtBP and can sensitize tumour cells to anoikis by binding to the repressor-binding 
site of CtBP.76   
 
1.2.5. Replication-selective adenoviral mutants 
 
The development of replication-selective oncolytic adenoviruses represents a 
promising anticancer approach with proven efficacy in cancer cells and tumour 
xenografts in vivo without cross-resistance to conventional clinical therapies.102,103 
The characteristics that make adenoviruses attractive as vectors are their broad 
organ tropism, the relatively easy genetic engineering and production and the 
potential of inserting large genes and for generating selectively oncolytic mutants.104 
One of the earliest engineered oncolytic viruses used in clinical trials is dl1520 
(ONYX-015).105-107 ONYX-015 is a modified adenovirus lacking the E1B55K protein, 
which typically causes p53 repression and degradation.105-107 ONYX-015 has been 
used in various clinical trials (phase I, II and III) for pancreatic, liver, and head and 
neck cancers and has been approved by the Chinese FDA for treatment of head and 
neck cancers. 102,108,109 p53, the so-called guardian of the genome, is responsible for 
several cellular functions, including apoptosis induction in DNA damaged cells, and 
cell cycle arrest, both of which need to be prevented for successful viral 
replication.105-107 Wild-type adenoviruses suppress p53 activity by expressing E1B and 
E4 genes. Since many tumours have deletions or mutations in the p53 pathway, E1B 
is not necessary for the virus to replicate in these cells.105-107 However, in normal, 
quiescent cells, viruses lacking E1B are unable to replicate because the cells have 
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wild-type p53 expression, which inhibits viral propagation and prevents cell cycle 
progression.106 ONYX-015 has been used successfully to treat tumour cells in vitro 
and tumour xenografts in animals, but it has been less successful in treating human 
cancers as single agent.102,108 Eventually, it was established that p53 status was not 
the critically restrictive factor, but rather complementation in tumour cells of the 
mRNA nuclear export functions of E1B55K and the lack of protection against the host 
immune response to viral infection because of the deletion in the E3B genes.110,111 
Both genes contributed to the attenuated efficacy of the virus. The dl1520 mutant, 
H101, was licensed for anticancer therapy in China in 2005 (Shanghai Sunway 
Biotech).109 Whereas tumour selectivity was shown for both ONYX-015 and H101, 
efficacy was only reported in combination with cytotoxic drugs.109,112,113 To date, 
safety has been demonstrated in clinical trials with these mutants in thousands of 
patients. 
Recently, more potent oncolytic mutants than the dl1520 mutants have been 
developed that retain functions essential for the viral life cycle by deletion of smaller 
gene regions and by modifying tropism to target tumours specifically to enable viral 
gene expression and amplification at the tumour site with minimal toxicity to normal 
cells.102,112 One example is the E1ACR2-deleted dl922-947 virus, that in combination 
with cytotoxic drugs such as 5-fluorouracil (5-FU) or gemcitabine enhanced cell killing 
in both in vitro and in vivo models of pancreatic cancer.114 Another example is the 
Ad∆∆ mutant (E1ACR2- and E1B19K-deleted) virus, which was shown to be more 
potent and efficacious in enhancing cell killing, than both wild type (Ad5tg) and 
dl922-947 viruses in combination with the cytotoxic drugs gemcitabine, irinotecan 
and cisplatin in preclinical pancreatic cancer models.115 Moreover, normal cells were 
not sensitized by the Ad∆∆ virus.115 In an ovarian cancer study, enhanced cell killing 
was induced in response to treatment with a chimeric mutant, Ad5/3-∆24 with the 
serotype-3 knob domain insertion in the fibre and the CR2-pRB binding region 
deleted, in combination with gemcitabine in vivo and in vitro.116 A study in 
medulloblastoma cells, showed that the replication-selective Ad5-∆-24-virus 
effectively reduced cell viability, although the virus was slightly less efficacious than 
wild type.117 These and several other reports demonstrate the need of combining 
48 
 
even the most potent oncolytic adenoviral mutants with other cytotoxic drugs and 
factors to improve anti-cancer efficacy. The potent oncolytic adenoviral mutant 
Ad∆∆ (Ad∆E1ACR2 and Ad∆E1B19K-deleted) was engineered to synergise with 
cytotoxic drugs by deletion of the E1B19K, resulting in a virus that enhanced 
chemotherapeutic drug-induced apoptotic cell death.118 Ad∆∆ interacted 
synergistically with the chemotherapeutic drugs docetaxel and mitoxantrone in PCa 
models both in vivo and in vitro  and with gemcitabine and irinotecan in pancreatic 
cancer models,115 whereas cell killing and viral replication were attenuated in normal 
cells.118 Moreover, Ad∆∆ also showed high specificity and potency in killing cancer 
cells in culture when administered alone. Other approaches to improve on viral 
specificity and potentially efficacy are the incorporation of selective promoters to 
drive viral replication and/or cytotoxic transgene expression targeting prostate119-121 
and other solid tumours.84,122-125  
There is substantial evidence of the successful application of oncolytic adenovirus in 
combination with chemotherapeutic drugs as shown in different clinical trials.126 
Clinical trials with encouraging results using oncolytic adenoviruses include a Phase-I 
study with the CG7060 virus, which was engineered to have the PSA promoter 
driving viral replication. CG7060 induced a decrease in circulating levels of PSA and 
showed anti-tumour activity in PCa.120 A mutant expressing the prodrug-coverting 
chimeric CD-TK enzyme, Ad5-CD/TKrep (E1B-55K and E3-deleted), was combined 
with 5-fluorocytosine (5-FC), intensity-modulated radiotherapy (IMRT) and 
ganciclovir in clinical trials resulting in anti-cancer efficacy for up to 4 years in 
prostate cancer patients.121 In addition, other Ad5-CD/TK-derived viral mutants and 
more recently the CG7870 virus (where E1A and E1B are under control of the rat 
probasin promoter and the PSA promoter-enhancer respectively), have been 
successfully evaluated in PCa clinical trials in combination with cytotoxic drugs 
and/or radiation-therapy.126,127 Recently the first Phase I clinical trials with 
AdΔ24RGD (that includes Ad∆24 an 8-amino-acid deletion in the CR-2 region of E1A 
and the insertion of an RGD-4C motif in the HI loop of the fiber protein) viral mutants 
were completed for recurrent ovarian cancer and malignant gliomas (NCT00562003 
and NCT01582516) with promising results; they showed tumour-selectivity and no 
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serious side-effects.128 In summary, numerous oncolytic adenoviral mutants are 
being developed pre-clinically to improve efficacy in the treatment of late-stage PCa. 
 
1.2.6 Sensitisation to chemotherapeutics by adenovirus E1A-gene expression 
 
In cancer cells and tumour xenografts, and in particular in prostate cancer models it 
has been demonstrated that E1A enhances the sensitization of cells to 
chemotherapeutic drugs through synergistic interactions to induce apoptosis and cell 
death, which is independent of but further enhanced by viral replication.95,118,129-131 
The E1A gene is spliced generating five proteins, of which E1A13S and E1A12S have 
been implicated in the chemosensitization.95,132-134 Although the E1ACR3-region does 
not seem to be essential to mediate the sensitization of cells.95,135 In a mouse model 
of embryonic fibroblast E1A was observed to induce sensitization to ionizing 
radiation enhancing apoptosis in a p53-dependent fashion.130  
In pancreatic cancer cells, gemcitabine-induced cell death was greatly enhanced 
when used in combination with the Ad∆E1B19K virus in vitro, the virus showed more 
efficiency in inducing apoptotic cell death than with the wild type.136 The 
combination of gemcitabine with Ad∆E1B19K induced tumour suppression in a 
pancreatic tumour xenograft model but had no effect in normal cells.136 
Furthermore, infection with the oncolytic virus dl922–947 of mitoxantrone- and 
docetaxel-treated cells has been shown to synergistically enhance cell killing of PCa 
cells both xenograft in vivo studies and in vitro.131 The Ad∆∆ virus was also 
demonstrated to be highly potent in PCa cells lines in combination with 
mitoxantrone and docetaxel.118 Moreover, the Ad∆∆ virus in combination with 
gemcitabine showed enhanced apoptotic cell-death in models of pancreatic cancer, 
cell killing was induced by synergy between Ad∆∆ and gemcitabine and not by viral 
replication.115 Interestingly, both Ad∆∆ and Ad5-wild type viruses enhanced cell 
killing through synergistic effects when combines with several dietary 
phytochemicals in PCa cell lines and in xenografts in vivo PCa.137 The highest efficacy 
was demonstrated for the  Ad∆∆ mutant in combination with equol and resveratrol, 
inducing caspase-dependent cell-death in PCa cells but not in normal cells.137 
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Furthermore, gemcitabine, equol and resveratrol attenuated viral replication, while 
E1A remained strongly induced promoting cell death.137 In another study, using  
glioma cells the Ad-∆-24 virus was observed to induce topoisomerase-I and enhance 
the sensitization to irinotecan (a topoisomerase-I inhibitor) in vitro and prolonged 
animal survival in vivo.138 However, the exact mechanism of E1A-dependent 
enhancement of sensitization to chemotherapeutic drugs remains elusive because of 
the great number of  factors that may intervene by binding to E1A,  the different 
genetic backgrounds of cells lines and the mechanism of action for specific 
chemotherapeutic drugs.95    
 
1.2.7 Alternative oncolytic viruses  
 
There are many oncolytic viruses that have been used in different clinical trials in 
combination with other therapies such as chemodrugs with promising results. 
Currently, viruses being used in clinical trials apart from adenovirus include reovirus, 
herpes simplex virus (HSV), measles virus (MV), vaccinia virus (VV), New castle 
disease virus (NDV), Coxsackie virus, Vesicular stomatitis virus (VSV), and 
Parvoviruses.139,140 Reovirus, NDV and VSV are small viruses with fast replicative 
cycles. Larger viruses that have been genetically modified include vaccinia virus, the 
Edmonton strain of measles virus, HSV or poliovirus.139 However, despite the 
promising results obtained with these viruses in reducing tumour growth and 
demonstrated safety, most of the clinical trials were not conclusive mainly because 
only small numbers of patients could be evaluated. 
 
1.2.7.a Herpes Simplex Virus (HSV) 
 
The HSV is a human pathogen that causes latent infections by hiding in neuronal 
tissue avoiding the host immune system. Although, HVS can be limited by pre-
existing immunity and hepatic elimination, HSV has wide tropism and large regions of 
the genome can be replaced. HSV has a 152kbp double-stranded DNA that can be 
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engineered by removing genes that are not required for replication, such as the 
neurovirulence factor genes that are deleted in all therapeutic HSV vectors.139 In a 
glioma phase I clinical trial a modified HSV virus, the G207 virus proved to be safe 
with positive responses to the treatment. The HSV G207 has the γ-34.5 and ICP6 
genes deleted. The normal function of the γ-34.5 gene is to downregulate the cellular 
antiviral response by blocking the double stranded RNA-dependent protein kinase 
(PKR), while the ICP6 gene encodes a viral ribonucleotide reductase (RR).141 The 
deletion of γ-34.5 inhibits the capacity of HSV to replicate in neural cells and the viral 
latency properties. Another study, in glioma cells, with a γ-34.5-deleted oncolytic 
HSV was shown to enhance efficacy both in vitro and in vivo in combination with 
temozolomide that induces a DNA damage repair response.140 Furthermore, another 
HSV mutant used in clinical trials is the NV1020 virus that has the γ-34.5, ICP0, ICP4 
genes and the latency-associated transcripts (LAT) deleted. Moreover, NV1020 has 
an insertion of an exogenous HSV thymidine kinase gene (TK) in the region where γ-
34.5, ICP0 and ICP4 were deleted, called the UL/S junction.142   The insertion of a TK 
gene was because of clinical safety reasons (the lack of TK expression makes the virus 
irresponsive to antiviral treatments).139,142  The NV1020 has been used in phase I 
clinical trials in patients with colorectal cancer and liver metastasis, and proved to be 
safe with no major toxicity in combination with chemotherapy.142-144 Additionally, 
the HSV oncolytic virus VEXGM-CSF (OncoVEXGM-CSF) with deletions in the ICP6 and γ-
34.5 genes and insertion of a CMV-promoter and a human granulocyte macrophage-
colony stimulating factor (GMCSF) instead of the γ-34.5 gene sequence, has been 
evaluated in phase I/II clinical trials in patients with cutaneous melanoma, breast 
cancer, head and neck cancer, and gastrointestinal cancer. OncoVEXGM-CSF proved to 
be safe and showed anti-tumour efficacy with the best results in melanoma 
patients.139,145 However, the trials were carried out with small numbers of patients. 
Other strategies have also been tested using modified HSV mutants such as the HSV-
G47∆ virus that has the antiangiogenic protein platelet factor-4 inserted instead of 
the ICP6 gene region or the βG47∆-dnFGFR virus with the dominant-negative 
fibroblast growth factor receptor inserted also instead of the ICP6 gene.146,147 These 
viruses significantly reduced tumour vasculature and enhanced therapeutic efficacy. 
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Also, simultaneous treatment of oncolytic HSV and metalloproteinases-1,8 (MMP-
1,8), enhanced HSV spread.140 Another study showed that a Us3-deleted HSV virus 
synergises with inhibitors of the PI3K/Akt pathway in vitro and showed high efficacy 
and low toxicity in vivo.140 One group showed that the histone deacetylase inhibitor 
trichostatin-A in combination with HSV enhanced efficacy in vivo and synergistic cell 
killing in vitro in brain and colon cancer cells.148 Moreover, cells overexpressing 
mitogen-activated protein (MAP) kinase or extracellular signal-regulated kinase (ERK) 
showed enhanced viral replication of γ-34.5-deleted HSV.140 Furthermore, the G207, 
HSV-1 and NV1020 mutants have been reported to cause cytolytic effects in the 
prostate cancer cell lines PC-3, DU145, LNCaP, and C4-2 in vitro.149 More recently, 
talimogene laherparepvec (T-VEC), previously known as OncoVEXGM-CSF, was proven 
to have anti-tumour efficacy in melanoma patients in a worldwide phase III clinical 
trial (NCT00769704) being the first oncolytic virus with demonstrated efficacy.150 In 
this trial T-VEC proved to be safe with only mild side effects and showed anti-tumour 
efficacy locally and systemically (distant metastases) by boosting a systemic immune 
response against tumour cells.150  
 
1.2.7.b Vaccinia Virus (VV) 
Vaccinia virus has been widely used as the vaccine for smallpox and has also become 
an attractive vector in oncolytic therapy. VV has a 190kbp double-stranded DNA 
encapsulated within a host cell-derived envelope and can harbour large 
transgenes.139 Moreover, VV is easy to modify genetically, easy to produce and 
replicates and spreads rapidly due to its motile characteristics, without the risk of 
genomic integration into host DNA.151 Modified VV has been shown, in several 
studies, to be highly efficient and safe even when administered systemically.151,152 JX-
594, is a Wyeth strain vaccinia virus that was evaluated in phase I clinical trials with a 
deleted TK gene, required for viral replication in normal but not tumour cells, and a 
GM-CSF insertion into the TK region, was shown to effectively spread intravenously 
to target tumours. JX-594 is currently being evaluated in trials targeting lung, renal 
and prostate cancers.153-155 In another study, murine cytokine-induced killer cells 
(CIK) that naturally target tumour cells were infected with a Western Reserve strain 
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of oncolytic vaccinia virus and re-administered to mice. The mutant was deleted in 
the TK and viral growth factor (VGF) genes, enabling viral replication in cells with 
deregulated cell cycle and EGF-R/Ras signaling pathways.156 Moreover, in a glioma 
study a double-deleted VV (TK and VGF deleted) in combination with rapamycin or 
cyclophosphamide was shown to enhance anti-tumour efficacy human glioma cell 
lines in vitro and administered systemically in vivo reducing tumour growth and 
prolonging survival in mice and rats.151 Moreover, the double-deleted VV also have 
shown efficacy in reducing tumour growth and prolong cell survival in xenograft 
models of paediatric neuroblastoma and sarcoma.157 Furthermore, this mutant 
Western Reserve VV expressed either GFP or firefly luciferase to monitor viral 
distribution. Vaccinia-infected CIK cells (CIK cells obtained from human peripheral 
blood) administered systemically in mice were shown to effectively deliver the virus 
to tumours and preventing an anti-viral immune response. This combination of 
vaccinia and CIK cells resulted in synergistic cell killing of colorectal tumour cells.156 
However, the potential application of this method in human patients has the 
limitation of harvesting patient cells ex vivo and to redeliver these cells to the 
patients which implies more expenses and extra-manipulation of samples. 
Additionally, the Western Reserve mutant JX-795 had increased efficacy and tissue 
selectivity in many cancer cells with deregulated IFN pathway. The JX-795 (WR-
delB18R) has the TK and B18R genes deleted, the B18R gene was removed since 
neutralizes type I interferon. Moreover, the JX-795 virus has an IFN-β inserted in the 
TK region. The JX-795 was shown to have increased tumour selectivity for cells with 
deregulated IFN pathway both in vitro in human ovarian cell lines and intravenous 
efficacy in in vivo in tumour mouse models derived from murine JC and colorectal 
CMT93 cells.140,158 
  
1.2.7.c Reovirus  
The non-pathogenic double-stranded RNA virus, Reovirus (respiratory enteric orphan 
virus) has a genome size that ranges from 16-27kbp with high potential when 
delivered systemically. The Dearing strain type 3 (RT3D) and other reoviral strains 
can only replicate in cells with overexpressed Ras (about 40% of all cancers), which 
54 
 
inhibits PKR-mediated antiviral mechanisms.139 The RT3D virus has been used in 
phase I clinical trials and only mild toxicity was reported.139 Currently, an oncolytic 
wild type reovirus (Reolysin) is under clinical development. Phase I/II clinical trials 
with Reolysin including patients with advanced prostate, ovarian, pancreatic, 
melanoma and lung cancers have shown that the virus had both antitumour activity 
and overall safety.155,159,160 Furthermore, recently Reolysin in combination with 
paclitaxel and carboplatin were evaluated for efficacy and overall survival in a phase 
III clinical trial for squamous cell carcinoma of the head and neck (NCT01166542), 
however the results of the study are still not published.161 In a phase II clinical trial 
for squamous cell lung cancer, Reolysin was combined with carboplatin and 
paclitaxel, and was proved to be safe. 161 Furthermore, promising results were 
reported demonstrating a reduction in tumour size in 92% of patients 
(NCT00998192). 
 
1.2.7.d Measles Virus (MV) 
Another viral vaccine strains that have been used for cancer therapy is the 
attenuated or modified MV; a 16kbp single-stranded RNA virus. The MV targets 
deregulated cell membrane receptors including CD46, folate receptor-α (FR-α) and 
signalling lymphocytic activation molecule (SLAM) family receptors in cancer 
cells.139,162  Moreover, MV strains have been modified to target cells with 
upregulated CD46 (a complement regulator) in the cancer cell membranes to, 
facilitate selective infection and lysis.139  A MV targeted receptor nectin-4 (active only 
during foetal development and not in fully developed tissue) that is abnormally 
expressed in tumour cells has been targeted in many types of cancers including 
breast, lung and ovarian tumour cells.163-166 However, the main disadvantage of MV 
is the pre-existent neutralizing antibodies against measles virus in around 95% of the 
western population and the subsequently suboptimal replication in the host.139 
Although, in a phase I clinical trial treatment with a modified MV with a human 
carcinoembryonic antigen (CEA) inserted upstream of the nucleoprotein (N) gene, 
the median overall survival of 12 months was twice as high as the median survival for 
untreated (6 months) patients with refractory ovarian cancer.167 Moreover, induction 
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of MV-induced oncolysis of mesothelioma cells co-cultured with dendritic cells (DC) 
caused in vitro maturation of specific CD8+ T-cells, when mature DC where co-
cultured with purified CD8+ T cells.168  In two phase I clinical trials with mesothelioma 
and myeloma patients treated with MV expressing the sodium iodide symporter 
(NIS) allowing for tracing of MV after systemic administration to monitored its viral 
replication. However, the virus had to be administered in combination with the 
immunosuppressant cyclophosphamide to avoid clearance by the immunesystem.139 
Additionally, murine T-cells infected with MV were shown to protect MV from low 
concentrations of anti-measles neutralizing antibodies. However, the efficiency of 
the infection was only 1-2% of cells.169 Therefore, more studies are required to 
improve the efficacy, infectivity and delivery of MV. 
 
1.2.7.e Vesicular Stomatitis Virus (VSV) 
 
Another virus vector that has been used to target tumour cells is the vesicular 
stomatitis virus (VSV); a single-stranded RNA of 11kbp. The approach with this virus 
consists of carrying the vector to the target cells in pre-infected cells (carrier cells).140 
Carrier cells that have been efficiently used include leukaemia cell lines, 
mesenchymal stem cells, endothelial and T-cells to target tumour-derived cells.170 
Additionally, enhanced viral replication of VSV has been observed in cancer cells with 
defective Ras-ERK and IFN pathways.171 However, the efficacy of VSV has been 
shown to be highly dependent on the type of cells. In PCa cell lines different 
sensitivity to VSV-infection was shown in LNCaP cells being more sensitive than PC-3 
cells.172 
 
1.2.7.f Myxoma Virus, Coxsackievirus and Newcastle Disease Virus (NDV) 
 
Additional studies showed that treatment with myxoma virus (a rabbit poxvirus), a 
double-stranded DNA of 160kbp is dependent on the overexpression of Akt for 
efficient propagation.140 Moreover, myxoma virus in combination with rapamycin 
enhanced viral replication in tumour cells but not in normal cells.173  In PCa cells, 
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various modified coxsackievirus strains, a 7kbp single stranded RNA virus, have also 
been effectively used. The coxsackievirus viruses A21 (CV A21) and the A21-
expressing the decay-accelerating factor (CV A21-DAFv) virus were used for systemic 
delivery in vivo, in PCa model with PC-3 and LNCaP xenograft tumour and were 
reported to cause tumour reduction, both viruses require the intercellular cell 
adhesion molecule 1 (ICAM-1) to infect cells.174 The A21-DAFv strain was generated 
from serial passages of CV-A21 strain in negative rhabdomyosarcoma (RD) cells 
negative for ICAM-1 and expressing DAF.174 The use of the non-pathogenic NDV as a 
therapeutic strategy was first reported in 1964 in patients with acute myelogenous 
leukaemia. NDV is an avian virus with a 16kbp single-stranded RNA genome that is 
highly limited systemically by immune-mediated clearance in humans.175 The 
oncolytic activity of the virus is thought to arise from the NDV-induced enhancement 
of systemic TNF-α secretion and the induction of sensitivity to TNF-α in neoplastic 
cells but not in normal tissue.155 The NDV tumour selectivity and viral replication 
derives from the interferon (IFN) defective pathway found in many tumours but not 
in normal cells.176 A deficient IFN pathway impairs tumour cell mechanisms of 
defence against viral agents causing these cells to be targeted for viral infection.176  A 
NDV virus with promising efficacy and proven safe is the 73-T virus, this virus was 
derived from a NDV strain that has been attenuated by 73 passages in vitro and 13 
passages in vivo in murine Ehrlich ascites tumour cells.177 The 73-T has shown 
efficacy inhibiting tumour growth in prostate (PC-3), epidermoid (KB8-5-11), colon 
(SW620, HT29 and MM17387), large cell lung (NCIH460) and breast (SKBR3) 
carcinoma xenografts.178 Another NDV strain, the PV701 that derives from the 
attenuated NDV MK107 strain,  has been used in phase I clinical trials for squamous 
cell carcinoma, peritoneal cancer, lung and liver solid tumours in which the virus 
showed only mild toxicity, where an antitumour response was observed only at high 
doses via intravenous.155,176,179 However, there are no current prostate cancer clinical 
trials with these virus strains. 
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1.3 MicroRNAs (miRNAs) 
1.3.1 Discovery of miRNAs 
 
There are many types of small RNAs including endogenous small interfering RNAs 
(siRNAs, Piwi-interacting RNAs (piRNAs) and microRNAs (miRNAs), that have been 
identified in many organism including plants, fungi and animals, where the main 
function is gene regulation through silencing and post-transcriptional regulation.180 
The main difference between miRNAs and other small RNAs is that miRNAs are 
derived from a distinctive hairpin structure.180 MicroRNAs are short non-protein-
coding RNA molecules of approximately 19 to 22 nucleotides that regulate genes at 
the translational level and are highly evolutionary conserved molecules.181 
MicroRNAs modulate important processes such as cell cycle, apoptosis, autophagy, 
cancer, diseases, metabolism, differentiation and development, tissue patterning and 
aging.182-184 MiRNAs were initially identified in Caenorhabditis elegans; the first ones 
discovered lin-4 (in 1993) and let-7 (in 2000).185,186 miRNAs account for 
approximately 1% of the mammalian genome regulating 30% of mammalian genes, 
and half of the known mammalian miRNAs are localized to highly conserved regions 
within introns of host genes and are co-expressed with these genes.187-190 Around 
80% of conserved vertebrate miRNAs are tissue specific, therefore, different patterns 
of miRNA expression can allow the identification of tumours of different origins and 
also to differentiate between tumours and normal tissue.191 
1.3.2 Biogenesis of miRNAs  
 
The miRNAs can be processed from transcripts either from independent genes or 
from introns of protein-coding genes (Fig. 14).192  
The miRNA biogenesis is a multi-step process where the miRNA genes are initially 
transcribed by the RNA polymerase II into a long transcript called primary miRNA or 
pri-miRNA (Fig.14).193 Pri-miRNAs can consist of hundreds to thousands of bases and 
are usually capped at the 5’-end and polyadenylated at the 3’ end. 194 Pri-miRNAs can 
have one or more secondary structures consisting of stem-loop structures, most 
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probably intermediates resulting from the process of maturation.195 Some miRNAs 
are produced individually from separate transcription units (mono-cistronic) while 
most miRNAs are produced from transcription units that generate more than one 
product (poly-cistronic) by transcribing clusters of distinct miRNAs.196  
Regardless of its mono- or poly-cistronic origin the transcription of pri-miRNAs is 
effectuated in the nucleus by the microprocessor complex (500-600 kDa) formed by 
Drosha (RNAase III endonuclease) and the cofactor DiGeorge syndrome critical region 
8 (DGCR8 or Pasha in flies and nematodes) (Fig. 14).197-200 The complex processes the 
pri-miRNAs into 70 to 80 nucleotide precursors miRNAs  (pre-miRNAs) with a 5’-
phosphate and a 3’ two nucleotide overhang, which folds into a mini-helical structure 
recognized by Exportin 5 (Exp5, member of the Ran transport receptor family) that 
allows pre-miRNA trafficking from the nucleus to the cytoplasm (Fig.14).201 In 
addition, pri-miRNAs can be processed independently of the microprocessor complex 
by the spliceosome from very short introns called Mirtrons and are originated from a 
single processed miRNA precursor although are not common (Fig.14).202  
 
 
Figure. 14. MicroRNA biogenesis. See text for explanation, modified from 203. 
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In the cytoplasm pre-miRNAs are processed by Dicer1 (an RNase III-like 
endonuclease; Dicer2 is only active in the cleavage of siRNAs) that recognizes at the 
Piwi/Argonaute/Zwille (PAZ) domain in the 3’-terminus of the pre-miRNA hairpin 
structure.204-206 Dicer1 forms a complex with the human immunodeficiency virus 
trans-activating response RNA-binding protein (TRBP or TARBP2) which is required to 
stabilize the interaction of Dicer1 with the pre-miRNA.207 The complex Dicer1-TRBP 
cuts the pre-miRNA structure at the end of the loop generating a duplex of 22 
nucleotides consisting of the mature strand miRNA and a passenger strand indicated 
by miRNA* (miRNA-miRNA* duplex)(Fig. 14).204-206 The miRNA duplex is then 
incorporated into the microRNA- or RNA-induced silencing complex (miRISC or 
RISC).208 The RISC complex is composed  by Argonaute protein (Ago, also called 
EIF2C1-EIF2C14 or Ago1-Ago4 209), the core protein within the complex in association 
with Dicer1 and TRBP, although Gemin3, Gemin4, Mov10, Imp8 and the glycine-
tryptophan protein of 182kDa (GW182) are also known to be part of this complex.196 
In RISC, the miRNA duplex is loaded onto an Ago protein where the two strands are 
separated.196 In RISC, the miRNA with less stable base pairing at the 5’-end remains 
associated with the Ago protein while miRNA* is unwound and degraded, the 
remaining mature miRNA is then guided by RISC to their targets.208,210 
 
1.3.3 Regulation of target genes by miRNAs 
 
The miRNAs regulatory mechanisms are very complex due to their capacity to 
regulate multiple gene targets, thus a single miRNA can target as many as 200 genes 
and multiple regulatory pathways.211 These miRNAs properties are a consequence of 
their imperfect complementarity to mRNA targets, which is a characteristic of their 
structure (Fig.14). Moreover, another miRNA recognition factor of mRNAs involves 
the Watson-Crick base pairing of the highly conserved nucleotides 2-8 in miRNAs, a 
region called the seed region or sequence that allows the miRNAs to bind to many 
potential targets.212 
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The pairing of miRNA-mRNA is mostly imperfect at the 3’-untranslated region (UTR), 
facilitating the translational repression of the gene, although the exact mechanism is 
still elusive. It is known that translational repression occurs during the ribosomal 
scanning of the 43S subunit and requires the poly(A) binding protein and eIF4G 
although physical interaction is not essential (Fig. 14).213,214 The pairing of 
nucleotides, although less common in mammals than plants, can also be perfect, in 
which case the mRNA is cleaved by Ago 2. There are four Ago proteins in mammals 
but only Ago 2 has cleavage activity in humans (Fig. 14).210,215  
The regulation of translation by miRISC starts with the recognition of the mRNA 5’-
terminal cap by eIF4E a subunit of the eIF4F complex. The subunits eIF4A and eIF4G 
are also part of the eIF4F complex.216 Another factor required for the initiation of 
repression is the eIF3 protein that interacts with eIF4G (through the eIF3e subunit), 
to recruit the 40S ribosomal subunit to the 5’-end, forming the 40S pre-initiation 
complex.212,216 The pre-initiation complex binds afterwards to the 60S ribosomal 
subunit to begin elongation at the AUG codon. The subunit eIF4g also interacts with 
the polyA-binding protein PABP1 that interacts with the 3’-end.217,218 The ability of 
eIF4G to interact with eIF4E and PABP1 causes the mRNA molecule to circularize.216 
The circularization of the mRNA molecule increases translational efficacy.219 
Processing bodies (P-bodies or glycin-tryptophan or GW-bodies in mammals) that are 
cytoplasmic structures involved in the storage and degradation of mRNA are also 
thought to be involved in miRNA regulation. The targeted gene (mRNA) and the 
miRNAs are guided in combination with RISC to the GW-bodies structure (Fig.14).220 
At miRISC translation is inhibited at the post-initiation stage by inhibition of the 
ribosome elongation.216 The mRNA then decays after the inhibition of ribosome 
elongation in a sequential process initiated by the interaction of miRISC with CCR4-
NOT complex facilitating the poly(A) tail deadenylation by PAN2-PAN3 denyalases 
(Fig 14), afterwards, m7G is removed and degradation of mRNA is effectuated by 
Xrn1 5’-3’ exonuclease.216  
However,  the outcome of the miRISC regulatory mechanism is downregulation of 
protein expression but not necessarily the downregulation of mRNA levels.221  
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1.3.4 The roles of miRNAs in cancer 
 
MicroRNAs are involved in key regulatory mechanisms within cellular pathways.184 
Therefore, it has been suggested that miRNAs can be involved in the regulation and 
development of tumourigenesis.182 Since the role of miRNAs is regulation of protein 
expression, changes in miRNA levels have been associated with cancer. For example, 
chromosomal localization of miRNAs at fragile chromosome sites or regions of 
frequent chromosomal instability (e.g. amplification, translocation or deletions) that 
have been associated with cancer account for nearly 52% of miRNA genes.222 Among 
the miRNAs whose deregulation have been implicated in human malignancies, the 
deletion of hsa-let-7 family has been associated with breast, lung and ovarian 
cancer.222 Moreover, amplification and translocation of the hsa-miR-17-92 cluster 
has been associated with lymphoma and T-cell acute lymphoblastic leukaemia, 
respectively.223 The amplification of hsa-miR-26a has been associated with 
glioblastoma.223 miRNAs can be divided according to the respective functions in 
cancer, as tumour suppressors (hsa-let-7 family and hsa-miR-15a/16),224,225 or 
oncogenes (hsa-miR-17-92 cluster and hsa-miR-hsa-miR-21 226,227) or both depending 
on the type of cancer.228 
Other potential mechanisms that directly contribute to a role of miRNAs in cancer 
are mutations in miRNA-containing genes and/or in the 3’UTR binding sites, and/or in 
pathways that regulate their expression during biogenesis and/or alterations of the 
number of copies of miRNAs that are expressed.228,229 Alterations in the miRNA 
expression patterns also have been demonstrated to define each specific type of 
cancer.191 Functional studies of individual miRNAs demonstrated that they can act 
both as oncogenes (oncomiRs) or tumour suppressors.230 
The miRNA signatures for tumours derived from different cellular origins seems to be 
unique, enabling the classification and matching of expression profiles to specific 
human cancers, and possibly to the grade of malignancy.231 Therefore patterns of 
miRNA expression can be an important ontogenetic source of information for 
tumours in addition to the expression profiling from mRNA microarray analysis.191 
Unique patters of expression of miRNAs offer information-rich signatures for cancer 
diagnosis, disease prognosis, treatment-responses and survival, prediction of 
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responses to therapy, and will potentially generate tools to delineate cellular 
pathways for more efficient targeting of novel cancer therapeutics.232,233  
 
1.3.5 The role of miRNAs in prostate cancer 
 
The roles of miRNAs in prostate cancer were first evaluated by Porkka in 2007, since 
then other studies have verified the implications of miRNAs in tumour progression or 
inhibition.234-238 In prostate cancer many miRNAs are differentially expressed, 
frequently those miRNAs are involved in the deregulation of anti- or pro-carcinogenic 
pathways. Many miRNAs studied in PCa were reported to exhibit a different 
expression pattern dependent on the study. Those inaccuracies were due to the type 
of study carried out, the cell lines, the type of tissue and the sample size.239   
As in other types of cancer, the deregulation of miRNA expression levels can trigger 
prostate cancer. Dicer, one of the miRNA processing regulators, has been shown to 
be upregulated in PCa in a direct correlation with the clinical stage of Gleason 
score.240 There are many deregulated miRNAs that have been implicated in prostate 
cancer either as oncogenes including hsa-miR-221/-222, hsa-miR-21, and hsa-miR-
125b or tumour suppressors including hsa-miR-101, hsa-miR-126, hsa-miR-146a, hsa-
miR-330, hsa-miR-34, and hsa-miR-200 (Table 5).241 It is known that the expression-
profiles of miRNAs are highly tissue specific, although miRNAs can also be 
differentially deregulated within the same tissue, which is the case for the PC-3, 
LNCaP and DU145 cells that are all derived from prostate cancer tissue. While LNCaP 
and DU145 cells express hsa-miR-200c and hsa-miR-141, PC-3 cells have lost the 
expression of these miRNAs.242 One miRNA that is implicated in PCa progression and 
resistance to hormone ablation treatment is the AR-induced overexpression of hsa-
miR-21, although the mechanism is not clear in glioblastoma cells it has been shown 
that p53, TGF-β and mitochondrial apoptosis tumour suppressor genes are targeted 
by hsa-miR-21 inducing proliferation.243,244 The androgen-dependent- overexpression 
of hsa-miR-125b in PCa cells induces proliferation and inhibition of apoptosis by 
targeting Bak.245 The screening of the expression of miRNAs in prostate cancer might 
aid in elucidating the mechanisms behind treatment resistance, to more specifically 
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target factors that are important regulators of this mechanisms and for developing 
biomarkers for prognosis and treatment outcomes. For example, LNCaP cells treated 
with resveratrol showed that commonly overexpressed miRNAs in prostate cancer 
such as the hsa-miR-17-92 cluster and hsa-miR-106a were downregulated.246 These 
miRNAs have been shown to have a strong anti-apoptotic activity when 
overexpressed, by interfering in MYC, PTEN and p21 pathways.247,248  
 
Table 5. Selected deregulated miRNAs identified in various cancers. 
 
Tumour suppressor (TS), oncogenic (OG); chronic lymphoid leukaemia (CLL).203,228   
1.4 Apoptosis 
 
The term apoptosis was first introduced in 1972249 to describe a well regulated 
evolutionary conserved type of programmed cell death distinct from necrosis. Both 
processes can occur sequentially, independently or simultaneously.250 It is important 
to distinguish the different mechanisms of programmed cell death since cytotoxic 
stimulus at certain doses can induce apoptosis but at higher doses can induce 
necrosis.251 The characteristics of apoptotic cell death are defined by cell shrinkage, 
membrane blebbing, nuclear condensation and fragmentation, the dispersion of 
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cellular components into apoptotic bodies, caspase activation and 
phosphatidylserine redistribution to the extracellular surface.252 249,253 Most of the 
current knowledge of apoptosis in mammalian cells is derived from the initial 
findings in the nematode Caenorhabditis elegans.254 Apoptosis is a homeostatic 
mechanism that serves to maintain cells and tissue during aging, development and as 
a defence to preserve the integrity of tissues with damaged cells caused by extrinsic 
factors such as infection of cytotoxic agents.255 Apoptosis occurs through two main 
pathways, the extrinsic pathway that involves the activation of cell surface receptors 
by external signals and the intrinsic pathway that is activated by death signals within 
the cell however, both pathways converge in the activation of caspases. 256  
  
1.4.1 Regulation of Apoptosis: extrinsic and intrinsic pathways 
1.4.1.a Extrinsic Pathway 
 
The extrinsic pathway is triggered by the activation of death receptors including the 
tumour necrosis factor receptor (TNFR) superfamily members CD95/FasR, TNFR1 and 
TNF-related apoptosis-inducing ligand-1 and 2 (TRAILR1 and TRAILR2) by the 
respective death ligands CD95L/Fas ligand (FasL), TNF-α, lymphotoxin-α and 
TRAIL.257,258 The common characteristics of the TNFR superfamily members are the 
cysteine-rich extracellular domain and an intracellular cytoplasmic death domain. 259 
The binding of ligands to their receptors induces the clustering of receptors and the 
trimerisation of ligands, triggers the recruitment of adaptor molecules in the 
cytoplasm to form the death-inducing signalling complex (DISC) (Fig. 15).182,183 The 
formation of DISC involves the activation and recruitment of pro-caspase-8 that by 
auto-cleavage forms caspase-8 (Fig. 15).260,261 Furthermore, cell death activation via 
Fas, TRAILR1 and TRAILR2, requires the recruitment of FAS-associated death domain 
(FADD) to DISC in addition to caspase-8.258,262 However, TNFR1-induced cell death 
causes the recruitment of TNFR-associated death domain (TRADD) and TNFR-
associated factor-2 (TRAF2).257,258,262 The formed DISC then induces three separate 
cell death pathways. The first pathway is induced by caspase-8 by proteolytic 
cleavage of the Bcl2 homology-3 (BH3)-only protein (Bid), subsequently Bid is 
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translocated to the mitochondria where it activates the mitochondria outer 
membrane permeabilisation (MOMP) process (Fig. 15).261,263 The second pathway is 
induced by direct activation of caspases where the effector caspases 3, 7 or caspase-
6 are targeted leading to cell death (Fig. 15).258,263 The third pathway is activated only 
in T cells and involves the activation of the receptor-interacting protein kinase-1 
(RIPK1).264  
 
Figure 15. Apoptosis: Extrinsic and intrinsic pathways. Apoptosis is led by the action of two 
pathways: The extrinsic and the intrinsic pathways. The extrinsic pathway involves the 
stimulation of death receptors of the tumour necrosis factor receptor superfamily by their 
respective ligands such as CD95/Fas, TNFR or TRAILR. The stimulation of death receptors 
induces the recruitment and activation of caspase-8 by FADD and TRADD to form DISC. 
Moreover, DISC in consequence can led to the proteolysis of BID inducing the translocation 
of truncated BID to the mitochondria triggering MOMP, or directly induced down-stream 
effector caspases. The intrinsic pathway involves the activation of MOMP and in 
consequence the release of cyt-c, resulting in the assembly of the apoptosome, a complex 
formed by caspase-9 and APAF1 that induces the down-stream effector caspases. Moreover, 
MOMP can be induced by BH3-only proteins in response to cell stress and DNA damage. The 
BH3-only proteins induce the oligomerization of Bax and/or Bak enabling the release of 
mitochondrial from the intermembrane space resulting in the activation of down-stream 
effector caspases. In the DNA damage response p53 is stabilize resulting in the activation of 
PUMA and NOXA to promote MOMP. Alternatively, the DNA damage response can also 
induce MOMP through the activation of caspase-2 that in association with PIDD and RAIDD 
form the piddosome, in consequence the piddosome activates MOMP. However, caspase-2 
can directly induce the activation of down-stream effector caspases.  Modified from 265.    
 
66 
 
1.4.1.b Intrinsic Apoptotic Pathway 
 
The intrinsic pathway is triggered by intracellular stimuli, in response to oxidative 
stress and DNA damage, radiation, toxins, hypoxia, hyperthermia, viral infections.266 
These cell insults induce the activation of MOMP which comprises the loss of 
mitochondrial-trans-membrane potential, by opening the membrane permeability 
transition (MPT) pores.267 Thus, MOMP triggers the release of mitochondrial 
cytochrome-c (cyt-c), activating the apoptotic downstream machinery resulting in 
the assembly of the caspase activating complex called apoptosome (Fig. 15). The 
apoptosome composed by cyt-c and the apoptotic-protease-activating-factor-1 
(Apaf-1) recruits and activates caspase-9 (Fig. 15).266,268 The activation of caspase-9 in 
consequence cleaves and prompts caspase-3, -6 or-7 leading to the cleavage of other 
cellular targets including the poly-adenosine diphosphate ribose (ADP)-polymerase 
(PARP) and the inhibitor of caspase-activated DNAse (ICAD).269 The breaking of ICAD 
releases CAD favouring the degradation of DNA fragments; meanwhile, the cleavage 
of laminin takes place by caspase-6, ultimately leading to cell dismantling and nuclear 
collapse.270 In addition to cyt-c, other factors are released from the mitochondria 
during MOMP such as the second mitochondria-derived activator of caspase 
(Smac)/direct inhibitor of apoptosis protein (IAP)-binding protein with low isoelectric 
point  (DIABLO) and high temperature requirement protein A2 (HTRA2/OMI), these 
factors shield caspase activity by attenuating caspase inhibitors such as X-linked 
inhibitor of apoptosis protein (XIAP).271-273  
MOMP is regulated by the interaction of pro- and anti-apoptotic members of the B-
cell Lymphoma 2 (Bcl-2) family that are classified according to their Bcl-2 homology 
(BH) domain.267 The members of the Bcl-2 family that have the BH1-BH3 domains 
such as Bcl-2-antagonist killer (Bak), Bcl-2–associated X protein (Bax) and BCL2-
related ovarian killer (Bok), are the pro-apoptotic effectors of MOMP. In contrast, 
BH1-BH4 members Bcl-2, B cell lymphoma-2-like X isoform L (Bcl-XL) and Bcl-w bind 
to Bax and Bak inhibiting their function, therefore blocking apoptosis and inducing 
cell survival.267,274 BH3-only family members such as   Bid, Bad, Bim, Bik, BNIP3, BMF, 
HRK, Noxa and Puma can be phosphorylated, cleaved or relocated to promote 
MOMP (Fig. 15). BH3-only proteins induce MOMP by promoting the oligomerization 
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of Bax and/or Bak in the outer mitochondrial membrane generating channels to 
allow the release of mitochondrial proteins and proceed with apoptosis in response 
to cell stress or infection.267,274,275 BH-3 family members can also induce MOMP by 
inhibiting anti-apoptotic effectors such as Bcl-2 within a pro-apoptotic response.267  
Alternatively, p53-stabilization in response to DNA-damage induces the activation of 
Puma and Noxa triggering MOMP and inducing apoptosis.276 In addition, the 
formation of the complex termed piddosome composed by p53-induced-protein with 
a death domain (PIDD) and RIP-associated protein with a death domain (RAIDD) in 
response to DNA-damage induces the activation of caspase-2 consequently 
promoting MOMP or direct caspase activation.277 Although the extrinsic and the 
intrinsic apoptotic pathways are clearly defined, they are not mutually exclusive 
processes.278 
 
1.4.2 Apoptosis and cancer 
 
One of the main factors that enable cancer progression is the deregulation of the 
apoptotic pathways. The link between apoptosis and cancer was first established by 
the induction of apoptotic cell death in response to radiotherapy in 1972 and was 
reinforced by the recognition of Bcl-2 as a proto-oncogene as part of the t(14:18) 
chromosome translocation in B- cell lymphoma that enabled prolonged survival of B-
cells by inhibition of apoptosis.249,279-281 There are many key apoptotic factors that 
can be deregulated during cancer progression like overexpression of Bcl-Xl and the 
downregulation of Bax and Bak, although these alterations may not be enough to 
promote cancer by its own and might require additional genetic alterations. 282-285   
One main regulator within the apoptotic pathway is the transcription factor p53 that 
regulates cell cycle arrest, apoptosis and DNA-damage repair functions. p53 induces 
apoptosis through transactivation of BH-3 family members including Bax, Bid, Puma 
and Noxa that induce MOMP and the release of apoptotic mitochondrial factors from 
the inter-membrane space and also by trans-repressing Bcl-2.275,286,287  
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1.4.3 MicroRNA regulation of apoptosis 
 
How miRNAs regulate apoptosis is still under investigation. However some evidence 
indicates that miRNA regulation of apoptosis depend on the cell environment and 
context.288 The regulation of apoptotic pathways by a single miRNA can induce two 
opposite responses depending on the cell type and tissue, for example, the inhibition 
of hsa-miR-24 increased cell growth in HeLa cells (cervical carcinoma) and in contrast 
decreased cell growth in A549 cells (lung carcinoma).184 In addition, several miRNAs 
are regulators of key apoptotic factors such as caspase-3, where hsa-miR-1d, hsa-
miR-148, hsa-miR-204, hsa-miR-210, hsa-miR-216 and hsa-miR-296 induce an 
increases in caspase-3 activity. In contrast, hsa-miR-214 inhibits capsase-3 activity.184 
Other factors include Bcl-2 activity which is post-transcriptionally regulated by hsa-
miR-15 and hsa-miR-16, most probably by direct binding to Bcl-2 mRNA. Inhibition of 
hsa-miR-15 and hsa-miR-16 resulted in increased Bcl-2 levels inducing proliferation 
evading, additionally, the c-Myc-regulated hsa-miR-17-cluster can induce cell 
proliferation and evade the apoptotic response.248,289 Furthermore, the miRNAs hsa-
miR-221/222 have been implicated in the reduction of caspase-3 and caspase-8 in 
TRAIL-sensitive cells favouring cell survival, in addition to the proto-oncogene Kit and 
tumour suppressor p27kip.289-291 Other studies have shown regulation of Pro-
apoptotic Programmed Cell Death 4 (PDCD4) by hsa-miR-21 in colorectal and breast 
cancer.292 In response to DNA-damage p53 can up-regulate hsa-miR-34 promoting 
cell death.230 The regulation of apoptosis by miRNAs and their de-regulation during 
cancer progression makes them interesting targets for investigating the mechanisms 
of cancer progression and therapy resistance. 
 
1.5 Autophagy 
 
Eukaryotic cells have developed throughout evolution a well conserved homeostatic 
and catabolic process named autophagy (self-eating)293 that enables cells to degrade 
their own cellular organelles and proteins allowing cellular biosynthesis under 
conditions of nutrient deprivation or metabolic stress.294 There are three autophagic 
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processes that have been described and characterized: macroautophagy, 
microautophagy and chaperone-mediated autophagy.295 Microautophagy is referred  
as the process where the cytoplasm is sequestered by invagination of the lysosomal 
or vacuolar membranes and is the least characterized of the three.295 The chaperone-
mediated autophagy is considered as a secondary response to starvation involving 
the direct translocation of target proteins through the lysosomal membrane.295 
Macroautophagy (hereafter referred to as autophagy), is the most studied of the 
autophagy mechanisms and involves sequestration of cytoplasm and intracellular 
organelles by cytosolic double- or multi-membrane autophagic vacuoles 
(autophagosomes). Autophagosomes fuse with lysosomes and the content is 
degraded.265,295 
 
1.5.1 Initiation and regulation of Autophagy 
 
The regulation of autophagic flux (the complete process of autophagy) is performed 
by a set of genes called autophagy-related genes (ATG) that were initially identified 
in yeast.296,297 The genes have been shown to be highly conserved among organisms 
and many homologues of these genes have been identified in higher eukaryotes 
including Caenorhabditis elegans,  Drosophila  melanogaster, mouse and man.297 
Autophagy is a multi-step process that can be divided into initiation, formation of 
autophagosomes (where the vesicle nucleation, elongation and completion are 
carried out), maturation and degradation.298 
In mammalian cells the initial autophagic steps are regulated by a Serine/threonine-
protein kinase complex, which consist of the human orthologues of ATG1 or ULK1/2 
(Unc-51-like kinase), ATG13 and the scaffold protein FIP200/RB1CC1 (Focal adhesion 
kinase family interacting protein of  200kDa; human orthologue of Atg17) (Fig. 
16).297,298 In addition to ULK1/2-ATG13-FIP200-complex, a second complementary 
regulatory conglomerate is formed by the human orthologues of vacuolar protein 
sorting 34 (hVps34) that is a class III phosphatidylinositol-3-kinase (PI3K-III) and by 
ATG6/ Bcl-2-interacting myosin- like coiled-coil protein-1 (Beclin-1; 60kDa) (FIG. 
16).299 The ULK1/2-ATG13-FIP200-complex collects stress signals that come from the 
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nutrient-sensing mammalian target of rapamycin Ser/Thr kinase complex 1 (mTOR 
Ser/Thr kinase complex 1 or mTORC1) (Fig. 16).298,300 The serine/threonine kinase 
protein mTOR of nearly 300kDa is part of the phosphatidylinositol kinase-related 
kinase (PIKK) family.301 mTOR was first described in 1991 as a target protein of the 
immunosuppressant and fungicidal drug rapamycin.302 mTOR forms two complexes, 
where mTOR is associated with the regulatory-associated protein of mTOR 
(Raptor;KOG1 ortholog), GbL/mLst8, PRAS40 and DEPTOR to form the mTORC1. 
Alternatively mTOR binds to the rapamycin-insensitive companion of mTOR (Rictor; 
Avo3 ortholog), GbL/mLst8, Sin1 (Avo1 ortholog), PRR5/protor and DEPTOR to form 
mTORC2.301,303  
The mTORC1 can be activated by growth signalling pathways like the insulin/insulin-
like growth factor (IGF-1)-PI3K-I (phosphatidylinositol 3-kinase class I)-Akt pathway 
and by high nutrient status. The protein kinase Akt and sufficient nutrient conditions 
positively regulates mTORC1, inducing phosphorylation and inhibition of ATG13 and 
ULK1/2, inhibiting autophagy.301 In addition, inhibition of mTORC1 by PTEN and TSC2 
or under starvation conditions, mTOR dissociates from ULK1.301 The inhibition of 
mTORC1 blocks the mTORC1-dependent phosphorylation of ATG13 and ULK1/2, 
inducing the activation of ULK1/2 (Fig. 16).304 Autophagy is induced by ULK1/2-
dependent phosphorylation of ATG13, FIP200/RB1CC1 and ULK1/2 auto-
phosphorylation.298,300,304 The auto-phosphorylation of ULK complex induces its 
accumulation, triggering vesicle formation by the formation of the isolation 
membrane or phagophore (Fig. 16).304  
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Figure 16. Autophagy flux. Autophagy starts with the de-repression of the mTOR Ser/Thr 
kinase, which inhibits autophagy by phosphorylating Atg13. The phosphorylation dissociates 
Atg13 from the ULK1/2 and FIP200 protein complex attenuating ULK1/2 kinase activity. In 
contrast, the inhibition of mTOR triggers the de-phosphorylation of Atg13, enabling the 
reconstitution of the Atg13-ULK1/2-FIP200 complex. Moreover, autophagy continues with 
vesicle nucleation where hVps34 is activated forming a multi-protein complex with Beclin-1, 
UVRAG and Vps15. There are two pathways involve in vesicle elongation. In one, Atg12 to 
Atg5 are conjugated in a process mediated by the E1-like enzyme Atg7 and the E2-like 
enzyme Atg10. The second involves the conjugation of PE to LC3B-I by the sequential action 
of Atg4, the E1-like enzyme Atg7 and the E2-like enzyme Atg3. The lipid conjugation of LC3B-I 
causes the conversion of LC3-I to the autophagic-vesicle-associated form LC3-II. The 
mechanism of retrieval mediated by the Atg9 complex is poorly understood. The maturation 
of the autophagosomes involves the fusion with lysosomes to create autolysosomes. In the 
autolysosomes, the content is degraded by lysosomal enzymes that required acidic 
conditions. The sites of inhibition and autophagy-flux inhibitors are marked by red arrows. 
Endoplasmic reticulum (ER), trans-golgi-network (TGN). Modified from 265 
    
1.5.2 Formation, maturation and degradation of the Autophagic vesicles 
 
The formation of autophagosomes occurs by the interaction of four groups of 
assembled proteins: the Atg1/Unc-51-like kinase (ULK) complex; the conjugation 
system composed of two ubiquitin-like proteins (Atg12 and LC3); the class III 
phosphatidylinositol 3-kinase (PI3K)/hVps34 complex; and two trans-membrane 
72 
 
proteins Atg9 associated and Atg18.305 The protein complexes are recruited at the 
phagophore assembly site (PAS) in the cytoplasm.305 The development of the 
isolation membrane or phagophore depends on the activation of hVps34 or PI3K-III, 
to generate phosphatidylinositol-3-phosphate (PI3P).298,306 The activation of hVps34 
depends on the formation of another complex that contains beclin-1, UV irradiated 
resistance-associated tumour suppressor gene (UVRAG) and the myristylated kinase 
hVps15 (p150/; PIK3R4; yeast Vps15).298,307 Beclin-1 initially discovered as a Bcl-2 
direct interacting protein is a protein linked to the trans-Golgi network (TGN) that 
provides the phagophore with membrane sources in addition to the endoplasmic 
reticulum.308,309 The release of beclin-1 from Bcl-2 is driven by the mammalian 
vacuole-membrane-protein-1 (VMP1), the binding of beclin-1 and VMP1 in addition 
to hVps34 is essential for the integration of the PI3K-III complex and where VMP1 is 
essential in subsequent steps of the vesicle elongation.310 However, Beclin-1 is also 
involved in other cellular functions including endocytic trafficking, phagocytosis, 
cytokinesis and in development. The regulation of gene expression of Beclin-1 is 
driven by FOXO3 and HIF1α.309 The vesicle elongation process that generates the 
autophagosomes is mediated by the Atg12-5-16 complex.298 Throughout the 
formation of the complex the ubiquitin-like protein ATG12 is activated by ATG7 (an 
E1-like enzyme) and binds to the E2-like enzyme ATG10, before being transported to 
ATG5 (Fig. 16). Furthermore, ATG5 binds directly to the membrane, however, this 
binding is negatively regulated by ATG12 and activated by ATG16 (Fig. 16).311 
Furthermore, the interaction of ATG16 with ATG5 induces oligomerization to form 
ATG16L that associates to form the ATG12-5-16 complex (Fig. 16).312 The second 
system involves the conjugation of ATG8 or microtubule-associated protein 1A/1B-
light chain 3 (LC3 or GATE16 and GABARAPL1 mammalian orthologues of yeast Atg8) 
by an action in cascade of proteases ATG4, the E1-enzyme-like Atg7 and the E2-
enzyme-like Atg3 (Fig. 16).265,298 The microtubule-associated protein 1A/1B-light 
chain 3 (LC3) was initially described as a microtubule-associated protein 1A and 1B in 
rat brain, LC3B is present in two forms identified as LC3B-I and LC3B-II at 18 and 16 
kDa respectively.313 LC3B-II has increased electrophoretic mobility that causes the 
apparent size of 16kDa on SDS-PAGE gel while the molecular weight is higher than 
that of LC3-I.313,314 Following synthesis, LC3B is immediately processed by ATG4 from 
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the precursor protein proLC3 by cleavage at the C-terminal Gly-120 amino acid.315 
During autophagic flux the cytosolic soluble form LC3B-I is further processed by ATG3 
and ATG7 inducing a reversible lipid conjugation with phosphatidylethanolamine (PE) 
to generate the autophagy-vesicle associated form LC3B-II.305 The ATG12–ATG5–
ATG16 complex targets LC3B-II to the phagophore membrane and is essential for the 
formation of autophagosomes.311 Moreover, the site of autophagosomes formation 
is conducted at the endoplasmic reticulum (ER)-mitochondria contact site in 
mammalian cells.316 The ER-mitochondrial contact sites regulate mitochondrial 
biogenesis and intracellular trafficking.317  The regulation of the phagophore-
elongation process to form the autophagosomes is tightly regulated by LC3B-II, 
therefore, the amount of LC3-II is directly correlated with the extent of 
autophagosome formation.265,298,314 The process of autophagosome maturation 
involves fusion of the autophagosomes with the lysosome in a multistep process.297 
The maturation process starts with the fusion of early endosomes vesicles forming 
multi-vesicular endosomes that successively fuses with autophagosomes generating 
amphisomes that finally merges with lysosomes.297  The maturation of the 
autophagosomes and subsequent fusion to lysosomes occurs only in the presence of 
the lysosomal proteins LAMP1 and LAMP2, the small GTPase Rab7 (RAB7A).297 The 
UVRAG protein targets RAB7 to the autophagosomal membrane facilitating the 
maturation events of the autophagosomes.318 The autophagosomes when formed 
have the same pH as the surrounding cytoplasmic environment although while 
merging to the lysosomes the internal pH of the autolysosomes becomes acidic, due 
to the presence of proton pumps rather than lysosomal enzymes.297 Prior to the 
fusion of autophagosomes to lysosomes the conjugated LC3B-II is removed from the 
outer membrane of the autophagosomes.319 Furthermore, LC3B binds to the protein 
p62/SQSTM1. The protein p62/SQSTM1 regulates the packing and delivering of 
polyubiquitinated unfolded proteins as part of the ubiquitination process of cargo 
proteins. Also is responsible for the clearance through autophagy of aggregated 
proteins, dysfunctional organelles and of toxic aggregates.320 The binding of 
p62/SQSTM1 with LC3B induces the formation of p62 aggregates which are 
sequestered into autophagosomes (Fig. 16). The formation of the autolysosome 
induces the degradation of the cargo and p62/SQSTM1 aggregates, however when 
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autophagy is impaired the p62/SQSTM1 aggregates and other ubiquitin-positive 
aggregates accumulate, making p62/SQSTM1 a suitable marker for autophagy-flux.321 
Within the autolysosomes the intracellular content is degraded by cathepsins 
(lysosomal hydrolases) that act optimally within the acidic compartment. The 
catabolically generated molecules (amino acids and other materials) are released 
from the autolysosome and incorporated into anabolic pathway.322,323 The inner 
membrane as well as the luminal content of the acidic vesicle then is degraded by 
lysosomal enzymes completing the autophagy flux.324  
Depending on the conditions autophagy can be either a pro-survival or a cell death 
mechanism, suggesting that autophagy is tightly connected to cell death and survival 
pathways and that the balance of homeostasis can be disrupted depending on 
stimulus. Moreover, experimental conditions can also induce or prevent autophagy, 
frequently resulting in contradictory reports which indicate that autophagy is a far 
more complex process than previously appreciated.  
 
1.5.3 Autophagy in cancer 
1.5.3.a The role of autophagy in promotion  of  tumourigenesis 
 
In normal human cells autophagy is a conserved process that is activated in order to 
maintain homeostasis within the cellular environment in response to metabolic 
stress to promote cell survival. It has been suggested that in cancer cells autophagy 
inhibits cell death pathways acting as an environmental adaptor enabling cancer cell 
proliferation.265 The evidence of the autophagy-induced stress tolerance within a 
tumour environment are considerable in both in vivo and in vitro models.298 Within 
the tumour environment unfavourable conditions such as nutrient deprivation and 
hypoxia may lead to autophagy activation and cellular survival by increased 
biosynthesis or catabolism and removal of high-energy consuming organelles.265 
Under hypoxic conditions autophagy can be induced by HIF-1α-dependent or 
independent activation, leading to mitochondrial degradation (mitophagy).325 
Mitophagy can induce cell survival either by reducing energy consumption or by 
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reducing the susceptibility of cells to mitochondrial outer membrane 
permeabilisation (MOMP) that induces apoptosis, a mechanism where ATG7 and 
ATG1 seem to be essential.265,326 Increased basal levels of autophagy have been 
described in several types of cancer cell lines and tumour tissue from breast, renal 
and pancreatic cancers.327-331 The first evidence of the involvement of autophagy in 
cancer progression and development was the observation that incidence of a mono-
allelic deletion of Beclin-1 (Becn1) was near 50% in breast, leukaemia, lymphomas, 
lung and liver tumours, and that complete deletion induced the impairment of 
autophagy.332 Moreover, in a breast cancer model with impaired autophagy due to 
the deletion of one allele of Beclin-1 was shown to induce cytoprotective mechanism 
that was overcome by reintroducing normal Beclin-1 restoring autophagy and Beclin-
1 tumour-suppressor activity.298,333 Other studies have shown that tumour 
promotion, genomic instability and aneuploidy are induced by the loss of 
autophagy.333 Furthermore, homozygous depletion of ATG7-/- and ATG5-/- is sufficient 
for tumour initiation however, not for tumour progression.334,335 Tumour formation 
has been observed in models of impaired autophagy and  p62/SQSTM1 
overexpression and is inhibited by re-established autophagic flux and p62/SQSTM1 
degradation.336 Additionally, increased tumourigenesis was observed when BIF1 and 
UVRAG failed to bind Beclin-1 induced either by abrogation or allele deletion, 
inducing downregulating of autophagy.298 Furthermore, necrosis-induced 
inflammation causes the secretion of growth factors to the tumour 
microenvironment promoting tumour-proliferation; this mechanism of cell survival 
was triggered in response to Akt-dependent inhibition of autophagy and the 
blockage-apoptosis-induced necrosis.337 However, autophagy also induces cell death 
(ACD, autophagic cell death).265 
1.5.4 Autophagy induces cancer cell death: Crosstalk between autophagy 
and apoptosis  
 
There are two cell death mechanism induced by autophagy, the less common self-
destructive autophagy or type-II programmed cell death where massive autophagy 
degrades the cytosol and organelles, inducing irreversible atrophy, damage and 
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consequently cell death. Type-I programmed cell death, where autophagy induces 
necrosis or apoptosis.265  
Type-II autophagic cell death or massive autophagy is a cell death mechanism which 
is not well understood.265 However, it has been reported that a Bax and Bak double-
knockout murine model the inhibition of apoptosis induced by DNA-damage 
triggered massive autophagy in embryonic fibroblasts, therefore inducing cell 
death.338 Nonetheless, the induction of massive autophagy was only shown when 
DNA-damage was induced, and no other apoptotic stimulus induced massive 
autophagy.338 In contrast, the knockout of the essential autophagic genes Atg5 and 
beclin-1 reduced cell death.338  
In type-I programmed cell death, autophagy causes cell death by necrosis or 
apoptosis dependent on the stimulus.265 There are many stimuli that induce both 
autophagy and apoptosis, like reactive oxygen species (ROS) that can induce the pro-
apoptotic MOMP and stimulate the proteolysis of ATG4 also stimulating 
autophagy.339 Moreover, p53 has been shown to be a linking factor between 
autophagy and apoptosis. The activation of p53, induced the inhibition of mTOR via 
the 5'-adenosine-monophosphate-activated protein kinase (AMPK) and the tumour 
suppressor tuberous-sclerosis-1 (TSC1) and TSC2, consequently inducing 
autophagy.277 Additionally, induction of autophagy through activation of p53, is 
mediated by the damage-regulated autophagy modulator (DRAM). Furthermore, it 
was also demonstrated that DRAM could be trans-activated by p53 and was essential 
in p53-mediated apoptosis.278 It was also demonstrated in T-cells, apoptosis was 
induced after initial stimulation of autophagy.340 In contrast, inhibition of the 
autophagic regulators Beclin-1 and ATG-7 resulted in impaired apoptosis.340 In 
addition, the apoptosis-inhibitor Bcl-2 inhibits Beclin-1-dependent autophagy in 
mammalian cells by binding to Beclin-1, showing that Bcl-2 acts as a shared regulator 
of apoptosis and autophagy.341 Furthermore, in glioma cells overexpression of Bcl-2 
inhibits autophagy through Beclin-1 and the Akt-mTOR pathways.342 In the context of 
inflammation, it was shown that the re-establishment of autophagy inhibited by Akt 
induced apoptosis or autophagic cell death as a consequence of metabolic stress.337 
The autophagy regulator ATG5 has been shown to have a dual role in autophagy and 
apoptosis, the cleavage of ATG5 by calpains triggers ATG5-pro-apoptotic functions. 
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Moreover, ATG5 lost its autophagy activity by translocation to the mitochondria 
where it inhibits Bcl-xL facilitating MOMP and inducing a caspase dependent 
apoptosis through interacting with Fas-associated via death domain (FADD).343 
Additionally, the overexpression of ATG5 induces autophagy and enhances 
susceptibility to apoptosis with doxorubicin.343  
 
1.5.5 Adenovirus infection and autophagy 
 
Also important, are the implications of viral infection on autophagy where different 
studies have shown that viral infections induce contrasting outcomes in autophagy. 
For example, it was reported that infection with wild type adenovirus (Ad5) strongly 
induced autophagy, seen by an increase in the conversion of LC3B-I to LC3B-II and 
the formation of the complex ATG12-ATG5 in lung cancer cells.344 In addition, Ad5 
induced autophagy in cervical and colon cancer cells.344 The inhibition of autophagy 
in lung cancer cells by the inhibitor 3-methyladenine (3-MA; inhibitor PI3K-III) 
decreased Ad5 viral replication.344 Another study in ovarian cancer cells showed that 
infection with dl922-947 induced autophagy as a survival mechanism, in contrast, the 
combination with cisplatin showed a caspase-3-independent apoptosis-like cell death 
mechanism.345 A previous study with glioma cells showed that infection with a 
replication selective adenovirus expressing the human telomerase reverse 
transcriptase (hTERT-Ad) induced autophagy-like cell death and no apoptosis; 
additionally, infection with hTERT-Ad induced autophagy in PCa cells (PC-3).346 
Recently, another study showed that infection of glioma cells with Ad5 and the 
oncolytic adenovirus Ad-∆-24-RGD (Ad∆24, CR2-deletion; RGD, Arg-Gly-Asp-motif 
inserted in the fiber protein gene) induced complete autophagy-flux. Viral induction 
of autophagy promoted cell lysis. Moreover, inhibition of ATG5 and ATG10 reduced 
viral-induced cell lysis. Furthermore, it was suggested that cell lysis was also 
supported by the activation of the extrinsic FADD/caspase-8 pathway although, it 
was only observed in leukaemia cells.347 Alternatively, a study of glioma cells infected 
with wild type adenovirus and Ad-∆-24-RGD showed an induction of autophagy 
except with the AdE1B∆19K virus (E1B19K gene deleted), showing that E1B19K 
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strongly contributes to autophagy induction.348 It was suggested, that the binding of 
E1B19K with the PI3K-III complex and Beclin-1 lead to autophagy induction, were 
E1B19K competes and antagonizes Bcl-2 protein and its function.348 However, the 
binding of E1B19K to Beclin-1 and the PI3K-III complex was only shown in HeLa cells 
and whether complete autophagic-flux occurred was not reported.348 The infection 
of glioma cells with the oncolytic adenovirus dl922–947 increased the conversion of 
LC3B-I to LC3B-II and reduced levels of p62, surprisingly the mutant also induced the 
activation of the autophagy-inhibitory pathway Akt/mTOR.349 In contrast, the 
inhibition of autophagy in infected cells caused increased cytotoxicity due to 
apoptosis.349 In a new study with osteosarcoma cells, the oncolytic virus OBP-702 
induced the overexpression of p53, leading to an enhanced combination of apoptosis 
and autophagy-mediated cell death. The viral-enhancement of cell death was shown 
to be regulated by DRAM and the hsa-miR-93/106b cluster.350 In summary, the 
regulation and outcome of autophagy in response to viral infection is dependent on 
the type of virus and cell, therefore it is important to characterize the cell response 
to viral infection aiming for the improvement or development of new cancer 
treatments.  
 
1.5.6 MicroRNA regulation of Autophagy 
 
The regulation of autophagy through microRNAs was observed for the first time in 
2009 when Beclin-1 was shown to be post-transcriptionally regulated by hsa-miR-
30a.351 Moreover, hsa-miR-30a caused downregulation of Beclin-1 and thus 
autophagy, inducing a decrease in the levels of LC3-II levels and double membrane 
vacuoles despite the treatment with rapamycin.351 Since then more miRNAs have 
been identified in autophagic regulation and associated with cancer and other 
pathologies.352 
Many miRNAs have been identified to regulate different stages of the autophagic flux 
that can be either pro- or anti-oncogenic. Within the oncogenic pathway, the miRNA 
hsa-miR-106a a member of a highly oncogenic miRNA family was found to be highly 
upregulated in myeloid Leukaemia cells targeting and downregulating ULK1 a 
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regulator of autophagy at the initial stage. In addition, in cisplatin-sensitive 
squamous-cell-carcinoma cells ULK2 among other proteins was identified as a direct 
target of hsa-miR-885-3p, the binding with hsa-miR-885-3p induces ULK2 
downregulation.353,354 Moreover, ATG13, ATG9 and ATG2 also have binding sites for 
hsa-miR-885-3p.355 The hsa-miR-181a has been shown to regulate autophagy upon 
starvation conditions and by the induction of rapamycin by targeting ATG5.356 In 
addition, hsa-miR-30a plays an important role in autophagy regulation, by directly 
targeting Beclin-1 during vesicle nucleation.351 Moreover, the overexpression of hsa-
miR-30a reduces rapamycin-induced autophagy. In contrast, rapamycin-induced 
autophagy affects endogenous levels of hsa-miR-30a.351,355 Furthermore, in HeLa 
cells cisplatin-induced autophagy was impaired by hsa-miR-30a, causing a reduction 
of tumour size in a liver tumour-xenograft.357 Furthermore, in leukaemia hsa-miR-30a 
inhibited autophagy by downregulating the expression of both beclin-1 and ATG5, in 
contrast the knockdown of ATG5 and beclin-1 inhibited autophagy enhancing 
imatinib-induced cell death by mitochondria-dependent intrinsic apoptosis.358,359 In 
addition, the impairment of hsa-miR-30a increased beclin-1 and ATG5 and reduced 
the cytotoxicity of the tyrosine kinase inhibitor imatinib.358,359  
 
1.6 Rationale for the thesis 
 
Prostate cancer (PCa)is the second most frequently diagnosed cancer in men in the 
world and the most common cancer in men in the United Kingdom (UK).1,15  
Moreover, PCa is the second leading cause of cancer-related deaths in the UK.15 
Initially, depending upon diagnosis the treatment of PCa involves androgen ablation 
therapy, however PCa inevitably relapses and results in the development of 
hormone-refractory metastatic disease (HRPC).3 There is no cure for HRPC and 
current treatments are only palliative including the cytotoxic drugs mitoxantrone and 
docetaxel, and radiotherapy.66 Therefore, novel therapeutic strategies with different 
mechanism of action are required for the improvement of PCa treatment. 
Replication-selective oncolytic adenoviruses are a promising anticancer strategy with 
proven efficacy in cancer cell lines and tumour xenografts in vivo; anti-tumour 
efficacy has been shown to be highly improved in combination with 
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chemotherapeutics in numerous models of cancers including prostate cancer.360 
Several preclinical studies have shown that synergistically enhanced cell killing in 
response to combinations of oncolytic adenoviral mutants and chemotherapeutic 
drugs is mainly dependent on the expression of the viral E1A gene. Some examples 
are the enhancement of drug-induced apoptotic death in combination with Ad∆∆ 
and dl922–947.118,131,360 It has been demonstrated that E1A is essential both for 
induction of chemosensitization of cancer cells and for viral replication.95,129,130,361 
The E1A gene encodes five proteins generated by alternative splicing, of which the 
13S and 12S variants are major forms. Importantly, E1A13S encodes the CR3 domain 
which is essential for viral induction of S-phase and consequently viral replication 
while E1A12S alone does not support viral replication.75 However, both E1A13S and  
E1A12S can potently interact synergistically with mitoxantrone and docetaxel in PCa 
cells to enhance cell killing.95 It has been established that specific regions in the E1A 
proteins bind to numerous cellular factors to regulate the host cell function and the 
viral life cycle, including binding to p300, p400 and pRb family proteins. However, the 
exact mechanisms of cell death induced by the combination of E1A-expression and 
chemotherapeutic drugs remain elusive.95 In this thesis I focused on investigating the 
roles of specific E1A gene regions involved in the sensitization to the cytotoxic drugs 
mitoxantrone and docetaxel in PCa cell lines by employing non-replicating E1A12S-
expressing mutants that were deleted in specific domains to prevent binding of 
cellular factors including p300, p400 and pRb. We hypothesised that by identifying 
specific E1A domains and/or cellular factors that are essential for synergistically 
improved cell killing in combination with the drugs, we would establish key 
mechanisms that could be explored in future studies to develop improved anti-
cancer therapeutics and or biomarkers for disease progression or treatment 
responses. 
 
1.6.1. Background to project 
 
All E1A-deleted mutants used in my work had been previously constructed by a PhD 
student in the team (Dr. Miranda-Rota).362 The mutants had been characterised and 
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sequenced and a great amount of sensitization and synergy data had also been 
produced.362 I initially verified and expanded on these studies that resulted in a 
publication combining my own and the previous findings.95 Part of these data are 
presented below (Section 1.6.2) to give a clear background to my further studies and 
the additional results leading to the publication are included in the Result (Sections 
3.1 and 6.1) together with the data produced during the second part of my project.  
 
1.6.1.a. Adenovirus-mediated sensitization to the cytotoxic drugs docetaxel 
and mitoxantrone is dependent on regulatory domains in the E1ACR1 gene-
region.  
 
Our first approach was to investigate several replicating mutants that were 
previously demonstrated to be defective in binding to p300/CBP (dl1101, dl1104), 
p400/p21 (dl1101, dl1102), pRb, p130 and p170 (dl922–947, dl1108), or pRb and 
p130 (dl1107), and determine cytotoxicity in human PCa cells.95 In brief, we observed 
higher potency of replicating adenoviral mutants with small deletions in the E1A-
region than of the clinically used E1B55K-deleted dl1520 mutant in both PC-3 and 
DU145 PCa cell lines (Fig. 17A). Moreover, in combination with the drugs 
mitoxantrone and docetaxel we determined that drug-induced cell killing was 
enhanced by the replicating E1A mutants with some variations between cell lines 
because of the differences in genetic alterations (Fig. 17C).95  
 
A) B) 
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C) 
 
Figure 17. Potent cell killing of prostate cancer cell lines by replicating E1A-deletion 
mutants in combination with mitoxantrone. A)EC50 values for the replicating mutants were 
determined from dose-response curves and presented as averages ± SD, n = 3. Significantly 
different values compared to Ad5 are indicated. B) Isobolograms generated from EC50 
values for combinations of the AdE1A12S mutant with mitoxantrone (Mit) or docetaxel (Doc) 
at four constant ratios (0.5. 2.5, 12.5 and 62.5 ppc/nM drug) in PC-3 and DU145 cells. The 
straight lines represent the theoretical values for additive effects and points below the line 
synergistic cell killing, one representative study (n = 3–4) C) Sensitization of the human PC-3, 
22Rv1 and DU145 cells to mitoxantrone by fixed doses of each virus at EC10 and EC25. Data 
presented as percentages of mitoxantrone EC50 values in each cell line, averages ± SD, n = 3. 
Statistical analysis by one-way Anova, *p,0.05 for drug EC50 values that were significantly 
lower than the corresponding Ad5 values. The dl312 (DE1A) non-replicating virus served as 
negative control. 
 
Previously, our group demonstrated potent synergistic cell killing with Ad5, dl1520 
and E1ACR2-deleted mutants (dl922-947, Ad∆∆) in combination with mitoxantrone 
or docetaxel in PCa models.95,118,131 The combination of cytotoxic drugs with the 
replicating E1A-deletion mutants effectively enhanced drug-induced cell killing.95 We 
speculated that in addition to E1A, additional viral gene products or viral replication 
might contribute to the sensitization of PCa cells to the chemotherapeutic drugs and 
therefore, constructed expression plasmids with the small E1A12S under control of 
the CMV promoter. We found that the expression of E1A12S declined over time in 
transiently transfected PCa cells. However, we still observed potent synergistic cell 
killing in combination with both mitoxantrone and docetaxel immediately after 
transfection (Fig. 17B). These findings demonstrated that the small E1A12S protein 
was sufficient to promote synergistic cell killing in combination with apoptosis-
inducing chemotherapeutic drugs. To enable in depth studies of the mechanism for 
this interaction we generated non-replicating AdE1A12S-expressing Ad5 mutants 
deleted in both E1B and E3 genes (to eliminate the transfection step and improve on 
E1A-expression); AdE1A1102, AdE1A1104 and AdE1A1108 that do not bind to p400, 
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p300/CBP and pRb, respectively. PCa cells infected with the selected mutants 
showed that all mutants except for AdE1A1104 were highly cytotoxic even in the 
absence of viral replication.95 In combination with mitoxantrone and docetaxel, all 
mutants except AdE1A1104 caused significant sensitization to both drugs in three 
PCa cell lines, PC-3, DU145 and 22Rv1 (Fig. 18). Furthermore, studies in vivo using PC-
3 xenografts and intra-tumoural administration of the replicating E1A-mutants 
combined with intra-peritoneal administration of docetaxel showed that the p300-
binding region in E1A is essential for the synergistic sensitization of PCa cells as 
suggested by the findings in cultured cells both with the replicating and non-
replicating E1A mutants (see Result section 3.1.7). 
 
 
Figure 18. All replication-defective E1A12S mutants sensitize prostate cancer cells to 
mitoxantrone and docetaxel except the AdE1A1104 virus. Drug dose responses in each cell 
line were evaluated after infection with AdE1A12S, AdE1A1102, AdE1A1104, and AdE1A1108 
mutants with AdGFP as negative control to determine changes in drug EC50 values. All cell 
lines were infected at doses killing ,10% of cells alone; PC-3 cells at 100 ppc (left panel), 
DU145 cells at 10 ppc (mid panel) and 22Rv1 cells at 2.5 ppc (right panel). Data represent 
averages 6SD, n = 4–5 independent experiments analysed by t-test comparing EC50 values 
for each combination to that of drug alone, expressed as percentages, *p,0.05 and up,0.01. 
 
These findings enabled us to further investigate the mechanisms involved in the 
synergistic cell killing in PCa cells. Preliminary results indicated that the synergistic 
interactions resulted from activation of apoptotic pathways. However, we had also 
observed that both mitoxantrone and docetaxel increased the expression levels of 
LC3B-II, and indicator of autophagy when LC3B-I levels are decreased. Other 
members of the team (Adam V, unpublished data and thesis) had previously 
observed that the replication–selective Ad∆∆ mutant could prevent these drug-
induced increases in LC3B-II/I ratios. To this end we set out, in the second part of the 
project, to explore whether there was a link between increased apoptosis and 
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decreased autophagy that might cause the synergistically, enhanced cell killing in 
response to virus-drug combinations. In addition to standard molecular and 
laboratory approaches we also employed a miRNA screen to address this question 
and also explore a wider network of potential pathway regulators in response to the 
combination treatments. We performed these studies in the PC3 cell line which 
demonstrated the highest drug- and virus- resistance and also the greatest degree of 
synergistically enhanced cell killing in response to the combination treatments. The 
results from this screen will be described in section 3.2. The findings in this thesis 
together with additional future studies will aid in delineating the mechanisms 
responsible for E1A-mediated sensitization in PCa cells. We anticipate that, taken 
together, the findings will form the basis for future developments of improved 
therapies for prostate cancer. 
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1.7 Aims of this thesis 
 
The overall aim of this work was to identify E1A regions that are involved in the 
sensitisation of prostate cancer cells, firstly to the cytotoxic drug mitoxantrone and 
secondly to docetaxel, while retaining cancer-selectivity. To further dissect the 
mechanisms involved in the enhancement of cell killing by the identification of 
cellular factors that are essential for the synergistic interactions, with the idea to 
develop improved therapies that target these cellular pathways.   
 
• To determine if the observed effects in response to combination treatments 
with AdE1A1102 and AdE1A1104 are reproduced by the corresponding 
replicating mutants dl1102 and dl1104.  
• To determine whether the viral mutants selectively sensitize prostate cancer 
cells but not normal cells.  
• To verify that the deletions in dl1104 and AdE1A1104 (p300-binding region) 
abrogate drug sensitization (e.g. no enhancement of apoptosis).  
• To verify the miRNA analysis and investigate the potential effects on cellular 
signalling pathways under sensitizing/synergistic conditions. For example, by 
determining changes in cell cycle progression, cell death and survival 
pathways, and by monitoring changes in protein expression of selected 
proteins that might be targeted by the identified miRNAs. 
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2. Materials and Methods 
2.1. Cell Culture Conditions 
 
The following human prostate cancer cell lines were used; PC-3 (grade IV 
adenocarcinoma bone metastasis, epithelioid morphology),363,364 22Rv1 (carcinoma 
epithelial cell line derived from serially propagated xenografts in mice after 
castration-induced regression and relapse of the parental, androgen-dependent 
CWR22, epitheloid morphology),364,365 DU145 (derived from brain metastasis, 
epithelioid morphology)364,366 and LNCAP (carcinoma from supraclavicular lymph 
node metastasis, fibroblastoid morphology).364,367 All cell lines were obtained from 
American Type Tissue Culture Collection (ATCC, VA, USA) and Cancer Research UK 
(CRUK, Clare Hall, London, UK). Human ovarian cell lines Skov3.ip1 and Skov3 
(obtained from Prof. Iain McNeish, Centre for Molecular Oncology), Skov3 was 
originally from CRUK Cell Services and Skov3.ip1 from Dr J Price (University of Texas 
MD Anderson Cancer Centre, TX, USA). The human embryonic kidney cell line 
HEK293 and the sub-line JH293 cells were obtained from CRUK Cell Services. All cell 
lines were cultured in Dulbecco’s Modified Eagle Medium (DMEM; CRUK) 
supplemented with 10% foetal calf serum (FCS; Sigma-Aldrich, Chemie, Germany), at 
37°C and 5% CO2. Normal human bronchial epithelial (NHBE) and prostate epithelial 
cells (PrEC) cells were cultured following the manufacturer’s protocol using the B-
ALI™ Bronchial Air Liquid Interface Medium BulletKit™ and PrEGM™ BulletKit™, 
respectively (Lonza Ltd, Switzerland). All cell lines were authenticated by short 
tandem repeat (STR) profiling (LGC Standards, Middlesex, UK) during the course of 
this study and only verified cell stocks were used. The viral infections were 
performed in serum-free DMEM for 2h in 6-well plates and in 2% FCS in DMEM when 
cultured in 96-well plates.  
 
 
 
 
 
 
 
87 
 
Table 6. Expression of proteins in the human prostate cancer cell lines used in this 
thesis.   
 
Information obtained from 363,365,366,368,369. 
 
 
 
 
 
88 
 
2.1.a Skov3 and Skov3ip1 
 
The ovarian cancer cell line Skov3 is a hypodiploid human cell line with 43 
chromosomes and duplicates every 28h.364 Moreover, Skov3 has been reported to be  
more infectible and more sensitive than its derived sub-clone Skov3ip1, in response 
to adenoviral infection.370-373 Skov3ip1 were derived from ascitic tumour cells of 
nude mice bearing a Skov3 tumour. Furthermore, SKOV3ip1 cells were demonstrated 
to be more invasive and malignant than the parental Skov3 cell line.373 Additionally, 
both cell lines are established as p53 null.374 However, in a cDNA array 1557 genes 
were differentially expressed.373 In Skov3ip1 cells 676 genes were upregulated and 
881 downregulated compared to Skov3.373 For example, HER2/neu was shown to be 
overexpressed in Skov3ip1 compared to Skov3, other genes found as differentially 
expressed were Pim-2, FGFR1 oncogene partner and Ras gene family members that 
were also upregulated in Skov3ip1.373 
 
2.2 Virus preparation and viral assays 
2.2.1 Viruses used in the study  
 
The viruses used in this study and their characteristics are listed in Table 7 and Figure 
19. Wild-type adenovirus species C type 5 (Ad5wt or Ad5), was used as control in 
many assays, Ad5wt virus expresses all adenoviral genes including the complete E1A 
gene.81 Generation of the double-deleted mutant Ad∆∆ (E1ACR2-region and E1B19K-
gene deleted) has been described previously.118   
The non-replicating, E1A-12S-expressing viruses used for this study do not have 
transcriptional activity, have the E1B and E3 genes deleted and were generated as 
described (Fig. 19; see appendix section 6 for characterization of viral mutants). The 
replicating dl1102 and dl1104 viruses were used in comparative assays with their 
non-replicating counterparts. The dl1102 and dl1104 have a dl309 backbone with the 
E3B genes deleted and express both E1A12S and E1A13S.375-377  
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Table 7. Virus used in this study and their genetic background 
 
 
Figure 19. The Ad∆∆ and the AdE1A12S replicating- and non-replicating mutants generated 
for our study. A549 cells were infected with Ad5 at 100ppc. The mRNA was purified from the 
cells 20h post-infection and was used to synthesise cDNA using Taqman Reverse 
transcription reagents and oligo-(dT) (Life Technologies Ltd, Applied Biosystems Division, 
Warrington, UK) for RT-PCR as described by the manufacturer. The reaction mixture was gel 
purified to separate 13S and 12S cDNA, followed by PCR-amplification of the cDNA 
corresponding to E1A12S. The pCR2.1-TOPO-12S was generated by insertion of the amplified 
and purified E1A12S cDNA for further amplification, digestion and isolation of the E1A12S 
gene that was cloned into a pShuttle-CMV vector (Stratagene, TX, USA). The pShuttle-CMV-
E1A12S was linearized and co-transfected with the E1- and E3-deleted pAdEASY plasmid into 
BJ5183 electrocompetent bacteria (Stratagene), for homologous recombination according to 
the manufacturer’s instructions (Stratagene). Generation of E1A1102, E1A1104 and E1A1108 
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cDNA was done by gene splicing by overlapping extension PCR (SOEing PCR). Primers were 
designed to generate the deletions corresponding to E1A1102, E1A1104 and E1A1108 and 
has been described previously.95 The generated cDNAs for the E1A12S mutants were cloned 
into the pCR2.1-TOPO vector and viral mutants were produced as described for AdE1A12S.95 
 
2.2.2 Viral production and characterization 
 
2.2.2.a Primary expansion 
 
Human Embryonic Kidney (HEK293) cells were seeded in a T175 flask in DMEM with 
10% FCS and infected with 30µl of CsCl2-purified stock-virus in 15 ml of 2% FCS in 
DMEM when cells were 75% confluent. Once the cells detached or showed 
cytopathic effect (CPE) approximately 48h post-infection, medium and cells were 
collected and stored at -80oC.  
 
2.2.2.b Viral Purification 
 
Four T175 flasks with HEK293 cells (~ 30x106 cells/flask) at 80% confluence were 
trypsinised and harvested for viral production. The HEK293 cells were seeded in a 
ten-layer Cell Factory (CF-10; Fisher Scientific) and incubated at 37°C and 5% CO2. A 
parallel T175 flask was seeded as a reference to monitor cell growth for 48-72h. 
When cells reached 80% confluence they were infected with the primary expansion 
(section 6.2.2.1) in 2% FCS in DMEM and 48-72h post-infection, once cells detached, 
medium and cells were collected. The cell suspension was centrifuged at 2000rpm 
for 10min using a Sigma 6K15 centrifuge (Sigma, Germany) at 4oC, the pellet was 
washed in PBS, centrifuged for 10 min at 1000rpm at 4οC and was re-suspended in 
12ml of 10mM Tris-HCl (pH 8.0) at 4oC. The virus-containing cell suspension was 
freeze-thawed 3 times (N2(l) and 37°C) in order to release viral particles remaining in 
cells and centrifuged using a Sigma 6K15 centrifuge for 10min at 6000rpm. The 
supernatant was collected and layered on a CsCl2 gradient, consisting of 10ml of 
1.25g/ml CsCl2 and 7.6ml of 1.4g/ml CsCl2 solution, and centrifuged for 2h at 
25,000rpm at 15°C (Beckman SW32i swing-out rotor; Optima LE-80K ultracentrifuge). 
The thick bottom band of the gradient suspension was extracted by piercing the tube 
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with a 19G needle, and layered on top of a 2.5ml 1.35g/ml CsCl2 solution, centrifuged 
for 15h at 40,000rpm at 15°C (Beckman SW55ti swing-out rotor; Optima LE-80K 
ultracentrifuge). The virus band was transferred to a tube and the volume made up 
to a total of 12ml with TSG buffer (96mM NaCl, 0.5mM Na2HPO4, 2.8mM KCl, 0.3mM 
MgCl2, 0.5mM CaCl2 and 30% (v/v) glycerol, pH7.5). The suspension was dialysed in a 
Slide-a-Lyser (Pierce Biotechnology, IL, USA) in a buffer containing 10mM Tris-HCl 
(pH7.5), 1mM MgCl2, 150mM NaCl and 10% (v/v) glycerol) for 24h at 4°C, to remove 
CsCl2. The purified virus was removed from the dialysis cassette, aliquoted and 
stored at -80°C.  
 
2.2.2.c Viral particle (vp) determination  
 
Viral particles were determined by measuring the DNA content of the viral 
preparation using the Quanti-iT Pico Green dsDNA Assay Kit (Invitrogen). Lambda-
phage DNA (provided with the kit) was used for standard dilutions starting from 
750ng/ml in 5-fold serial dilutions. Viral stocks were undiluted (neat) or diluted in TE 
buffer (10 mM Tris-HCl, 1 mM EDTA, pH 7.5) at A) 1:2, B) 1:6 and C) 1:10 dilutions, 
and each sample was assayed in triplicates in 96-well plates. The Pico Green reagent 
diluted 1:200 (100 µl) was added to each well. The absorbance of the samples was 
determined at 535nm after excitation at 485nm using the Tecan Infinite F200 plate-
reader (Mannedorf, Switzerland) with the Magellan Software version 6.3. The DNA 
concentrations of the lambda-phage DNA-dilutions were plotted versus fluorescence 
using the GraphPad Prism software. Viral particle counts (vp/ml) were calculated by 
linear regression analysis taking the dilution of the samples into account, and 
assuming that 1 µg DNA = 2.7x1010 viral particles (vp).  
 
2.2.2.d Determination of infectious units (pfu) 
 
A limiting dilution tissue culture assay, TCID50 (tissue culture inhibitory dose 50%), 
was used to determine viral replication. JH293 cells (a sub-clone of the HEK293 cell 
line that has better adherence properties in monolayer culture) were seeded at a 
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density of 1x104 cells/well (96-wells) in 200 µl of 10% FCS in DMEM and incubated at 
37°C in 5% CO2 for 24h in triplicate plates. The purified viral mutants were added to 
the top row (12 wells) in 20µl aliquots from a pre-diluted sample (diluted in 0% FCS in 
DMEM), mixed and 20µl transferred to the next row of wells and so on resulting in 
serial 10-fold dilutions down the plate, leaving the last row of wells uninfected as 
control cells. Samples were diluted in the range from 1x102 to 1x1013. A previously 
characterized Ad5wt control virus (stock) with known activity was always included as 
a positive control, diluted 1x107 times in 0% FCS in DMEM.  The plates were 
incubated for up to 10 days (minimum 7 days) when each well was scored for 
cytopathic effects (CPE). The titre of each sample was calculated with a modified 
Karber-Spearman equation and the results were expressed in plaque-forming units 
(pfu)/ml 378.  
 
Log TCID50 = A – D (S – 0.5) 
Where, 
A = Log of the highest dilution showing CPE in more than 50% of the wells 
D = Log of the dilution factor. 
S = summation of the proportion of positive wells in each row.  
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2.2.2.e Identification of viral genomes by PCR  
 
Table 8. Set of primers for viral characterization. 
 
*Deletion 1102= dl1102/AdE1A1102 and 1104= dl1104/AdE1A1104 
**Deletion in CR2=Ad∆∆ and AdE1A1108 
 
To characterize the viral mutants, identity was determined by qualitative PCR. Viral 
DNA was extracted from 200 µl of purified virus using the DNA Blood Mini Kit 
(Qiagen, West Sussex, UK) according to the manufacturer’s protocol. Eight primer 
sets specific for Ad5 and one E1A-specific primer set were used for each viral mutant 
(Table 8). Each sample (30µl of PCR-mix) was incubated with the Advantage 2 PCR Kit 
(Clontech, CA, USA) and amplified (Gene Amp PCR system 9700; Life Technologies 
Ltd, Applied Biosystems). Amplified products were analysed together with a Quick-
Load® 100 bp DNA Ladder (New England Biolabs) on a 1.5% agarose gel in the 
presence of Ethidium Bromide (EtBr). 
2.2.3 Viral infection of cells and preparation of lysates  
 
Cells were infected with the non-replicating AdE1A12S, AdE1A1102, AdE1A1104, 
AdE1A1108, and AdGFP  (Fig. 19) at 2.5 ppc for 22Rv1 or 100ppc for PC-3, in 1ml/well 
(6-wells) of 0% FCS in DMEM. After 2h of infection, medium was aspirated and 
exchanged with 2ml/well of mitoxantrone at 50nM (Onkotrene, Baxter, Norfolk, UK) 
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in 10% FCS-DMEM was added for 48h. The cells were washed with PBS, trypsinised, 
centrifuged at 1200rpm in an Allegra X-22 Centrifuge (Beckman Coulter, CA, USA) 
and the pellet was lysed with 100µl of lysis Buffer (1mM EDTA, 0.01M Na3PO4, 
0.150M NaCl, 1%NP40 v/v, 1% Sodium Deoxycholate w/v, 0.1% SDS w/v, including a 
PhosSTOP Phosphatase Inhibitor Cocktail and an EDTA-free Protease Inhibitor 
Cocktail Tablets (ROCHE diagnostics, West Sussex, UK), placed on ice for 30 min, and 
stored at -80oC. Total protein was quantified by diluting 2µl of the whole cell extract 
in 200µl of Bradford Reagent (Bio-Rad, Hertfordshire, UK), diluted 1:5 in distilled H2O 
per well in a 96 well plate. A standard curve (0, 1, 2, 2.5, 3, 3.5 and 4 µl), using the 
1:5 reagent dilution was prepared with 1µg/µl BSA (Sigma-Aldrich). The absorbance 
was determined at 595 nm (Beckman DU520 spectrophotometer) and samples were 
quantified by generating a standard curve and adjusting the values with a linear 
regression of the standard curve of absorbance vs concentration. Samples were 
diluted to a final concentration of 1µg/µl in NuPAGE 4x lithium dodecylsufate (LDS) 
sample buffer (Invitrogen) and distilled water. 
 
2.2.4 Immunoblotting (Western blotting) 
 
Polyacrylamide gels were prepared at 10-12% (dependent on protein size) and 
samples were loaded; 20µg total protein/well for each sample. The samples were 
separated by electrophoresis at 100-150V for 1h in a Tris-glycine-SDS-PAGE buffer 
solution. The separated samples were transferred from the gel to a Polyvinylidene 
Fluoride membrane (PVDF, Millipore) using a Trans-Blot Semi-Dry System (Bio-Rad) 
for 45 min at 20V.  The membranes were incubated for 5 min in methanol and 
washed in PBS containing 0.01% Tween (PBS-Tween), 6 x 5 min. The membranes 
where incubated with the primary antibodies (Table 9), in PBS-Tween containing 5% 
BSA (Sigma-Aldrich) overnight at 4°C, washed, incubated with the respective 
secondary antibodies (Table 9) at a 1:2000 dilution for 1h in PBS-Tween-BSA, washed 
and incubated for 1 min with the Amersham ECL Plus™ Western Blotting Detection 
Reagents reagent. The bands were detected with Super RX Fuji Medical X-Ray Film 
(Fujifilm; Düsseldorf, Germany), developed at different time points with a Curix 60 
Developer (Agfa, Middlesex, UK) or by using the Syngene equipment (Synoptics Ltd, 
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Cambridge, UK) to scan for chemiluminescence and to quantify protein expression 
relative to loading controls (Gene Tools version 4.01; Synoptics Ltd, Cambridge, UK). 
 
Table 9. List of antibodies used in this thesis. 
 
 
2.2.5 Cell viability assay 
 
The prostate cancer cell lines PC-3, DU145 (1x104 cells/well) and 22Rv1 (2x104 
cells/well) were seeded 24h prior to treatment and infection in 96-well plates in 
triplicates to perform cell viability assays. The cells were infected with 5-fold serial 
dilutions of viruses and drugs at initial concentrations of 200µM for mitoxantrone 
and 1x105ppc for each virus. Untreated cells and wells containing medium alone 
were used as controls, for total viable cells and background (medium) respectively. 
Six or three days post-treatment, the CellTiter 96(R) AQueous MTS reagent (Promega 
Southampton, UK) was added to the plates. The tetrazolium salt MTS, [3-(4, 5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, 
is reduced to a soluble formazan compound by mitochondrial dehydrogenases 
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present in metabolically active cells, a reaction catalysed by phenazine methosulfate 
(PMS), an electron coupling reagent. The soluble formazan compound absorbs light 
at 490nm and the number of living cells is directly proportional to the concentration 
in the sample. The medium of the treated cells in the 96-well plates was replaced 
with 100µl per well of the MTS solution (80µl DMEM, 20µl MTS and 1µl PMS per 
well). After 2-4h of incubation at 37°C and 5% CO2 absorbance was measured in an 
OpsysMR plate reader (Dynex Technologies Inc, Chantilly, VA, USA). The absorbance 
values were processed by subtracting the absorbance values of wells with medium 
alone (background signal) and expressed as percentages of the absorbance of 
untreated cells (viable cells = 100%). The data were analysed by generating dose-
response curves for each treatment using GraphPad Prism5.01 (GraphPad Software, 
CA, USA) to generate EC50 values (effective dose killing 50% of cells). 
 
2.2.5.a Combination studies 
 
For the combination assays, cells were seeded in 96-well plates and after 24h the 
cells were treated at selected concentrations based on the results from dose-
response curves and EC50 values. Concentrations that killed <30% of cells were 
chosen. PC-3 cells were treated with mitoxantrone from 200 - 2000nM and infected 
with viruses at 50 - 4000ppc, both alone and in combination. The 22Rv1 cells were 
treated with mitoxantrone from 50 - 1000nM and infected with viruses at 25 - 
500ppc alone and in combination. NHBE and PrEC cells were treated with 200nM 
mitoxantrone and infected with 5ppc and 10ppc with replicating and non-replicating 
viruses alone or in combination. Three days post-treatment the MTS assay was 
performed to determine cell viability. The data was analysed for percentage cell 
death and plotted as bar graphs for each treatment using GraphPad Prism 5.01. 
Theoretical additive values were estimated for each combination and dose by adding 
the averages of viable cells for drug and virus. Statistical significance was determined 
by Students t test (p<0.01). 
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2.2.6 Synergy Assays 
 
To quantify cell death and determine synergistic interactions, the PC-3 (1x104 
cells/well) and 22Rv1 (2x104 cells/well) cells were seeded in 96-well plates in 
triplicates. Viruses (dl1102, dl1104, AdE1A12S, AdE1A1102 or AdE1A1104) (Fig. 19) 
and mitoxantrone were added to the cells either alone or in combination at fixed 
ratios to enable determination of the combination index (CI) using the quantitative 
isobologram method, as previously described.361,379-381 Viruses and drugs were 
diluted five-fold starting at concentrations of 200µM for mitoxantrone and 1x105ppc 
for each virus (Table 10). The fixed ratios of virus to drug were 62.5, 12.5, 2.5 and 0.5 
ppc/nM, based on previous studies in our group.95 Untreated cells and wells 
containing medium alone were used as controls, for total viable cells and background 
(medium) respectively. 
 
Table 10. Full dose ranges of virus and drug in the 96-well plate layout. Combinations of 5-
fold dilutions of viral mutants with drug at fixed ratios. 
 
 
Six days post-treatment the MTS reagent was added to the plates to determine cell 
death. The data were analysed by generating dose-response curves and EC50 values 
for each treatment using the GraphPad Prism software. To determine the nature of 
the interactions (synergistic, additive or antagonistic effects), isobolograms were 
generated by plotting the respective EC50 value for each agent alone and in 
combinations. The results were analysed according to Chou and Talalay379 and as 
previously described by our team.380 Virus and drug interactions were considered 
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synergistic when CI≤0.9, additive for 0.9<CI<1.1 and antagonistic when CI≥1.1.CI 
values were calculated using a formula modified from:381 
 𝐶𝐼 = 𝐸𝐶50𝑉𝑐
𝐸𝐶50𝑉𝑎
+ 𝐸𝐶50𝐷𝑐
𝐸𝐶50𝐷𝑎
, 
 
Where 
 
EC50Va = EC50 for the virus alone 
EC50Vc = EC50 for the virus in combination 
EC50Da = EC50 for the drug alone 
EC50Dc = EC50 for the drug in combination 
 
2.2.7 Infectability assay in cancer cell lines 
 
The prostate cancer cells lines PC-3 and 22Rv1 and the ovarian cancer cell lines Skov3 
and Skov3ip.1 were seeded in 6-well plates at a density of 1x105 cells per well. After 
24h, cells were infected with the non-replicating AdGFP at a fixed dose of 0, 10 and 
100ppc in serum free DMEM for 2h. Medium was replaced with 10% FCS in DMEM 
after infection and cells were incubated for 48h at 37°C and 5% CO2. After 48h, cells 
were harvested for flow cytometry analysis. The cells were washed with cold PBS and 
detached by trypsinisation, DMEM supplemented with 10% FCS was added to 
neutralise trypsin, cells were centrifuged at 1700rpm in an Allegra X-22 Centrifuge 
(Beckman Coulter, CA, USA) for 3min, the pellets were washed with PBS and 
centrifuged for 1700rpm (Allegra X-22 Centrifuge; Beckman Coulter, CA, USA) for 
3min and re-suspended in PBS for FACS analysis. A total of 1x104 events (cells) were 
acquired for each condition using a FACSCalibur (Becton Dickinson, Cowley, UK) and 
analysed with Cell Quest Pro Software (Becton Dickinson).  The GFP-positive cells 
were detected and quantified at 525nm using the green fluorescence channel 1 (FL-
1). 
 
 
2.2.8 Reverse transcription quantitative PCR (RT-qPCR) 
 
The PC-3 and 22Rv1 cells were seeded in 6 well plates at 2x105 and 4x105 cells/well, 
respectively. The cells were infected at 400ppc for PC-3 and 10 ppc for 22Rv1 cells in 
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serum free DMEM, 2h post-infection medium was changed and cells were treated 
with mitoxantrone at 50nM in 10% FCS in DMEM for 48h. The cells were trypsinised 
and processed for RNA extraction according to the RNeasy mini kit handbook 
protocol for total RNA extraction (QIAGEN® West Sussex, UK). RNA samples were 
treated to remove any DNA contamination with RNAse-free DNase Treatment and 
Removal Reagent, (DNA-free™; Ambion, Life Technologies, CA, USA). RNA 
concentrations were determined using a Nanodrop® ND-1000 Spectrophotometer 
(Labtech International Ltd, East Sussex, UK), measuring the absorbance ratio of 
260nm/280nm where a ratio close to 2.0 implies RNA purity (DNA free). Generation 
of cDNA was carried out using the TaqMan® Reverse Transcription kit (Life 
Technologies, AB) according to the manufacturer’s protocol using Oligo(dt)16 as 
primers. The cDNA samples were prepared for RT-qPCR analysis for p21-CDKN1A 
using the Forward primer: TGGAGACTCTCAGGGTCGAAA (21bp) and the Reverse 
primer: GGCGTTTGGAGTGGTAGAAATC (22bp) (Life Technologies Ltd, Invitrogen 
division, Paisley, UK), using Power SYBR® Green PCR Master Mix (Life technologies 
Ltd, AB) according to the manufacturer’s protocol. Data were normalized against the 
respective GAPDH value to obtain ∆Ct values. The ∆Ct value of each sample was 
normalized against the control untreated samples to get the ∆∆Ct value, used to 
calculate the fold change that was expressed as percentages of the control. 
∆Ct= CtSample- CtControl 
∆∆Ct=∆Ctsample- ∆Ctcontrol 
Normalized target gene expression in fold change=2-∆∆Ct 
 
Where ∆Ctsample is the Ct value for any sample normalized to an endogenous 
housekeeping gene and ∆Ctcontrol is the Ct value for the calibrator also normalized to 
the endogenous housekeeping gene. 
 
Fold change percentage= (2-(∆∆Ct))x100 
 
2.2.9 Mitochondrial membrane potential depolarization 
PC-3 cells were seeded 24h prior to treatments in 6-well plates at a density of 
1x105cells/well. The cells were infected in duplicates with AdE1A12S virus for 2h in 
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1ml/well of serum-free DMEM.  After 2h, the cells medium was changed to 10% FCS 
in DMEM with or without the addition of mitoxantrone (1000nM). Staurosporine at 
1nM (Sigma-Aldrich) and rapamycin 100nM (Sigma-Aldrich) were included as positive 
controls for apoptosis and autophagy, respectively. A pan-caspase-inhibitor zVAD-
fmk (25µM; Calbiochem, CA, USA) was also used as a caspase-cascade control. After 
96h, medium was collected from each well; cells were washed with PBS, trypsinised 
and transferred to 5ml tubes (BD Falcon™, USA). The cells were centrifuged at 
1200rpm in an Allegra X-22 Centrifuge (Beckman Coulter, CA, USA), washed with PBS 
and stained with Tetramethylrhodamine ethyl ester (TMRE; Sigma-Aldrich). TMRE 
(1mg/ml), 40µl, was added to the cell suspension (500µl of PBS) and incubated for 
30min at 37°C in the dark. After 30min the cells were washed with PBS and stained 
with 1μg/ml of 4',6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich) for 10min at 
24°C. The cells were assessed in a BD LSRFortessa™  (Becton Dickinson, Oxford, UK) 
gated with lasers 585nm versus 445nm and analysed by the BD FACSDiva™ software 
(Becton Dickinson). 
2.2.10 MicroRNA (miRNA) analysis 
 
For the microRNA (miRNA) array analysis PC-3 cells were seeded in 6-well plates. 
After 24h, cells were infected with AdE1A12S (100ppc) or treated with mitoxantrone 
at 50nM (concentrations previously shown to sensitize PC-3 cells and enhance cell 
killing 95) or a combination of both agents. Duplicate wells were harvested for each 
condition and the 24h time point was repeated in a second experiment. The cells 
were harvested at 24h and 48h post-infection and total RNA was extracted. The RNA 
samples were analysed for changes in miRNA expression by LC Sciences (TX, USA), 
using a miRNA microarray platform with 850 human miRNAs based on the Sanger 
miRNA database.382 From the generated and analysed original data (LC Sciences), we 
made a selection of miRNAs that had a signal intensity of 500 or higher and that were 
statistically significant (p<0.01; Students t-test). To determine the differences in 
expression between the various treatments, the results were processed and 
expressed as a ratio; single agent-treated/untreated, combination-
treated/untreated, combination-treated/the sum of the single agents, and the 24h 
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compared to 48h values.  The ratios were converted into log2 scale to assess 
differential directions and magnitudes.383 A positive log2 value indicates an up- 
regulation and a negative log2 value indicates downregulation. Accessible databases 
and tools such as Ensembl.org, mirbase.org, PubMed, mirTarBase.org, TargetScan 
Human, miRecords, miRDB, microRNA.org, transmir miR2disease and published 
reports,231,233-238,384,385 were used for selection of relevant miRNAs and their targets. 
We also took into account whether the miRNAs had been previously reported to play 
a role in specific pathways in cancer cells and tissue with special focus on prostate 
cancer.  
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3. Results 
 
3.1 AdE1A12S requires p300 to sensitize prostate cancer cells to 
chemotherapeutic drugs 
  
We have previously demonstrated that E1A-expression alone was sufficient to cause 
synergistic cell killing in combination with mitoxantrone and docetaxel.131,362 To 
identify specific E1A-regions responsible for the sensitisation of PCa cell lines to 
cytotoxic drugs, several AdE1A12S non-replicating mutants with various E1A 
deletions (1102, 1104 and 1108; Fig. 19) and without E1B and E3 genes were 
previously generated in our group.362 The absence of the E1A13S, E1B and E3 genes 
enabled the study of the E1A deletions without interference from additional viral 
proteins or viral replication. 
 
The mutant AdE1A1102 does not bind p400, a co-transcription factor involved in 
ATP-dependent chromatin remodelling activity and cell cycle control. AdE1A1104 
does not bind p300, a co-transcription factor with intrinsic histone acetyltransferase 
(HAT) activity. Furtheremore, AdE1A1108 does not bind the tumour suppressor pRb 
protein which inhibits cell cycle progression.83 The conclusions from these studies 
were that AdE1A1104 was unable to sensitize PCa cells to mitoxantrone and 
docetaxel. In contrast, AdE1A1102 and AdE1A1108 enhanced mitoxantrone and 
docetaxel induced cell death, both in treatment-sensitive (22Rv1) and more resistant 
(PC-3) PCa cells.95  
 
3.1.1 Mitoxantrone induces cyclins A and B in PC-3 cells but not in 
22Rv1 cells.  
 
Previous data demonstrated that the combination of mitoxantrone with non- 
replicating E1A mutants increased the G2/M cell population, in comparison to 
treatment with mitoxantrone or virus alone, in both PC-3 and 22Rv1 cells.95 This 
increase was only detected when infecting with AdE1A12S, AdE1A1102 and 
AdE1A1108 that sensitized the cells to mitoxantrone. AdGFP was used as control 
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virus and did not induce changes in phase distribution, resulting in the same profile 
as mitoxantrone alone.95 
 
In order to further extend these findings, we explored the regulation of cell cycle, by 
determining the expression levels of cell cycle proteins under similar treatment 
conditions, in both PCa cell lines (PC-3 and 22Rv1).   
 
 
 
Figure 20. Changes in expression patterns of cell cycle regulatory proteins in PC-3 cells 
infected with non-replicating E1A12S mutants (100ppc) in combination with Mitoxantrone 
(50nM) for 48h. SDS-PAGE gel loaded with 20µg total protein/lane per sample. Immunoblot 
is representative of three experiments.  
 
In PC-3 cells, treatment with mitoxantrone for 48h induced expression of cyclins A 
and B (Fig. 20). However, this induction of cyclins A and B was not altered in cells 
infected with all viral mutants. Mitoxantrone slightly attenuated cyclin D expression 
both alone and in combination with all viral mutants (Fig. 20). The viruses did not 
induce detectable changes in cyclin D levels. Moreover, Cyclin E was upregulated in 
cells treated with  mitoxantrone alone, but not in combination with the viral mutants 
(Fig. 20). Only infection with AdE1A12S, AdE1A1102 alone appeared to induce cyclin 
E (Fig. 20). Moreover, infection with AdE1A1108 in combination with mitoxantrone 
reduced the levels of cyclin E. These data indicate that the E1A12S mutants had 
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minor effects on expression levels of cyclins, while mitoxantrone induces cyclin A and 
B, as expected due to previously generated cell cycle data.95 In addition, G2/M phase 
cell cycle arrest has shown to be induced by the overexpression of p21,386 therefore 
we investigated changes in the protein-levels of p21 under chemosensitizing 
conditions.  However, the expression of p21 was below the limit of detection in PC-3 
cells by immunobloting. In summary, increases in the G2/M cell population in PC-3 
cells treated with the combination of the viral mutants and mitoxantrone could not 
be conclusively explained by observed changes in cell cycle-related proteins. 
Therefore, further experiments were performed to unravel the mechanisms for 
synergy.  
 
 
Figure 21. Changes in expression patterns of cell cycle regulatory proteins in 22Rv1 cells 
infected with non-replicating E1A12S mutants in combination with Mitoxantrone (50nM) 
for 48h. SDS-PAGE loaded with 20µg total protein/lane per sample. Immunoblot is 
representative of three experiments.  
 
In contrast to the findings in PC-3 cells, mitoxantrone decreased the expression levels 
of cyclin A and B in 22Rv1 cells (Fig. 21). All viral mutants induced an increase in 
expression of cyclin A compared to uninfected cells, but was reduced in combination 
with mitoxantrone. Moreover, none of the viruses induced cyclin B while 
mitoxantrone decreased the expression and remained low in the presence of virus 
(Fig. 21). We did not observe significant changes in expression levels of Cyclin D with 
viruses alone or in combination with mitoxantrone. Although, a tendency to higher 
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Cyclin D levels was noted in mitoxantrone-treated cells. Moreover, Cyclin E was 
slightly induced by infection with all viral mutants and combination with 
mitoxantrone appeared to attenuate this induction.  In summary, viral infection 
induced cyclins- A and E and D. Moreover, cyclin B was not induced by AdE1A12S and 
AdE1A1108. Additionally, mitoxantrone strongly attenuated the expression of all 
cyclins (except possibly Cyclin D). However, these effects were not specific for any of 
the viral mutants and may reflect cellular changes in response to infection only.  
 
 
Figure 22. Changes in expression patterns of p21 in 22Rv1 cells infected with non-
replicating E1A12S mutants. in combination with Mitoxantrone (50nM) or docetaxel (1nM) 
for 48h. SDS-PAGE loaded with 20µg total protein/lane per sample. Immunoblot is 
representative of three experiments. 
 
In addition, we assessed the expression of p21 in 22Rv1 cells. Treatment with 
mitoxantrone alone and in combination with all mutants induced p21 (Fig.22). 
Infection with the viral mutants induced p21 to a lesser degree than mitoxantrone, 
except AdE1A1108 and AdGFP where the expression of p21 was similar to that of the 
untreated control cells. Additionally, the expression of p21 was induced by docetaxel 
alone and in combination with the AdE1A12S mutants, except AdE1A1108 and 
AdGFP, where AdE1A1108 attenuates mitoxantrone-induced p21 expression (Fig. 
22). The induction of p21 expression in response to docetaxel treatment was similar 
to virus-induced expression, although less than levels induced by mitoxantrone. 
Moreover, no differences were observed for the various mutants in combination 
with docetaxel or mitoxantrone. In summary, mitoxantrone induces p21 contributing 
to cell cycle arrest in 22Rv1 cells, although, the involvement of the viral mutants in 
the expression of p21 was not clear and further studies would be needed for 
conclusive data. 
 
kDa 
 
21 
 
43 
 
106 
 
3.1.2 The AdE1A12S and AdE1A1102 viral mutants enhance 
mitoxantrone-induced p21 mRNA expression in PC-3 cells but not in 
22Rv1 cells. 
 
Since the levels of expression of p21 in PC-3 cells were too low to be detected by 
immunoblotting, we assessed the expression of p21 mRNA by RT-qPCR in both PC-3 
and 22Rv1 cells.  
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Figure 23. Fold change percentage (FC %) of p21 mRNA expression in PC-3 cells.  PC-3 cells 
infected with AdE1A viral mutants alone and in combination with 50nM of mitoxantrone or 
1nM docetaxel for 48h. Data points were normalized as described in section 6.7. n=3. 
Student t-test, significant compared to mitoxantrone alone *p<0.05 .  
 
 
PC-3 cells treated with mitoxantrone showed an induction of p21 in both infected 
and uninfected cells (Fig. 23). The treatment with mitoxantrone induced the 
expression of p21 by 3-fold compared to untreated cells, the combination with 
AdE1A1104 showed similar expression as mitoxantrone alone (Fig. 23). The 
combination of mitoxantrone with AdE1A1102 and AdE1A12S showed an 
enhancement in p21 expression of 12- and 9-fold respectively in comparison to 
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untreated cells. The combination of mitoxantrone with AdE1A1102 was significantly 
increased compared to mitoxantrone alone (Fig. 23). Infection with AdE1A1102, 
AdE1A1108 and AdE1A12S viruses showed a slight increasing trend in the expression 
of p21 compared to untreated cells, but not by AdE1A1104. The treatment with 
docetaxel alone did not induce p21. In contrast, the expression of p21 was enhanced 
with docetaxel in combination with all viruses. Docetaxel in combination with 
AdE1A12S showed the highest increase in p21 expression (3-fold increase in 
comparison to untreated cells) (Fig. 23). These results surprisingly indicate that 
mitoxantrone (as observed in 22Rv1 cells) induces p21 in PC-3 cells. This might 
contribute to G2/M cell cycle arrest, although through a p53-independent pathway. 
Furthermore, the combination of mitoxantrone with the AdE1A1102 and AdE1A12S 
viruses further increased p21 mRNA expression.  
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Figure 24. Fold change in percentage (FC %) of  p21 mRNA expression of in 22Rv1 cells. 
22Rv1 cells were infected with the AdE1A1102 mutant at 10ppc, with and without 50nM of 
mitoxantrone, for 48h. Data points were normalized as described in section 6.7. n=2. 
 
The expression of p21 mRNA was also assessed in 22Rv1 cells to verify the 
immunoblot findings. In accordance with the previous data, treatment with 
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mitoxantrone alone and in combination with all AdE1A12S viral mutants induced a 
10-fold increase in p21 mRNA expression compared to untreated cells (Fig. 24). 
However, only slight changes were observed in mRNA levels of p21 in response to 
infection with the viral mutants alone (Fig. 24). Treatment with docetaxel did not 
induce changes in p21, except in combination with AdE1A1102, where p21 increased 
>20-fold (Fig. 24). In summary, these results indicate that the induction of p21-mRNA 
by mitoxantrone was higher in 22Rv1 cells than in PC-3 cells. The AdE1A1102 and 
AdE1A12S mutants further increased the expression of p21 mRNA only in PC-3 cells, 
while in 22Rv1 cells the viral mutants did not induce any changes in p21-mRNA 
levels. 
 
3.1.3 Differential sensitivity in response to differential infectivity? 
Alternative cancer model in ovarian cells.  
 
Previous data have demonstrated different levels of infectivity between the PCa cell 
lines 22Rv1 and PC-3. Moreover, PC-3 cells showed more resistance to viral infection, 
while 22Rv1 were more sensitive.362 Furthermore, I and other members of my group 
have observed different responses to the various treatments between the two cell 
lines.362 These differences complicated the dissection of the pathways underlying the 
synergy since cell-specific factors might play a role in the synergistic mechanisms. To 
explore whether the observed differences in PC-3 and 22Rv1 were caused by the 
different levels of infectivity and viral uptake, we explored a pair of matched ovarian 
cell lines, Skov3 and Skov3ip1.371 Skov3 was previously reported to be more sensitive 
to viral infection and Skov3ip1 less sensitive and also more invasive and 
metastatic.371,373 We speculated that these cells may help us identify possible viral 
and drug targets for further studies.  
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3.1.3.a Skov3ip1 cells are four times more sensitive to viral infection than 
Skov3 cells. 
 
We conducted infectivity assays, as well a dose response assays, to determine the 
differences in sensitivity to viruses alone (Ad5wt, Ad∆∆ and AdE1A12S) and in 
combination with mitoxantrone in Skov3 and Skov3ip1 cells.   
 
Figure 25. Percentage of cells expressing GFP 48h post-infection with a non-replicating 
AdGFP mutant. Prostate cancer cell lines 22Rv1, PC-3, and ovarian cancer cell lines Skov3 
and Skov3ip1 were infected with a non-replicating AdGFP virus at 10 and 100ppc for 48h and 
analysed by flow cytometry. Each bar indicates the percentage of GFP+ cells in 1x104 cells. 
n=1.  
 
We compared infectivity in prostate and ovarian cancer cell lines to determine the 
level of viral uptake using a GFP expressing virus (AdGFP). As expected 22Rv1 cells 
were more infectable than PC-3 cells in a 5:1 ratio at 10 ppc and 3:1 ratio at 100 ppc 
(Fig.25). However, our results contrasted with previously published data, where 
Skov3 cells were reported to be more sensitive to viral infection than Skov3ip1.372 
The ovarian cancer cells Skov3 were more resistant to viral infection than Skov3ip1, 
and were also more resistant than PC-3 cells. In contrast Skov3ip1 cells were more 
sensitive to infection at a 5:1 ratio compared to Skov3, and showed similar 
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infectability to 22Rv1 cells at 100 ppc. However, at 10 ppc 22Rv1 were more sensitive 
to viral infection.  
 
 
 
3.1.3.b Skov3ip1 and Skov3 cells have similar sensitivity to AdE1A12S in 
combination with mitoxantrone  
 
Although our results of cell infectivity were contradictory to previous reports, where 
Skov3 cells were more sensitive to infection than Skov3ip1 cells, the differences 
found between these cell lines were comparable to the differences in infectivity of 
PC-3 and 22Rv1 cells (Fig.25). Therefore, a dose-response assay to virus and 
mitoxantrone was set up in order to determine whether the differences in infectivity 
and viral uptake were reflected in sensitivity to cell killing.  
The cells were infected using serial dilutions (5-fold) of the viruses Ad5wt, Ad∆∆ 
(E1ACR2-region and E1B19K-gene deleted; replication competent) and AdE1A12S 
(replication-incompetent with E1B and E3 genes deleted) or treated with 
mitoxantrone. At 72h post-treatment the cells were analysed and the data were 
collected to determine the EC50 values.  Unexpectedly the results showed that Skov3 
cells were more sensitive than Skov3ip1 to all the treatments except for AdE1A12S. 
The Skov3 cells had the highest sensitivity to the Ad∆∆ virus (mean EC50 of 35.2 ± 
9.02), Skov3ip1 cells showed a similar order of sensitivity to Skov3 cells (Fig. 26); 
being more sensitive to Ad∆∆ (mean EC50 of 65.10 ± 43.8) and less to Ad12S (mean 
EC50 of 2680 ± 2486) (Fig. 26). The sensitivity of both cell lines to AdE1A12S was 
significantly different (p≤0.05) to Ad5wt and Ad∆∆.  The relative sensitivity of viruses 
was similar in both cell lines.  
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Figure 26. Differences in sensitivity of ovarian cancer cell lines Skov3 and Skov3ip1 cells to 
viral infection and mitoxantrone treatment. Skov3 and Skov3ip1 cells were treated with 
serial 5-fold dilutions of mitoxantrone alone or the replicating viruses Ad5wt, and Ad∆∆ and 
the non-replicating AdE1A12S, for 72h. This graph shows the mean EC50 values of four 
independent experiments in triplicates. The mean EC50 values are shown in the table (ppc for 
virus and nM for mitoxantrone), and their correspondant SE. One-way ANOVA, significance 
*p≤0.05.  
 
The differences in sensitivity to each virus in the two cell lines were not significant. 
Therefore, these matched cell lines could not be used for our intended studies. 
Despite having different degrees of viral uptake, the differences in sensitivity to 
AdE1A12S-mediated or mitoxantrone-mediated cell killing were not significant and 
consequently would not be a suitable model for mechanistic studies.  
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3.1.4 Synergistic effects of infection with replicating and non-
replicating E1A viral mutants in combination with mitoxantrone in PC-3 
and 22Rv1 cells. 
 
During the course of this project we were completing previous sensitization studies 
that demonstrated that AdE1A12S mutants sensitize PCa cell lines to mitoxantrone 
enhancing cell killing. To further investigate whether these interactions causing 
enhanced cell killing were synergistic and comparable between non-replicating and 
replicating mutants, I set up assays at fixed ratios to determine combination index 
(CI).95 Four constant ratios of viruses and drug dose-response curves were selected 
based on previous preliminary studies in our group where EC50 values for each agent 
were determined.362 Selected ratios were tested to determine the CIs; additive, 
antagonistic or synergistic interactions. These experiments were aimed at 
determining which E1A deletion(s) in oncolytic adenoviral mutants could best 
sensitize cells and enhance cell killing in combination with mitoxantrone. 
Additionally, we investigated if the replicating mutants dl1102 and dl1104 showed 
similar effects to their respective non-replicative counterparts. 
 
3.1.4.a Mutants with E1A p300-binding region intact induce potent synergy 
in combination with mitoxantrone in PC-3 cells 
 
I tested the AdE1A12S virus and the replicating dl1102 and dl1104 and non-
replicating AdE1A1102 and AdE1A1104 E1A mutants in combination with 
mitoxantrone in PC-3 cells. I assessed the percentage of cell death six days post-
infection; these data were used to construct dose-response curves in order to 
determine the EC50 values for each treatment. Having determined the EC50 values, 
the CI values were calculated, to determine whether the interactions were 
synergistic (CI≤0.9), additive (CI 0.9-1.1) or antagonistic (CI≥1.1) (Fig. 27).  
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Figure 27. Mean CI values of PC-3 cells infected with AdE1A12S virus, the replicating and 
non-replicating 1102 and 1104 viruses, in combination with mitoxantrone at four different 
ratios. The ratios 0.5, 2.5, 12.5 and 62.5 ppc/nM were selected based on previous findings, 
to determine synergistic (CI≤0.9), additive (CI 0.9-1.1; dashed lines) or antagonistic (CI≥1.1) 
effects. Mean CI values are from five independent experiments in triplicates with the 
respective SEM.  Significance p≤0.05(*) by t-test when compared to the theoretical additive 
value (0.9-1.1).  
 
The average CI values for the combination treatment of mitoxantrone and AdE1A12S 
were significantly lower in PC-3 cells than the theoretical additive value (Add) at all 
ratios (4/4), showing strong synergistic interaction (Fig.27). In addition, dl1102 in 
combination with mitoxantrone showed synergy in 3 out of 4 ratios. The combination 
of the non-replicating AdE1A1102 with mitoxantrone showed synergy trend in 2 out 
of 4 ratios (0.5 and 2.5 ppc/nM), whereas 2 out of 4 ratios showed additive effects. 
These results demonstrate that AdE1A1102 has a similar propensity to dl1102 in 
acting synergistically in combination with mitoxantrone however, dl1102 induced 
synergy more effectively. The dl1104 virus acted synergistically in combination with 
mitoxantrone in 2 out of 4 ratios (2.5 and 62.5ppc/nM) (Fig. 27). Moreover, 
AdE1A1104 in combination with mitoxantrone acted synergistically in 3 out of 4 
ratios and antagonistically in 1 out of 4 (0.5 ppc/nM). These results indicate that in 
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PC-3 cells the combination of mitoxantrone with dl1102 and AdE1A12S viruses 
caused the most potent synergistic cell death and indicate that the p300-binding 
region is a determinant factor for this interaction, since the deletion in both dl1104 
and AdE1A1104 reduced synergistic cell killing. The poor synergistic effects with the 
AdE1A1104 virus (E1A∆p300 binding region) are consistent with our findings where 
AdE1A1104 did not seem to improve the efficacy of mitoxantrone in PC-3 cells.95   
3.1.4.b Combination of the replicating E1A viral mutant dl1102 and 
mitoxantrone act synergistically in 22Rv1 cells.  
 
Additionally, we analysed 22Rv1 cells for synergistic interactions. In these cells, 
dl1102 was the only one that showed a predominantly synergistic effect in 3 out of 4 
combination ratios (2.5, 12.5 and 62.5 ppc/nM) (Fig 28) in combination with 
mitoxantrone, with 1 out of 4 combinations being additive. Similar results were 
observed in PC-3 cells. In contrast to PC-3 cells, the combination with AdE1A12S 
showed no synergy, but an antagonistic trend in 2 out of 4 ratios and additive effects 
in two ratios. Furthermore, the combination with AdE1A1102 resulted in antagonistic 
interactions at all ratios, in contrast with the synergistic trend in PC-3 cells with this 
virus. The combination with dl1104 showed synergy in 1 out of 4 ratios (0.5ppc/nM, 
CI=0.75) and 2 out of 4 were above the theoretical additive value indicating 
antagonism, in contrast to the more synergistic responses observed by these 
combinations in PC-3 cells. With AdE1A1104, 1 out of 4 ratios was synergistic 
(2.5ppc/nM, CI=0.33) and one ratio showed an antagonistic trend (Fig. 28). 
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Figure 28. Mean CI values of 22Rv1 cells infected with AdE1A12S virus and the replicating 
and non-replicating 1102 and 1104 viruses, in combination with mitoxantrone at four 
different ratios. The ratios 0.5, 2.5, 12.5 and 62.5 ppc/nM of viral mutants and mitoxantrone 
were evaluated to calculate CI values, to determine synergy (CI≤0.9), additive (CI= 0.9-1.1; 
dashed lines) or antagonistic (CI≥1.1) effects. Average CI values are from 4 experiments 
measured in triplicates. Significance p≤0.05(*) by t-test, compared to the theoretical additive 
value (0.9; Dashed line) 
 
In summary, these results showed different interactions in response to the 
combination of viral mutants and mitoxantrone in PC-3 and 22Rv1 cells, being 
predominantly synergistic in PC-3 and antagonistic in 22Rv1 cells. However, with the 
dl1102 virus, synergy was observed in both cell lines showing that the virus was 
highly effective and potent enough to enhance cell killing by mitoxantrone. The 
combination of AdE1A12S, AdE1A1102, and dl1104 with mitoxantrone showed cell-
line-dependent synergistic interactions.  
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3.1.5 The replicating adenoviral mutants do not enhance cell killing in 
combination with mitoxantrone in normal human cells 
 
Normal human bronchial epithelial cells (NHBE) and normal prostate epithelial cells 
(PrEC) were used to determine if the deletions in the dl1102 or dl1104 replicating 
mutants could potentially be applied to generate more selective oncolytic mutants 
with minimal effects in normal tissue. Therefore, we assessed their ability to 
replicate in NHBE cells by determining the viral replication efficacy, measured by 
TCID50 assay over time from 24-72h (Fig. 29). 
 
 
Figure 29. Viral replication in normal human bronchial epithelial cells (NHBE). TCID50 assay 
to determine infective viral particle plaque forming units (pfu). NHBE cells were infected at 
100ppc and harvest after 24, 48 and 72h(h.p.i). Cell lysates were titred in the TCID50 assay, 
serially diluted from 1x10-3 to 1x10-9 in JH293 cells. Three experiments by duplicate, averaged 
± SEM. Student t-test *p<0.005.95  
 
NHBE cells infected with both dl1102 and dl1104 showed significantly less replication 
than Ad5wt at 48h and 72h. NHBE cells infected with the dl1102 showed only 2.30 
pfu/cell at 48hpi and 6.1pfu/cell at 72hpi, while no replication was observed for the 
dl1104. Ad5wt virus, showed an increase to 8.41 pfu/cell at 48hpi and 25.1pfu/cell at 
72hpi. At 72h the differences in replication were significant when comparing all three 
viruses. The dl1104 infected cells showed poor viral replication compared to both 
Ad5wt and dl1102 at all-time points. The greatly decreased viral replication of both 
dl1102 and dl1104 in NHBE cells (Fig. 29), suggested that both mutants have 
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impaired replication in non-cancerous tissue. In contrast in PCa cells both dl1102 and 
dl1104 showed levels of viral replication similar to those of Ad5wt95  
We also determined the toxicity of the virus and mitoxantrone as single agents and in 
combination in NHBE cells to further verify that the replicating viruses do not cause 
more than additive cell death with mitoxantrone in these cells.   
 
 
Figure 30. Normal human bronchial epithelial cells (NHBE) treated alone and in 
combination with adenoviral mutants and mitoxantrone. NHBE cells were infected with the 
replicating dl1102, dl1104, Ad5wt, Ad∆∆ and the non-replicating AdE1A1102 and AdE1A1104 
at 10 ppc alone (white bars), treated with mitoxantrone alone (black bar) at 200nM and in 
combination (crossed and striped bars). Cell viability was determined by MTS assay 72h post-
treatment. The theoretical additive (Additive effect) values are indicated by grey bars, 
Student t-test *p<0.05 compared to expected additive cell killing, n = 2.95 
 
To determine if adenoviral mutants enhance cell killing in combination with 
mitoxantrone in NHBE cells, the cells were infected with viruses at 10ppc and treated 
with 200nM mitoxantrone alone and in combination (Fig. 30). The treatment with 
mitoxantrone alone reduced cell viability to about 50%. The infection with the Ad5wt 
resulted in more than additive effect in combination with mitoxantrone, 
demonstrating the non-selectivity of this virus. The combination of mitoxantrone 
with the non-replicating (AdE1A1102 and AdE1A1104) and replicating (dl1102, 
dl1104 and Ad∆∆) adenoviral mutants caused less than additive effects. The infection 
with the non-replicating AdE1A1102 and AdE1A1104 reduced cell viability to a 
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slightly higher degree than the replicating counterparts.  Moreover, the Ad∆∆ 
showed higher potency compared with dl1102 and dl1104, although the reduction in 
cell viability did not sensitize NHBE cells to mitoxantrone. These results demonstrate 
that the replicating viruses selectively synergize with mitoxantrone in tumour cells 
but not in normal cells. 
 
 
Figure 31. Primary human prostate epithelial cells (PrEC) treated alone and in combination 
with adenoviral mutants and mitoxantrone. PrEC cells were infected with the replicating 
dl1102, dl1104, Ad5wt, Ad∆∆ and the non-replicating AdE1A1102 and AdE1A1104 at 10 ppc 
alone (white bars) and in combination with 200 nM mitoxantrone (M) (crossed and striped 
bars). Cell viability was determined by MTS assay 72 h later. The theoretical additive (Addit) 
values are indicated by grey bars, Student t-test  *p<0.05 compared to expected additive cell 
killing, n = 2.95 
 
To verify our findings in the NHBE cells we also infected normal human PrEC cells 
with the replicating and non-replicating viral mutants at 10ppc and treated them 
with 200nM mitoxantrone alone and in combination (Fig. 31). Treatment with 
mitoxantrone alone reduced cell viability by less than 5% at this concentration, 
indicating less sensitivity to the drug than in NHBE cells. In general, PrEC cells were 
less sensitive to both infection and the drug.  Similar to the findings in NHBE cells 
Ad5wt in combination with mitoxantrone induced more than additive cell killing. 
Additionally and similarly to NHBE cells, the combination of mitoxantrone with the 
replicating and non-replicating adenoviral mutants did not induce more than additive 
effects on cell killing in PrEC cells. In contrast to NHBE cells, PrEC cells were more 
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sensitive to the infection with the replicating viruses than the non-replicating 
mutants, with dl1102 and Ad∆∆ being more potent than AdE1A1102. However, 
neither dl1102 nor Ad∆∆ induced more than additive cell killing in combination with 
mitoxantrone. Surprisingly, AdE1A1104 showed higher potency and reduced cell 
viability at a higher percentage than its replicating counterpart. Importantly these 
results show in two normal cell lines, that the viral mutants dl1102 and Ad∆∆ are as 
potent as the Ad5wt but do not sensitize the normal cells to chemotherapeutic 
drugs, validating their tumour selectivity. 
3.1.6 The dl1102 mutant potently reduces tumour growth in 
combination with docetaxel in PC-3 xenografts in vivo 
 
In order to verify our findings in vivo, PC-3 cells were subcutaneously inoculated in 
athymic mice and infected with the replicating and non-replicating E1A mutants.  The 
non-replicating AdE1A12S, AdE1A1102 and AdE1A1104 mutants were not efficacious 
in reducing tumour growth alone or in combination with docetaxel.95 In contrast, the 
replicating dl1102 and dl1104 significantly inhibited tumour growth in combination 
with docetaxel, indicating that the viruses sensitized tumour cells to the drug. 
However, only dl1102 was potent enough to significantly reduce tumour growth 
alone (Fig. 32).  
 
  
Figure 32. PC-3 xenografts in vivo treated with docetaxel alone and in combination with 
replicating E1A mutants. A) Animals with PC-3 subcutaneous tumour xenografts were 
treated with the dl1102 (filled triangle) or dl1104 (filled circle) mutants or mock treated with 
dl312 (filled square) at 1x109 vp (i.t. injections on day 1, 3, and 5) with and without docetaxel 
at 10 mg/kg (D10; i.p. administration on day 2 and 8, open squares), and tumour growth was 
monitored. *p,0.05, treatments compared with mock and single-agent treatments (one-way 
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ANOVA), *p<0.05 for dl1102 alone compared to mock, n = 6. B) In a second study animals 
with PC-3 subcutaneous tumour xenografts were treated as above with the indicated 
suboptimal doses of viral mutants at 1x109vp and docetaxel at 10 mg/kg (D10) or the 
respective combinations. Median time to tumour progression (tumour volume .500 µl) was 
determined by Kaplan-Meier survival analysis (8–10 animals per group). *p<0.05, 
combination-treated compared with docetaxel.95 
 
These results verified the in vitro findings, where the potent sensitization of prostate 
cancer cells was induced by the replicating E1A oncolytic mutant dl1102, but not 
dl1104. In addition, in a study with C57Bl/6 athymic mice induced with PC-3 
subcutaneous tumour xenografts the median time to progression was determined to 
be 40, 30 and 28 days for animals infected with dl1102, dl1104 and treated with 
docetaxel respectively. In contrast, more than half of the animals treated in 
combination did not show tumour progression at the end of the study, 70 days after 
treatment. These results showed the potent anti-tumour efficacy in vivo of the 
replicating dl1102 and dl1104 in combination with docetaxel and verified our 
previous results in vitro where enhanced synergistic cell killing in response to the 
combination treatments was shown.  
  
 
3.1.7 In summary 
 
• Mitoxantrone induces cyclins A and B in PC-3 cells but not in 22Rv1 cells. 
• The AdE1A12S and AdE1A1102 viral mutants enhance mitoxantrone-induced 
p21 mRNA expression in PC-3 cells but not in 22Rv1 cells. 
• Synergistic effects on cell killing with replicating and non-replicating E1A 
viral mutants in combination with mitoxantrone in PC-3 and 22Rv1 cells. 
Mutants with E1A p300-binding region intact induce potent synergy in 
combination with mitoxantrone in PC-3. Combination of the replicating E1A 
viral mutant dl1102 and mitoxantrone act synergistically in 22Rv1 cells. 
• The replicating adenoviral mutants do not enhance cell killing in combination 
with mitoxantrone in PrEC and NHBE human normal cells.  
• The dl1102 mutant potently reduces tumour growth in combination with 
docetaxel in PC-3 xenografts in vivo. 
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3.2 Analysis of miRNAs that are differentially expressed in PC-3 cells 
treated with AdE1A12S or mitoxantrone or a combination of both.  
 
Our work demonstrated that the small E1A12S-protein was essential for sensitizing 
PCa cell lines to the chemotherapeutic drugs mitoxantrone and docetaxel, which are 
currently used as front line treatments for hormone refractory PCa.95,362 Previously 
we demonstrated synergistic cell killing in PC-3 cells (Miranda, 201295; Section 3.1.5), 
with both drugs in combination with AdE1A12S and AdE1A12S-mutants. 
Identification of the cellular mechanisms involved in sensitization to E1A has been 
elusive.95 Some reasons are that the E1A-protein can bind to a plethora of cellular 
factors with related functions and that have overlapping binding sites in E1A. Most of 
these factors are involved in regulation of cell death, survival, and cell cycle 
pathways. To elucidate the mechanisms and pathways that caused the observed 
synergistic cell killing requires extensive in depth studies in each cell line. We 
speculated that a more rational approach including mRNA or miRNA array-screening 
would enable us to get insights into the cellular pathways that are involved. We 
chose PC-3 cells because of the insensitivity to each single agent and the significantly 
synergistic enhancement of cell killing when virus and drug were combined. 
We hypothesised that the expression of miRNAs might be affected by either 
chemotherapeutic drugs and/or expression of E1A12S and that the combination-
treated cells would reveal a different pattern of miRNA expression. We anticipated 
that data from a sensitive and comprehensive miRNA array analysis would guide us 
towards the cellular pathways and targets that are involved in the sensitization and 
that these targets could be further exploited in developing improved therapies for 
PCa. 
 To this end, a miRNA array analysis was performed using 850 human microRNAs 
based on the Sanger miRNA database (LC Science, TX, USA). PC-3 cells were infected 
with AdE1A12S (100ppc) or treated with mitoxantrone (50nM) or a combination of 
both for 24 and 48h. These doses were demonstrated to cause synergistic cell death 
in parallel studies.95 The differences in the expression of miRNAs in response to each 
agent alone and in combination were quantified and compared to untreated and 
non-infected cells and to the theoretical combination of both single agents. All 
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miRNAs with an average signal of intensity of >500 and that were statistically 
significant (p<0.01; Students t-test) were selected for the analysis. In total 73 miRNAs 
fulfilled these parameters. Moreover, a Log2 positive value indicates upregulation 
and a negative Log2 value indicates a downregulation.  
3.2.1. In PC-3 cells miRNAs are differentially expressed 24h post-infection 
with the AdE1A12S virus compared to untreated cells. 
 
Highly significant differences (p<0.001) in the expression of 29 miRNAs were 
observed in PC-3 cells infected for 24h with the AdE1A12S virus compared to 
untreated and uninfected cells. The highly significant miRNAs showed upregulation in 
15 out of 29 miRNAs (Log2>0.0; Table 11) whereas 14 out of 29 miRNAs were 
downregulated (Log2<0.0; Table 11). Interestingly, hsa-miR-16, hsa-miR-19b, hsa-
miR-26a, hsa-miR-27a, hsa-mir29a were upregulated by AdE1A12S and have 
previously been reported to be expressed at low levels in PCa.231,234-238 Also, hsa-miR-
1246 and hsa-miR-574-3p have been reported to be upregulated in PCa, and hsa-
miR-483-5p and hsa-miR-574-5p in other cancers, while AdE1A12S significantly 
downregulated these miRNAs.  However the greatest changes (Log2>1.3 and <-1.3) in 
miRNA levels in response to AdE1A12S was observed for hsa-miR-106a, hsa-miR-
106b and hsa-miR-19b, hsa-miR-20a and hsa-miR-29a that had increased expression 
and hsa-let-7e, hsa-miR-1268,  hsa-miR-483-5p, hsa-miR-542-5p, hsa-miR-574-3p/5p, 
hsa-miR-638 and hsa-miR-923 that had decreased expression, all of which have been 
validated to be altered in PCa and/or other cancers.231,234-238 
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Table 11. Differentially expressed miRNAs in PC-3 cells 24h post-infection with the 
AdE1A12S virus (100ppc) compared to uninfected and untreated cells. 
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow).  
 
The information available for the miRNAs hsa-mir1268, hsa-miR-1275, and hsa-miR-
542-5p did not allow us to establish a complete profile in terms of their expression in 
cancer. It is also important to point out that there is no information available for the 
miRNAs hsa-miR-923 and hsa-miR-1280 since they are not considered as mature 
miRNA sequences, these miRNAs are likely fragments of the 28S rRNA and of a tRNA 
respectively.387 The miRNA hsa-miR-1826 is considered to be a fragment of the 5.8S 
rRNA and is therefore not a mature miRNA.387 These findings suggest that at least 
four miRNAs that are known to be expressed at low levels in PCa (hsa-miR-19b, and 
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hsa-miR-29a, hsa-let-7e and hsa-miR-638) were significantly up- or downregulated by 
the E1A12S protein, indicating a role of these miRNAs in cell growth and death.   
 
3.2.2 In PC-3 cells miRNAs are differentially expressed at 24h post-treatment 
with mitoxantrone compared to untreated cells. 
 
Significant differences (p<0.001) in miRNA expression were observed in PC-3 cells 
treated with mitoxantrone for 24h compared to untreated and uninfected cells. 
Eleven out of 19 miRNAs were downregulated (red-Log2 column; Table 12) and eight 
out of 19 upregulated (green-Log2 column; Table 12). The largest differences in the 
change of expression (Log2<-2.0) among downregulated miRNAs were shown by hsa-
miR-1268, hsa-miR-638 and hsa-miR-923, although only hsa-miR-1268 and hsa-miR-
638 are considered as mature sequences of miRNA.382  While no information about 
the miRNA hsa-miR-1268 that could be useful for our purposes was found, this 
miRNA was downregulated by both AdE1A12S and mitoxantrone. The upregulated 
miRNA hsa-miR-423-5p showed the largest difference compared to untreated 
samples (Log2=1.65). Interestingly, hsa-miR-100, hsa-miR-16, hsa-miR-200b and hsa-
miR-222 were upregulated by mitoxantrone and have previously been reported to be 
expressed at low levels in PCa. In contrast, hsa-miR-1246 and hsa-miR-99b are known 
to be overexpressed in PCa and mitoxantrone reduced the expression levels.231,234-238 
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Table 12. Differentially expressed miRNAs in PC-3 cells 24h post-treatment with 
mitoxantrone (50nM), compared to untreated and uninfected cells. 
 
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow). 
 
The changes in the expression of miRNAs due to the treatment with mitoxantrone 
showed fewer regulated miRNAs (total 19) compared to samples infected with the 
AdE1A12S virus (total 29; Table 11). Moreover, eleven out of nineteen miRNAs hsa-
let-7c, hsa-let-7d, hsa-miR-100, hsa-miR-125b, hsa-miR-182, hsa-miR-191, hsa-miR-
200b, hsa-miR-222, hsa-miR-423-5p, hsa-miR-92a and hsa-miR-99b  were not 
regulated by the treatment with the virus but changed in response to mitoxantrone 
alone. Interestingly the expression of the miRNAs hsa-let-7e, hsa-miR-1246, hsa-miR-
16 and hsa-miR-1826 (Table 12) showed a similar pattern of expression to miRNAs of 
samples infected with the AdE1A12S virus (Table 11). The hsa-miR-16, hsa-let-7e and 
hsa-miR-1826 were upregulated and hsa-miR-1246 was downregulated by both 
AdE1A12S and mitoxantrone. In contrast, samples infected with the virus alone 
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showed a change in the expression of twenty different miRNAs (hsa-miR-106a, hsa-
miR-106b, hsa-miR-125a-5p, hsa-miR-1275, hsa-miR-1280, hsa-miR-151-3p, hsa-miR-
17, hsa-miR-19b, hsa-miR-20a, hsa-miR-21, hsa-miR-24, hsa-miR-26a, hsa-miR-27a, 
hsa-miR-29a, hsa-miR-30d, hsa-miR-483-5p, hsa-miR-542-5p, hsa-miR-574-3p, hsa-
miR-574-5p and hsa-miR-99a) that were not regulated when treated by 
mitoxantrone as a single agent. 
 
3.2.3 In PC-3 cells miRNAs are differentially expressed at 24h post-treatment 
with AdE1A12S in combination with mitoxantrone compared to untreated 
and uninfected cells. 
 
The differences in the expression of miRNAs in PC-3 cells simultaneously treated with 
mitoxantrone at 50nM and infected with the AdE1A12S virus at 100ppc were 
compared to untreated and uninfected samples. The expression of 16 out of 37 
miRNAs were downregulated (red Log2 column; Table 13) and 21 out of 37 miRNAs 
were upregulated (green Log2 column; Table 13) in response to the combination. 
Moreover, 9 out of 16 downregulated miRNAs (hsa-miR-191, hsa-miR-320a, hsa-miR-
320c, hsa-miR-320d, hsa-miR-425, hsa-miR-483-5p, hsa-miR-574-3p, hsa-miR-574-5p, 
hsa-miR-99b; red) and 12 out of 21 upregulated miRNAs (hsa-let-7g, hsa-miR-128, 
hsa-miR-16, hsa-miR-19b, hsa-miR-23a, hsa-miR-23b, hsa-miR-26a, hsa-miR-26b, hsa-
miR-27a, hsa-miR-27b, hsa-miR-29a and hsa-miR-30b; green) have previously been 
reported to be expressed at higher and lower levels respectively in PCa.231,234-238  
The largest differences in the expression of downregulated miRNAs (Log2<-2) were 
shown by the miRNAs hsa-miR-483-5p, hsa-miR-574-3p, hsa-miR-574-5p, hsa-miR-
638 and hsa-miR-923. Although they were significantly different, the miRNAs hsa-
miR-483-5p, hsa-miR-574-5p hsa-miR-638 and hsa-miR-923 have not been validated 
in PCa and the latter is not consider a mature miRNA sequence.387 The largest 
difference in the expression of upregulated miRNAs (Log2>1.20) was shown (in 
decreasing order) by the miRNAs hsa-miR-27b, hsa-miR-27a, hsa-miR-20b, hsa-miR-
19b, hsa-miR-30b, hsa-miR-20a and hsa-miR-26b (Table 13).  
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Table 13. Differentially expressed miRNAs in PC-3 cells at 24h post-treatment with 
the combination of AdE1A12S (100ppc) and mitoxantrone (50nM) compared to 
untreated and uninfected cells.  
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow). 
 
The number of significantly differentially regulated miRNAs was higher in the 
combination-treated cells than in cells infected with virus only (37 versus 29) (Table 
11 and 13). Additionally, 19 out of 37 miRNAs (hsa-miR-106a, hsa-miR-106b, hsa-
miR-1268, hsa-miR-1280, hsa-miR-16, hsa-miR-17, hsa-miR-19b, hsa-miR-20a, hsa-
miR-21, hsa-miR-24, hsa-miR-26a, hsa-miR-29a, hsa-miR-483-5p, hsa-miR-574-3p, 
hsa-miR-574-5p, hsa-miR-638, hsa-miR-923, hsa-miR-93) were regulated both by the 
virus alone and the combination treatment showing the same pattern of expression 
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(Table 11 and 13). In contrast, the combination-treated cells compared to 
mitoxantrone-treated cells, showed that only 7 out of 37 miRNAs (hsa-let-7d, hsa-
miR-1268, hsa-miR-16, hsa-miR-191, hsa-miR-638, hsa-miR-923 and hsa-miR-99b) 
were regulated in both sets (downregulated). Moreover, the intricate complexity of 
the miRNA regulatory mechanism is shown by hsa-miR-191 that had a different 
pattern of expression in the combination (downregulated; Table 13) compared to 
mitoxantrone alone (upregulated; Table 12) and was not modified by the virus alone 
(Table 11). The regulation of hsa-miR-191 could be induced by mitoxantrone while in 
the context of viral infection another miRNA might affect its regulation.    
3.2.4 In PC-3 cells, simultaneously treated with mitoxantrone and infected 
with AdE1A12S for 24h, differentially expressed miRNAs show a more than 
additive deregulation when compared to the theoretical sum of the miRNAs 
in single agent-treated cells. 
 
The differences in the expression of miRNAs when the combination-treated cells 
were compared to the sum of the single agent treatment with AdE1A12S and 
mitoxantrone for 24h (Table 14), were highly significant (p<0.001) for 14 miRNAs. 
Four of these miRNAs (hsa-miR-1826, hsa-miR-191, hsa-miR-320a and hsa-miR-425) 
were downregulated in the combination-treated cells compared to the sum of the 
single agents. Ten miRNAs were upregulated (Table 14), (hsa-miR-16, hsa-miR-23a, 
hsa-miR-23b, hsa-miR-26b, hsa-miR-27a, hsa-miR-27b, hsa-miR-30b and hsa-miR-
99a) and nine of these were previously reported as downregulated in PCa.231,234-238 In 
addition, hsa-miR-191, hsa-miR-320a and hsa-miR-425 that were downregulated in 
the combination compared to the sum of the single agents are known to be 
overexpressed in PCa and other cancers (Table 14).231,234-238 Table 14 shows that 12 
out of 14 deregulated miRNAs in response to the combination treatments compared 
to the sum of the single agents have been found to be validated and have altered 
expression in PCa cells and tissue (Table 14; Dark blue). 
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Table 14. Differentially expressed miRNAs in PC-3 cells simultaneously infected 
with AdE1A12S (100ppc), and treated with mitoxantrone (50nM) compared to the 
sum of miRNAs changes in single agent-treated cells. 
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow). 
 
By comparing the expression of miRNAs in the combination to the sum of single 
agent treatments shown in Table 14 and the expression of miRNAs in the 
combination compared to untreated samples shown in Table 13, we observed that 
the miRNAs hsa-miR-125a-5p, hsa-miR-99a and hsa-miR-1826 only changed when 
compared to the sum of single agent treatments but not when the expression of the 
combination was compared to untreated samples. However, the expression of 10 out 
of 14 miRNAs (hsa-miR-16, hsa-miR-191, hsa-miR-23a, hsa-miR-23b, hsa-miR-26b, 
hsa-miR-27a, hsa-miR-30b, hsa-miR-30c, hsa-miR-320a, and hsa-miR-425) showed a 
similar pattern of expression in both analysis (Table 13 and 14).      
 
3.3 Differentially expressed miRNAs in PC-3 cells treated with 
AdE1A12S, mitoxantrone and the combination of AdE1A12S and 
mitoxantrone for 48h. 
 
3.3.1 In PC-3 cells, miRNAs are differentially expressed also after 48h when 
infected with the AdE1A12S virus compared to untreated cells. 
 
The differences in the expression of miRNAs were highly significant 48h post-
infection with AdE1A12S in PC-3 cells, resulting in 33 and 27 out of 60 miRNAs being 
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downregulated and upregulated respectively (Table 15). Fifteen downregulated 
miRNAs (hsa-let-7i, hsa-miR-106a, hsa-miR-106b, hsa-miR-107, hsa-miR-151-3p, hsa-
miR-151-5p, hsa-miR-20a, hsa-miR-21, hsa-miR-17, hsa-miR-182, hsa-miR-24, hsa-
miR-25, hsa-miR-30c, hsa-miR-30d and hsa-miR-93), were previously reported to be 
upregulated in PCa.231,234-238 Ten of the twenty-seven upregulated miRNAs (hsa-let-
7a, hsa-let-7b, hsa-let-7c, hsa-let-7d, hsa-let-7e, hsa-miR-1826, hsa-miR-361-5p, hsa-
miR-638, hsa-miR-92a, and hsa-miR-92b) were reported to be downregulated in 
PCa.231,234-238 Forty-two of the sixty (Table 15; dark blue) miRNAs have been reported 
as deregulated in PCa. The differences in the expression (in decreasing order of fold 
change) of hsa-miR-923, hsa-miR-601, hsa-miR-574-5p, hsa-miR-483-5p, hsa-miR-
638, hsa-miR-1280, hsa-miR-1268 and hsa-miR-574-3p were considerably higher 
(Log2> 2.0) than for other upregulated miRNAs (Table 15). However, the miRNAs hsa-
miR-1280 and hsa-miR-923 are not considered to be mature sequences of miRNA,387 
and except for hsa-miR-574-3p all other mature miRNA sequences with Log2>2.0 
belong to the 18 out of 60 miRNAs that have not yet been validated in PCa cells or 
tissue. The differences in the expression of downregulated miRNAs was largest Log2< 
-2.0 for hsa-miR-21, hsa-miR-26b, hsa-miR-27a, hsa-miR-99a, hsa-miR-29a, hsa-miR-
20a and hsa-miR-106a. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
131 
 
Table 15. Differentially expressed miRNAs in PC-3 cells 48h post-infection with the 
AdE1A12S virus (100ppc) compared to uninfected and untreated cells.  
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow). 
 
The differences in the expression of miRNAs in PC-3 cells at 48h post-infection with 
the AdE1A12S virus showed an increase in the number of deregulated miRNAs 
compared to 24h, increasing from 29 to 60 miRNAs (Table 11 and 15). From the 60 
significantly deregulated miRNAs, 25 were also deregulated at 24h hsa-let-7e, hsa-
miR-106a, hsa-miR-106b, hsa-miR-1268, hsa-miR-1275, hsa-miR-1280, hsa-miR-151-
3p, hsa-miR-16, hsa-miR-17, hsa-miR-1826, hsa-miR-20a, hsa-miR-21, hsa-miR-24, 
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hsa-miR-26a, hsa-miR-27a, hsa-miR-29a, hsa-miR-30d, hsa-miR-483-5p, hsa-miR-574-
3p, hsa-miR-574-5p, hsa-miR-638, hsa-miR-923, hsa-miR-92b, hsa-miR-93, hsa-miR-
99a) (Tables 11 and 15). Moreover, from the 25 miRNAs only hsa-miR-1826 and hsa-
miR-99a were regulated at both time points in the same manner (up- and down-
regulated respectively), the remaining 23 miRNAs showed a different regulation after 
infection (Tables 11 and 15), this implies that changes in the miRNA expression are 
time-dependent and that secondary regulatory mechanisms are activated at later 
time points. 
3.3.2 In PC-3 cells, miRNAs are differentially expressed also at 48h post-
treatment with mitoxantrone compared to untreated cells. 
 
The pattern of expression of highly significant changes in miRNAs in PC-3 cells 
treated with mitoxantrone for 48h, showed that 20/45 miRNAs were upregulated 
and 25 out of 45 were downregulated in response to the treatment (Table 16). 
Moreover, 11/20 upregulated miRNAs (hsa-let-7b, hsa-let-7c, hsa-let-7d, hsa-let-7e, 
hsa-miR-125a-5p, hsa-miR-15b, hsa-miR-16, hsa-miR-1826, hsa-miR-29c, hsa-miR-
92b, and hsa-miR-99a) were reported to be downregulated in PCa or other types of 
cancer (Table 16). In contrast, 14 out of 25 downregulated miRNAs (hsa-miR-106a, 
hsa-miR-106b, hsa-miR-107, hsa-miR-151-3p, hsa-miR-151-5p, hsa-miR-17, hsa-miR-
191, hsa-miR-20a, hsa-miR-24, hsa-miR-30d, hsa-miR-320a, hsa-miR-425, hsa-miR-93, 
hsa-miR-99b, were reported to be upregulated in PCa or other types of cancer  (Table 
16).231,234-238 The largest difference was for hsa-miR-29c (Log2= 2.04), that has been 
previously demonstrated to be downregulated in cancer, although it has not been 
implicated in PCa.231,234-238 The hsa-miR-29c was not considered for further analysis 
since, as well as the miRNAs hsa-miR-30d hsa-miR-425, hsa-miR-98 and hsa-miR-99a, 
were not verified in a second experiment (Section 3.4). And only those miRNAs 
verified in the second experiment were considered for further analysis. 
When results for the treatment with mitoxantrone were compared to those for 
infection alone at 48h, we observed that 36 out of 45 miRNAs were being regulated 
by both treatments (Table 16 and 15). From the 36 miRNAs that changed at both 
time points only 7 miRNAs (upregulated with mitoxantrone green; hsa-miR-16, hsa-
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miR-182, hsa-miR-21, hsa-miR-99a; downregulated, red; hsa-miR-320a, hsa-miR-361-
5p, and hsa-miR-99b) showed a different pattern of expression, whereas 29 miRNAs 
showed a similar pattern of expression (Table 16 and 15). 
In the analysis we observed that when the miRNAs treated with mitoxantrone for 
48h were compared to the 24h samples, there was an increase in the number of 
miRNAs being deregulated from 19 up to 45 (Table 12 and 16). Moreover, only 13/45 
(hsa-let-7c/d/e, hsa-miR-100, hsa-miR-1246, hsa-miR-16, hsa-miR-182, hsa-miR-
1826, hsa-miR-191, hsa-miR-222, hsa-miR-423-5p, hsa-miR-99a and hsa-miR-99b) 
miRNAs were regulated by the treatment at both time points 24h and 48h (Table 12 
and 16). The expression of 8/13 miRNAs that were regulated in response to the 
treatment at both time points showed a different pattern of expression, whereas the 
miRNAs hsa-let-7c/d/e and hsa-miR-1246 were downregulated at 24h (red) and 
upregulated at 48h (green) (Table 12 and 16). The miRNAs hsa-miR-191, hsa-miR-222 
and hsa-miR-99a and hsa-miR-100 were upregulated at 24h (green) and 
downregulated at 48h (red) (Table 12 and 16). Only 5 out of 13 miRNAs (upregulated 
hsa-miR-16, hsa-miR-182, hsa-miR-1826 and hsa-miR-423-5p, green; downregulated 
hsa-miR-99b red) showed the same pattern of expression at 24h and 48h. However, 
at 48h most of these miRNAs (except hsa-miR-1826 and hsa-miR-99b) showed almost 
half Log 2 higher expression in the 24h samples (Table 12 and 16).  
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Table 16. Differentially expressed miRNAs in PC-3 cells 48h post-treatment with 
Mitoxantrone (50nM) compared to untreated and uninfected cells. 
 
  
p-values determined by t-test; highly significant p-values (p<0.001; yellow). 
 
The changes in the pattern of expression of different miRNAs, such as let-7c/d/e, 
may reflect that the regulatory pathways of these miRNAs are dependent on the 
activation or deregulation of other miRNAs or genes. There might be a progressive 
signalling cascade that changes over time. Moreover, miRNAs such as hsa-miR-16 
showed no change in the pattern of expression at 48h compared to 24h, although 
there was a change in absolute magnitude of the difference, decreasing from 0.83 at 
24h to 0.2 at 48h. Although the regulatory mechanisms seem to be far more 
complex, the differences in the miRNA expression indicate that miRNAs such as hsa-
miR-16 or hsa-hsa-miR-100 that might be primary targets and could trigger the 
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regulation of secondary target miRNAs (such as hsa-let-7c/d/e or has-hsa-miR-99a) 
that are acting as late effectors within one or more signalling pathways in a time-
dependent manner. Moreover, the miRNAs could also be induced at an early stage 
but repressed at a late stage by other targets. The direct regulation of such miRNAs is 
not part of this study, but is an interesting point that should be assessed in future 
studies.  
 
3.3.3 In PC-3 cells, miRNAs are differentially expressed also after 48h when 
simultaneously infected with AdE1A12S and treated with mitoxantrone 
compared to untreated cells. 
 
The combination of mitoxantrone (50nM) and AdE1A12S (100ppc), resulted in 
upregulation of 23 out of 45 and downregulation of 22 out of 45 miRNAs after 48h 
when compared to the untreated samples (Table 17). The upregulation of 11/23 
miRNAs (hsa-let-7a/b/c/d/e/f, hsa-miR-106a, hsa-miR-107, hsa-miR-125a-5p, hsa-
miR-15b, hsa-miR-1826, hsa-miR-638 and hsa-miR-92b) is interesting since these 
miRNAs have been reported to be downregulated in cancer tissues (Table 17). 
Moreover the expression of 11/22 miRNAs (hsa-miR-106a, hsa-miR-107, hsa-miR-
151-3p, hsa-miR-151-5p, hsa-miR-17, hsa-miR-191, hsa-miR-20a, hsa-miR-24, hsa-
miR-30d, hsa-miR-425, hsa-miR-93, hsa-miR-99b) that were downregulated by the 
combination treatments were previously reported to be upregulated in PCa (Table 
17).231,234-238 From the total of 45 miRNAs deregulated by the combination only 9 
have not been verified in PCa (Table 17; light blue), whereas in 4 miRNAs the 
information is not available (Table 17; NA).  
The largest differences in the expression of miRNAs were shown by hsa-miR-1246, 
hsa-miR-1826 and hsa-miR-638 (Log2> 2.0, upregulated; green) and hsa-miR-222, 
hsa-miR-24, hsa-miR-31 and hsa-miR-93 (Log2< -1.20, downregulated; red) (Table 
17). 
When compared to the treatments alone, 36 out of 45 miRNAs were deregulated in 
response to the combination and were also regulated by the virus alone (Table 15). 
Moreover, 37 of 45 miRNAs were regulated by the combination and with 
mitoxantrone alone. The expression of 37 of 37 miRNAs in response to mitoxantrone 
136 
 
alone showed a similar pattern of expression when compared to the combination 
(up- and downregulated samples; Tables 15 and 17). When we compared the 
infected samples we observed that 36 of 36 miRNAs also showed the same pattern 
of expression as the combination (Tables 14 and 17). The expression of 30 out of 45 
miRNAs (hsa-let-7b/c/d/e, hsa-miR-100, hsa-miR-103, hsa-miR-106a, hsa-miR-107, 
hsa-miR-1275, hsa-miR-1308, hsa-miR-151-3p, hsa-miR-151-5p, hsa-miR-17, hsa-miR-
182, hsa-miR-1826, hsa-miR-20a, hsa-miR-21, hsa-miR-221, hsa-miR-222, hsa-miR-
23a, hsa-miR-23b, hsa-miR-24, hsa-miR-27a, hsa-miR-29a, hsa-miR-30d, hsa-miR-31, 
hsa-miR-423-5p, hsa-miR-92b, hsa-miR-93 and hsa-miR-99b) overlapped with those 
in the AdE1A12S-infected samples, mitoxantrone-treated samples and the 
combination-treated samples when compared to the untreated samples. The 
expression of only 2 out of 45 miRNAs, hsa-let-7f and hsa-miR-125b, were not 
deregulated by any of the single agents treatments (Tables 14, 15 and 15).  
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Table 17. Differentially expressed miRNAs in PC-3 cells simultaneously infected 
with AdE1A12S (100ppc) and treated with mitoxantrone (50nM) compared to 
untreated cells at 48h after treatment. 
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow). 
 
When the expression of miRNAs in cells treated with mitoxantrone in combination 
with AdE1A12S-infection at 48h was compared to the same treatment at 24h, an 
increase was observed from 37 to 45 differentially expressed miRNAs (Tables 13 and 
17). The expression of 18/45 miRNAs (hsa-let-7b, hsa-let-7d, hsa-miR-106a, hsa-miR-
1280, hsa-miR-17, hsa-miR-191, hsa-miR-20a, hsa-miR-21, hsa-miR-23a, hsa-miR-23b, 
hsa-miR-24, hsa-miR-29a, hsa-miR-320d, hsa-miR-425, hsa-miR-638, hsa-miR-923, 
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hsa-miR-93, hsa-miR-99b) changed at both time points compared to the untreated 
samples. Although, only the expression of hsa-miR-191, hsa-miR-425, hsa-miR-99b 
(downregulated) and hsa-miR-21 (upregulated) maintained the same pattern of 
expression as in the 24h samples (Tables 13 and 17).  
 
3.3.4 In PC-3 cells, simultaneously treated with mitoxantrone and infected 
with AdE1A12S for 48h, differentially expressed miRNAs show a more than 
additive deregulation when compared to the theoretical sum of the miRNAs 
in single agent-treated cells.  
 
The expression of miRNAs in PC-3 cells treated with mitoxantrone (50nM) in 
combination with AdE1A12S (100ppc) for 48h compared to the theoretical sum of 
the miRNA in single agent-treated cells, showed upregulation in 7 out of 15 miRNAs 
(hsa-miR-1246, hsa-miR-128, hsa-miR-15b, hsa-miR-182, hsa-miR-1826, hsa-miR-183, 
and hsa-miR-30d) and downregulation in 8 out of15 miRNAs (hsa-miR-103, hsa-miR-
191, hsa-miR-221, hsa-miR-222, hsa-miR-31, hsa-miR-574-5p, hsa-miR-720 and hsa-
miR-99b) (Table 18). It has previously been reported that hsa-miR-128, hsa-miR-15b, 
hsa-miR-1826 were decreased in PCa tissue and we found these miRNAs to be 
upregulated by the combination treatment. Similarly, hsa-miR-191, hsa-miR-574-5p 
and hsa-miR-99b were demonstrated as upregulated in PCa while these miRNAs 
were downregulated by the treatment. The largest differences in expression were for 
hsa-miR-1246 and hsa-miR-1826 (Log2> 1.20; upregulated) and hsa-miR-574-5p 
(Log2<-2.0; downregulated) (Table 18).  
We demonstrated that the expression of 11 out of 15 miRNAs (hsa-miR-103, hsa-
miR-128, hsa-miR-182, hsa-miR-1826, hsa-miR-221, hsa-miR-222, hsa-miR-30d, hsa-
miR-31, and hsa-miR-99b), were changed when comparing the combination to the 
sum of both single agents  (AdE1A12S and mitoxantrone). The same miRNAs were 
also changed when the cells were infected with virus alone. Moreover, the 
deregulation in the expression of hsa-miR-574-5p and hsa-miR-720 was only 
significant when comparing the combination to the sum of the single agents (Tables 
17 and 18). The expression of 13/15 miRNAs (hsa-miR-103, hsa-miR-1246, hsa-miR-
15b, hsa-miR-128, hsa-miR-182, hsa-miR-1826, hsa-miR-191, hsa-miR-221, hsa-miR-
222, hsa-miR-30d, hsa-miR-31, and hsa-miR-99b) also changed when cells were 
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treated with mitoxantrone alone (Tables 16 and 18). When the miRNAs shown in 
Table 18 were compared to the miRNAs shown in Table 16, all miRNAs were found to 
be regulated using both analysis, except for hsa-miR-128, hsa-miR-574-5p and hsa-
miR-720 (Tables 16 and 18). However, hsa-miR-720 is not considered a mature 
miRNA sequence.387 In addition, the pattern of expression was identical except for 
hsa-miR-30d (upregulated, Table 18; downregulated Table 17).  
 
Table 18. Differentially expressed miRNAs in PC-3 cells simultaneously infected 
with AdE1A12S (100ppc) and treated with mitoxantrone (50nM) compared to the 
theoretical sum of miRNA changes in single agent-treated cells. 
 
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow). 
 
The expression of the set of miRNAs shown in Table 18 (48h) compared to the set 
shown in Table 14 (24h), showed that only hsa-miR-1826 and hsa-miR-191 were 
deregulated at both time points. The expression of hsa-miR-1826 was downregulated 
at 24h and was upregulated at 48h (Tables 14 and 18). Hsa-miR-191 was 
downregulated at both time points, although with a greater decrease at 24h (Log2= -
0.75 at 24h and -0.57 at 48h). The regulation of the miRNAs showed that 8 out of 15 
where downregulated at 48h compared to 4 out of 14 at 24h. Moreover,  except for 
191 no other miRNAs were modified at 24h, this may indicate that these miRNAs 
could be downregulated indirectly as secondary targets by other miRNAs (primary 
targets) or gene expression changes as a consequence of the treatment.  
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3.4 Verification of differentially expressed miRNAs in PC-3 cells treated 
with AdE1A12S, mitoxantrone and the combination for 24h; second 
experiment.  
 
Subsequently, a second miRNA array experiment was analysed comparing the 
differences in miRNA expression for the simultaneously treated and infected cells 
with the theoretical sum of the changes in single agent-treated cells, AdE1A12S 
(100ppc) and mitoxantrone (50nM). We selected the 24h time point to investigate 
more direct effects on the changes in miRNA expression in response to the 
treatments. A total of 73 miRNAs were differentially expressed with all treatments 
after 24h (average signal-intensities 500 and statistically significant p<0.01; Students 
t-test). From these, 49 were selected based on previous identification in the first 
array experiments (both 24 and 48h, highlighted in orange in Table 11-18). To 
identify the potential targets for each miRNA, several accessible databases and tools 
were used, such as Ensembl.org, mirbase.org, PubMed, mirTarBase.org, TargetScan 
Human, miRecords, miRDB, microRNA.org, transmir and miR2disease base, in 
combination with literature searches.231,234-238 These analyses resulted in 
identification of 49 miRNAs that were involved in the regulation of cell death and 
survival pathways.  
 
3.4.1 Up-regulation of miRNAs in PC-3 cells in response to the combination 
treatment with AdE1A12S and mitoxantrone 
 
The upregulation of miRNAs in PC-3 cells in response to the combination of 
AdE1A12S and mitoxantrone (combo) compared to the sum of the changes in single-
agent-treated cells (AdE1A12S + mitoxantrone) is shown in Table 19. All miRNAs 
except hsa-let-7e, hsa-miR-1268 and hsa-miR-1275 have been demonstrated to be 
expressed in PCa cells and tissue.231,234-238 The differences in the expression of the 
miRNAs were significant when log2>0.20 including hsa-let-7c (0.37), hsa-let-7d 
(0.30), hsa-let-7e (0.32), hsa-let-7f (0.35), hsa-let-7g (0.38), hsa-miR-1268 (0.54), hsa-
miR-23a (0.23), hsa-miR-23b (0.28), with the largest increase for hsa-miR-1246 
(0.61). Moreover, hsa-mir125a-5p, hsa-miR-125b, hsa-miR-25, hsa-miR-26a showed 
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minimal upregulation (log 2=0.01-0.04) and it is questionable whether such a small 
change is sufficient to induce a response on target genes. The changes in expression 
of hsa-miR-92b, hsa-miR-27a, hsa-miR-16, hsa -hsa-miR-15b, hsa -hsa-miR-128, hsa -
hsa-miR-1275, and hsa -let-7b were intermediate, from 0.1 < log 2 < 0.2. 
Furthermore, hsa-let-7d, hsa-let-7e, hsa-let-7f, hsa-let-7g are part of the let-7 cluster 
and hsa-miR-23a and hsa-miR-23b part of the hsa-miR-23 cluster, including hsa-miR-
23, -10, -24, -26, -27 and -30,388,389 and were highly significant (p<.001); this indicates 
that these clusters are regulated by the same promoter and/or the same 
transcription factors. Interestingly, the majority (17 out of 21) of the upregulated 
miRNAs in the combination treated cells has been reported as downregulated in PCa 
tissue and cell lines, compared to normal tissue, except hsa-miR-1246 and hsa-miR-
25.231,235-239,390  
 
Table 19. Up-regulated miRNAs in PC-3 cells treated with a combination of 
AdE1A12S and mitoxantrone compared to the sum of single-agent-treated cells, at 
24h post-treatment.  
  
p-values determined by t-test; highly significant p-values (p<0.001; yellow).  
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These results suggest that by combining adenoviral E1A12S gene expression with 
mitoxantrone-treatment, specific miRNAs that are frequently deregulated 
(downregulated) in PCa, are targeted and their expression is enhanced. It is possible 
that upregulation of a specific miRNA or cluster of miRNAs thereby prevent further 
cancer growth and even sensitize the cells to cell killing. The information available in 
the literature regarding hsa-miR-1268 (Log2= 0.54) and hsa-miR-1275 (Log 2= 0.11) 
was limited and did not permit complete analysis, thus this work is to my knowledge 
the first to report on the involvement of these miRNAs in PCa. However, more 
studies are necessary to validate these data and to explore the functional 
implications. 
 
3.4.2 Target selection of upregulated miRNAs in PC-3 cells in response to the 
combination treatment with AdE1A12S and mitoxantrone 
 
To verify the potential implications of the upregulated miRNAs identified under 
chemosensitizing conditions, a search for potential targets validated in PCa and other 
types of cancer was performed using available databases and publications. In cases 
where the miRNA targets have not been validated in cancer, we used the published 
reports to include other pathologies to complement our data (Table 20). 
 
Most of the miRNAs that were upregulated in response to our treatment 
combination have been reported to be downregulated in PCa (17 out of 21; Table 
20). Interestingly, 15 out of those 17 (miRNAs hsa-let-7a/b/c/d/e/f/g, hsa-miR-125a-
5p, hsa-miR-125b, hsa-miR-128, hsa-miR-15b, hsa-miR-16, hsa-miR-23a, hsa-miR-23b 
and hsa-miR-27a) have been implicated in the induction of apoptosis by increasing or 
inhibiting the expression of their respective target genes (including p53, casp3 and 
Bcl-2), or regulating the autophagic pathway through the PI3K/Akt/mTOR. 
Consequently, when those miRNAs are downregulated cell survival and proliferation 
are promoted.374,389-398  
For example, the hsa-miR-125b has been shown to target and down-regulate Mcl-1, 
Bcl-w and interleukin (IL)-6R levels resulting in apoptosis-induction.391 Moreover, 
hsa-miR-125b was shown to reduce the mitochondrial membrane potential and 
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induce pro-caspase-3 cleavage, indicating that the induction of apoptosis by hsa-miR-
125b was mainly by the inhibition of members of the Bcl-2 family. In contrast, the 
downregulation of hsa-miR-125b contributes to chemo-resistance and tumour 
development in hepatocellular carcinoma.391  
 
 
Table 20. Cellular genes reported as targets for upregulated miRNAs in this study. 
Validated gene targets for each miRNA. 
  
 
The overexpression of the hsa-miR23b has been shown to target Src kinase and Akt, 
decreasing tumour growth in nude mice.393 In renal cancer the reduction of hsa-miR-
23b was associated with increased expression of PTEN and a reduction of PI3K and 
total Akt was also observed.399 Another miRNA that targets the apoptotic pathway is 
the hsa-miR-128 that when overexpressed inhibits PCa cell invasion.400 An example 
of miRNA regulation is the hsa-let-7a that induces cell cycle arrest at the G1/S- phase 
when it is upregulated by direct binding to the mRNAs of E2F2 and CCND2 in PCa.395 
Furthermore, the overexpression of let-7c inhibits cell proliferation and clonogenicity 
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by targeting IL-6, Myc, Lin-28 and AR in PCa cells.396 The hsa-miR-15/16 cluster has 
been shown to induce tumour suppression by targeting Bcl-2, CCND1 and WNT3A in 
PCa, inhibiting cell survival and proliferation.397 The overexpression of hsa-miR-1246, 
a target of the p53 family (H1299 cells), was shown to induce apoptosis by targeting 
and downregulating DYRK1A (Down-syndrome marker) in U2OS cells.374  The 
overexpression of hsa-miR-23a/27a/24-2 cluster has been shown to trigger 
endoplasmic reticulum stress (ER stress) inducing apoptosis in HEK293T cells.389 
Moreover, cell proliferation induce by Myc is regulated through the repression of 
hsa-miR-miR-23a and hsa-miR-miR-23b.401  
 
3.4.3 Down-regulation of miRNAs in PC-3 cells in response to the 
combination treatment with AdE1A12S and mitoxantrone, after 24h. 
 
Table 21 illustrates the miRNAs that were downregulated by the combination 
treatment (combo) compared to the sum of changes in miRNA expression in the 
single agent-treated cells (AdE1A12S + mitoxantrone; 12S+M). The identified hsa-
miR-361-5p, hsa-miR-423-5p, hsa-miR-1826 and hsa-miR-107 are known as 
deregulated in different types of cancer, although none of them has been reported 
and validated in PCa. Even though, hsa-miR-107 has not been identified specifically in 
PCa, it has been demonstrated to belong to a group of miRNAs located next to the 
hsa-miR-15/16 gene cluster which is frequently downregulated in PCa.225 The hsa-
miR-107 has high homology with hsa-miR-103 with differences only in one 
nucleotide.402 Hsa-miR-103 has been validated as deregulated in PCa.385 In contrast 
to the upregulated miRNAs, only a few miRNAs exhibited large log2 differences 
(Table 20 and 21). Most of the downregulated miRNAs had log2 values <-0.20 (21 out 
of 28), with hsa-miR-21 having the greatest negative log 2 value of -1.13. Other 
highly different miRNAs were hsa-miR-100 (-0.31), hsa-miR-103 (-0.40), hsa-miR-106a 
(-0.27), hsa-miR-107 (-0.46), hsa-miR-151-3p (-0.30), hsa-miR-151-5p (-0.25), hsa-
miR-17 (-0.28), hsa-miR-1826 (-0.23), hsa-miR-191 (-0.41), hsa-miR-20a (-0.21), hsa-
miR-222 (-0.28), hsa-miR-31 (-0.37), hsa-miR-320a (-0.38), hsa-miR-320b (-0.22), hsa-
miR-320c (-0.32), hsa-miR-320d (-0.20), hsa-miR-93 (-0.30) and hsa-miR-99b (-0.20). 
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The miRNAs that had lesser changes in expression (log2 value > -0.10) were hsa-let-
7i, hsa-miR-361-5p, hsa-miR-92a, hsa-miR-29a, hsa-miR-182. These small changes 
imply limited involvement in the response to the treatment and may not be part of 
the regulatory mechanisms of chemosensitization. However, miRNAs such as hsa-let-
7i, hsa-miR-92a and hsa-miR-182 are known to be activated as clusters such as the 
hsa-let-7 family, hsa-miR-17-92 and hsa-miR-183-96-182 clusters. Thus, despite the 
lesser changes in expression levels they might still be involved in the regulatory 
machinery triggering the chemosensitization of the cells. 
 
 
Table 21. Down-regulated miRNAs in PC-3 cells treated with a combination of 
AdE1A12S and mitoxantrone under synergistic conditions compared to single 
agent-treated cells, after 24h of treatment.   
  
 
p-values determined by t-test; highly significant p-values (p<0.001; yellow).  
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The hsa-miR-107 had the most significant difference (p=4.96E-3; Log2= -0.46). Most 
of the miRNAs (18 out of 28) that were downregulated by the combination treatment 
have been reported as upregulated in cancer. Hsa-miR-100, hsa-miR-103, hsa-miR-
1826, hsa-miR-221, hsa-miR-222, hsa-miR-29a, hsa-miR-31, hsa-miR-361-5p, hsa-
miR-92a, were downregulated by the treatment and it was previously reported that 
these miRNAs were typically upregulated in cancer.231,234-238 However, there are 
several contradictory reports suggesting that hsa-miR-221, hsa-miR-222, hsa-miR-29, 
hsa-miR-31, hsa-miR-92 are also upregulated in cancer. In this study, we considered 
miRNAs as up- or downregulated according to the published data of their regulation 
in PCa cells or cancerous tissue and reported in two or more studies. Contradictory 
results also have been reported for hsa-let-7i, hsa-miR-191, hsa-miR-24 and hsa-miR-
99 but are predominantly indicated as upregulated. It is likely that hsa-miR-29a and 
hsa-miR-92a do not play significant roles in the response to treatment since the log2 
values are close to zero, although more experiments and validation are required 
prior to this conclusion. The hsa-miR-1826 was downregulated (Log2= -0.23), and it 
was recently identified as a tumour suppressor in renal cancer cells.403 However, hsa-
miR-1826 has also been identified as a fragment of the 5.8S rRNA387 and is thus not 
considered as a true miRNA and was not included in further analysis.  These results 
demonstrate that the cancer-dependent upregulation of these miRNAs could be 
attenuated in response to the combination treatment. 
3.4.4 Target selection of downregulated miRNAs in PC-3 cells in response to 
the combination treatment with AdE1A12S and mitoxantrone 
 
We searched for the targets of downregulated miRNAs in response to the 
combination treatments, using the same criteria of selection as mentioned in section 
3.4.2 for the upregulated miRNAs.  
 
Table 22 includes miRNAs that typically are upregulated in cancer cells; the 
mitoxantrone and AdE1A12S combination induced downregulation of these miRNAs. 
Thus it is important to consider the mechanistic implications in the downregulation 
of some of this miRNAs in response to the treatments. 
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Table 22. Cellular genes reported as targets for the miRNAs identified as 
downregulated in this study.  
 
 
For example, the regulation of the cell cycle is inhibited by the hsa-miR-106 family by 
targeting p21 to facilitate cell proliferation.404 Moreover, the overexpression of the 
hsa-miR-106b-25 and hsa-miR-17-92 clusters have been shown to regulate the TGFβ 
signalling by preventing cell cycle arrest and apoptosis in gastrointestinal cells.405 In 
addition, a correlation was found in the impairment of PTEN in PCa progression and 
the overexpression of hsa-miR-22 and the hsa-miR-106b/25 cluster that targets 
PTEN.212 Another highly expressed miRNA in cancer progression is the hsa-miR-21; its 
overexpression has been shown to induce cell proliferation induced by an androgen-
stimulus in PCa. In contrast, the inhibition the hsa-miR-21 facilitates the induction of 
apoptosis triggered by FOXO3a by repressing hsa-miR-21.406,407 Another example is 
the amplification of the hsa-miR-17 cluster that is associated with malignant 
lymphomas.288 In A549 it has been shown that the downregulation of hsa-miR-24 
inhibits cell growth.288 In melanoma, the transcription factor FOXO3 inhibits cell 
migration by downregulating the hsa-miR-182, in contrast FOXO3 is impaired when 
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the hsa-miR-182 is overexpressed.408 In an orthotopic xenograft mouse model of 
hepatocellular carcinoma the inhibition of the hsa-miR-191 reduced tumour size 
while in vitro cell proliferation was inhibited and apoptosis was induced.409 The hsa-
miR-221/222 has been shown to target and inhibit the tumour suppressor p27, 
inducing cell proliferation in PC-3 cells, while the knock-down of hsa-miR-221/222 
increased clonogenicity.291 In addition, the overexpression of hsa-miR-221/222 and 
the downregulation of hsa-miR-23b/-27b can be considered a poor prognosis marker 
in metastatic castrate-resistant PCa.384 Another miRNA that can inhibit apoptosis via 
the inhibition of PTEN is the hsa-miR-17-92 cluster through the hsa-miR-19 
component, inducing tumour progression.410 Recently the induction of apoptosis and 
autophagy by p53 has been shown to be enhanced by hsa-miR-93/106b which 
inhibits p21.350 The hsa-miR-93/106b has been shown to be regulated by adenoviral 
E1A and E2F1 in human osteosarcoma.350 
 
3.4.5. Summary 
 
Taking all data from the miRNA analysis into consideration I found, as could be 
expected, a trend that cell death and survival pathways appeared to play major roles 
in the response to the combination treatment. Therefore, we selected potential key 
regulators that were indicated as targets for the AdE1A12S and mitoxantrone 
combination, to investigate the corresponding pathways further by determining 
changes in the expression levels of selected proteins. Most of the indicated targets 
are known to be involved in regulation of the cell cycle, cell proliferation, apoptosis 
and autophagy networks and include p53, Akt, Bcl-2, p62, LC3B-I/II, mTOR, Caspase3, 
FOXO1/3, PTEN and E2F1. 
Further validation of changes in miRNA and/or the corresponding mRNA levels would 
be necessary to delineate the specific regulation by the treatments and the 
respective pathways. These extensive investigations are planned for future projects 
and were beyond the scope of my PhD project due to time-limitations. In the next 
part of the project, I therefore focused on verifying changes in expression of proteins 
that are representative of these pathways and are typical key factors in the 
regulation of cell death and survival.    
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3.4.5. a In Summary 
 
• Most identified miRNAs have previously been reported to be deregulated in 
PCa 
• The majority of upregulated miRNAs in response to the combination 
treatments have been previously reported to be downregulated in PCa. In 
addition, downregulated miRNAs in response to the combination treatments 
have been previously reported to be upregulated in PCa 
• Regulation of cell death and survival pathways (apoptosis, autophagy and 
proliferation) have been reported for the identified miRNAs that were 
differentially expressed in response to the combination treatments. Some of 
the key regulatory factors that were indicated as targets include Akt, Bcl-2, 
p62, LC3B and p53. 
• Most of the differentially expressed miRNAs in response to the combination 
treatments were previously reported to be regulated either by the MYC or 
E2F1 transcription factors. 
• The miRNAs hsa-miR-1268 and hsa-miR-1275 modulated in response to the 
combination treatments have not been previously reported to be involved in 
the progression of PCa. 
 
3.5 Validation of changes in expression of selected miRNA targets  
  
The miRNA analysis predicted the role of regulatory factors implicated in cell death 
and survival pathways, including autophagy and apoptosis, which might be involved 
in the enhancement of cell death in response to the combination treatments (virus 
and mitoxantrone). To address the role of selected factors that were indicated to be 
altered in response to the combination treatment, we determined changes in 
expression levels of the corresponding proteins. The selection was based on the 
miRNA analysis, previous findings in the laboratory and with established functions in 
cell death and survival pathways reported in the literature. Initially, we assessed the 
ratio of LC3B-II to LC3B-I, the degradation of p62/SQSTM1, the expression of Bcl-2 
and the phosphorylation of Akt by immunoblotting in PCa cells under synergistic 
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conditions. These key factors are typical markers of autophagic flux (LC3B and 
p62/SQSTM1), deregulated apoptosis (Bcl-2) and protein translation and survival 
signalling (Akt).   
To validate that the observed differential changes in the expression of miRNAs were 
reflected in changes in potential downstream target proteins, I investigated the 
expression-changes of these proteins by immunoblotting. Due to differences in virus 
and drug batches compared to the earlier preparations of samples for the miRNA 
analysis (performed in 2009) we conducted a broad screen of virus and drug dose-
responses by cell viability assays (section 6.2; Fig. 53) and immunoblotting. The PCa 
cell lines PC-3 (AR-p53-) and 22Rv1 (AR+p53+), were treated and screened at different 
concentrations of mitoxantrone (50-2000nM) alone or infected with the AdE1A12S 
(50-4000ppc). I also included the replication-selective mutant Ad∆∆ (50-2000ppc) 
and Ad5wt (50-2000ppc) to explore whether similar factors were involved in the 
enhancement of cell killing previously reported for Ad∆∆ and Ad5wt.118    
To monitor autophagic activity in PCa cells lines, we assessed the expression ratio of 
LC3B-II to LC3B-I. The microtubule-associated protein 1A/1B-light chain 3 (LC3/Atg8), 
is a 17 kDa cytosolic protein.411 During autophagy initiation, as part of the 
autophagosome membrane elongation, the cytosolic form of LC3-I becomes 
conjugated with phosphatidylethanolamine (PE) to form LC3-II. 411 The conjugated 
LC3-II is then recruited by the autophagosomes where it accumulates in the 
membrane until it is degraded by lysosomal hydrolases in the autolysosomal lumen 
when autophagy is completed (Autophagy flux).411 Therefore, an increase in the ratio 
of LC3B-II to LC3B-I is considered as an indicator of autophagosome accumulation,  or 
autophagic activity.313 Despite that the molecular weight of LC3B-II is larger by its 
conjugation with PE than LC3B-I, LC3B-II migrates faster than LC3B-I in SDS-PAGE; 
detection of LC3B-II and LC3B-I is at 17kDa and 15kDa, respectively.313  
In addition, we investigated the changes in expression of the polyubiquitin-binding 
protein p62/SQSTM1 as a second autophagic marker. The p62/SQSTM1 can 
polymerise and form protein bodies within the autophagosomes and lysosomal 
structures and bind to LC3-II.412 The levels of p62 are dependent on autophagic 
activity; whereas inhibition of autophagic flux favours p62 accumulation, complete 
autophagy flux causes p62 degradation.313,412 Importantly, p62 levels can also be 
151 
 
modified by autophagy-independent mechanisms including oxidative stress, 
apoptosis and proteasomal degradation.313,413 
 
3.5.1 Autophagic activity is increased in response to mitoxantrone but 
decreased when simultaneously infected with AdE1A12S for 24h. 
 
To assess the expression of LC3B and p62, PC-3 cells were treated with increasing 
concentrations of mitoxantrone ranging from 50nM to 2000nM or/and infected with 
AdE1A12S in a range from 50ppc to 4000ppc, for 24h and 48h (Fig. 33 and 34). The 
cells were treated with staurosporine (1nM) and rapamycin (100nM), as apoptotic 
and autophagic inducers, respectively. The concentrations of viruses and 
mitoxantrone alone were selected according to viral and drug concentrations that 
killed less than 20% of cells, (50-500nM and 250-1000ppc), and also more extreme 
doses above that range killing more than 20% of cells (mitoxantrone at 2000nM; 
virus at 2000ppc and 4000ppc) to include a wider range of doses. The results are 
expressed as fold change (small changes of 1.0 ± 0.10 were not considered to 
represent significant  changes).313   
In this experiment, the ratio of LC3B-II to LC3B-I in PC-3 cells treated with 
mitoxantrone for 24h, showed a 1.27-fold-increase with 50nM and no change with 
250nM compared to untreated control. Moreover, the highest difference in the ratio 
were shown at higher concentrations of mitoxantrone with 500nM, 1000nM and 
2000nM were 1.7, 2.15 and 2.19-fold-increases were observed respectively, 
compared to untreated control. The changes in the ratio of LC3B-II to LC3B-I induced 
by increasing doses of mitoxantrone were dose dependent (Fig. 33A). Furthermore, 
in order to complement the LC3B data, we assessed the expression of p62/SQSTM1, 
observing decreased expression with increasing concentrations of mitoxantrone 
showing a 0.65-fold decrease with 50nM, and 0.24, 0.27 and 0.21-fold with 500nM, 
1000nM and 2000nM, respectively, compared to untreated control. In contrast, 
there was a 2.11-fold increase with 250nM mitoxantrone (this remarkable increase 
with 250nM was not observed at other time points). This experiment, showed a 
predominantly decreasing trend in the expression p62/SQSTM1 with increasing 
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concentrations of mitoxantrone (except at 250nM) compared to untreated control 
cells.       
The infection with the AdE1A12S virus induced small decreases in the ratio of LC3B-II 
to LC3B-I at 50ppc, 250ppc and 500ppc at 0.89, 0.82 and 0.85, respectively. Higher 
concentrations of the virus showed no changes in the ratio of LC3B-II to LC3B-I (with 
1000ppc, 2000ppc and 4000ppc) compared to untreated control. The changes in the 
ratio of LC3B-II to LC3B-I in response to AdE1A12S were not significant, in contrast, 
the changes induced by mitoxantrone increased more than 2-fold with the highest 
concentrations (Fig 33A). These results indicate that mitoxantrone induces the 
accumulation of autophagosomes, whilst the AdE1A12S virus might slightly 
counteract or inhibit the process.   
Furthermore, the infection with AdE1A12S decreased the expression of 
p62/SQSTM1, similarly to mitoxantrone although to a lesser extent. The infection 
with 50ppc, 250ppc, 500ppc and 1000ppc caused 0.67, 0.79, 0.61 and 0.58-fold 
changes compared to untreated control. Moreover, at higher concentrations the 
reduction was greater with 2000ppc and 4000ppc causing 0.38 and 0.30-fold changes 
compared with the untreated control, indicating that increasing viral particles 
strongly reduces the levels of p62/SQSTM1. The decreases in the levels of 
p62/SQSTM1 might indicate that in response to either agent p62/SQSTM1 might be 
degraded. Moreover, the degradation of p62/SQSTM1 in combination with an 
increase in the ratio of LC3B-II to LC3B-I is frequently associated with increased 
autophagic flux.313 Therefore, summarizing the data with the single agents in PC-3 
cells at 24h, the increases in the ratio of LC3B-II to LC3B-I and the reduction in the 
levels of p62/SQSTM1 indicates that the treatment with mitoxantrone might be 
inducing higher autophagic activity with increasing concentrations of the drug. 
However, the infection with the AdE1A12S virus, might also contribute to the 
degradation of p62/SQSTM1 despite the absence of elevated LC3B-II to LC3B-I ratios. 
We suggest that AdE1A12S might reduce p62/SQSTM1 in the absence of 
autophagosome formation, which is likely caused by non-autophagic processes such 
as apoptosis-induction as observed for staurosporine. Thus, more conclusive assays 
would be needed to complement and verify these data. 
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A) 
 
B) 
 
Figure 33. Changes in the ratio of LC3B-II to LC3B-I and expression of p62/SQSTM1 in PC-3 cells at 
24h post-treatment with mitoxantrone and/or infection with the AdE1A12S virus. A) PC-3 
cells treated with mitoxantrone at increasing concentrations, 50nM - 2000nM, or infected 
with the AdE1A12S virus, at 50ppc - 4000ppc. Cells were also treated with staurosporine at 
1nM and rapamycin at 100nM as indicators of apoptotic and autophagic activity. B) PC-3 
cells treated with mitoxantrone for 24h at 250nM, 500nM, 1000nM and 2000nM in 
combination with the AdE1A12S virus at 500ppc, 1000ppc and 2000ppc. A-B) The intensity of 
the bands was quantified using Gene Tools version 4.01 (Synoptics. Ltd, Cambridge, UK). The 
variation in the ratio of LC3B-II to I was calculated after normalizing the intensity of each 
band to the loading control, β-tubulin (Ratio; red). Norm: indicates the fold change (FC) of 
each sample compared to untreated control, for LC3B indicates the ratio of LC3B II/I of each 
sample compared to the ratio of LC3B II/I of the untreated control.  Fold changes of 
untreated samples is 1.00. One experiment, representative of three repetitions.  
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1000ppc and 2000ppc no changes were seen (1.10 and 0.96-fold respectively) 
compared to untreated cells (Fig. 33B). Moreover, compared to the single treatments 
the combination of 250nM with 500ppc enhanced the drug-induced increases in the 
ratios of LC3B-II/I, whilst high concentrations of the virus had no influence.  In 
contrast, the treatment with 500nM mitoxantrone in combination with AdE1A12S at 
500ppc, 1000ppc and 2000ppc resulted in no changes in the ratio of LC3B-II to LC3B-I 
compared to untreated control while mitoxantrone-induced increases in LC3BII/I 
were reduced by AdE1A12S. Thus, the increases in the LC3B-II to LC3B-I ratios in 
response to mitoxantrone alone, were prevented by the virus independent of the 
viral dose. At 1000nM mitoxantrone in combination with AdE1A12S increases in the 
LC3B-II to LC3B-I ratio of 1.60, 1.43 and 1.15-fold were observed with 500ppc, 
1000ppc and 2000ppc viral particles, respectively, compared to 2.15-fold with 
mitoxantrone alone (Fig. 33B). Interestingly, the combination with 1000nM 
mitoxantrone and all viral concentrations (500ppc, 1000ppc and 2000ppc) prevented 
(dose-dependent) full activation of LC3B-II in response to mitoxantrone. However, 
the ratios were slightly elevated when compared to untreated or virus infected cells. 
Perhaps, these doses of mitoxantrone were potent enough to partially overcome the 
viral inhibitory effects. Moreover, the treatment with 2000nM mitoxantrone and 
infected with 500ppc, 1000ppc and 2000ppc of AdE1A12S showed no increases in 
the LC3B-II to LC3B-I ratios compared to control or single infected cells. The strongest 
decrease was observed with 2000nM in combination with 1000ppc (0.64-fold-
decrease). Interestingly, mitoxantrone seemed to induce the conjugation of LC3B-I to 
form LC3B-II (autophagosome formation) in a dose range of 250nM to 1000nM, 
while the AdE1A12S virus counteracted this induction. The expression of 
p62/SQSTM1 showed a decrease in response to the treatment with mitoxantrone at 
250nM in combination with AdE1A12S at 500ppc, 1000ppc and 2000ppc, 0.76, 0.75 
and 0.49-fold decreases respectively, compared to untreated control. These results 
contrast with the induction of p62/SQSTM1 observed with mitoxantrone alone at 
250nM, suggesting that the virus contributes to downregulation of p62/SQSTM1 in 
these combinations. However, it is important to point out that the values of 
mitoxantrone at 250nM do not correspond with those at other concentrations of 
mitoxantrone. Cells treated with 500nM mitoxantrone showed a potent decrease in 
155 
 
p62/SQSTM1 expression when infected with AdE1A12S at 500ppc, 1000ppc and 
2000ppc, 0.24, 0.21 and 0.17-fold, compared to untreated control. Additionally, 
these results showed that in these combination treatments, the low levels of 
p62/SQSTM1 are caused by mitoxantrone. Moreover, all combinations of virus with 
1000nM mitoxantrone showed potent decreases of p62/SQSTM1 expression, with 
500ppc, 1000ppc and 2000ppc of AdE1A12S, 0.36, 0.17 and 0.21-fold-decrease 
respectively, most likely induced by mitoxantrone (Fig. 33). The treatment with 
2000nM mitoxantrone in combination with AdE1A12S showed the greatest decrease 
in p62/SQSTM1 at this time point, when infected at 500ppc, 1000ppc and 2000ppc 
decreases of 0.08, 0.23 and 0.14, respectively, were noted compared to untreated 
samples. The low levels of p62/SQSTM1 and LC3B-II in response to mitoxantrone at 
2000nM in combination with AdE1A12S at all doses are most likely due to cell death; 
inducing the degradation of both p62/SQSTM1 and LC3B-II as observed with 
staurosporine (Fig. 33).    
In summary, the results in PC-3 cells at 24h in response to the treatment 
combinations, suggest that mitoxantrone promotes autophagy-activity at increasing 
concentrations of the drug observed by increased levels of LC3B-II/-I and reduced 
p62/SQSTM1 levels whilst AdE1A12S blocks drug-induced autophagy initiation. 
Moreover, the inhibition of autophagy by the virus was overcome in combination 
with high concentrations of mitoxantrone. 
 
3.5.2 Autophagic activity is increased in response to mitoxantrone but 
decreased when simultaneously infected with AdE1A12S for 48h. 
 
The levels of expression of LC3B-II and p62/SQSTM1 were also examined at 48h to 
determine autophagic activity in response to each agent alone and in combination.  
To assess changes in LC3B-II/I ratios at 48h, we treated PC-3 cells with increasing 
concentrations of mitoxantrone or the AdE1A12S virus (Fig. 34A). We observed great 
increases in LC3B-II induction at all concentrations of mitoxantrone. PC-3 cells 
treated with 50nM, 250nM, 500nM, 1000nM and 2000nM mitoxantrone showed 
2.20-, 3.19-, 8.46-, 14.21- and 7.38-fold increases in the ratio of LC3B-II to LC3B-I 
compared to untreated control. In addition, the LC3B-II/I ratio with 2000nM was less 
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than that of 500nM and 1000nM mitoxantrone, while at 1000nM we observed the 
highest LC3B-II/I ratio. Taken together, mitoxantrone induced an increase in the 
levels of expression of LC3B-II compared to LC3B-I (as observed at 24h), indicating 
formation or accumulation of autophagosomes. In addition, the differences in the 
LC3B-II/I ratio were greater at 48h than at 24h, as well as the decline in the ratio at 
the highest concentration of mitoxantrone (2000nM). The expression of 
p62/SQSTM1 was also assessed at 48h post-treatment in PC-3 cells. Interestingly, the 
treatment with 50nM and 250nM mitoxantrone induced 1.99 and 2.09-fold increases 
in the expression of p62/SQSTM1 compared to untreated control. In contrast, 
decreases were observed at 500nM, 1000nM and 2000nM mitoxantrone showing 
0.88, 0.23 and 0.40-fold changes, respectively. Therefore, the treatment with low 
doses of mitoxantrone increased the levels of p62/SQSTM1, while higher doses 
appeared to contribute to the degradation of p62. Furthermore, these results 
showed that in PC-3 cells mitoxantrone treatment for 24h and 48h induces the 
formation or accumulation of autophagosomes in a dose-response manner. 
Additionally, when considering the levels of p62/SQSTM1, our data indicate that 
mitoxantrone induces autophagic flux at all doses after 24h and at the higher doses 
after 48h.   
The infection of PC-3 cells with AdE1A12S for 48h caused increases in the ratios of 
LC3B-II to LC3B-I with  50ppc, 250ppc, 2000ppc and 4000ppc resulting in 1.57, 1.54, 
1.68, 1.71 and 1.7-fold respectively, compared to untreated control (Fig. 34B). When 
infected with 1000ppc a reduction was observed (0.85-fold decrease). At all viral 
concentrations (except at 1000ppc) there was an increase in the ratio of LC3B-II to 
LC3B-I compared to untreated control, although the increases were notably less than 
with mitoxantrone. These increases in the ratios were not dose-dependent as 
observed by the small increases in LC3B-II/I ratios between low and high viral doses. 
 In addition, the infection with AdE1A12S resulted in increased levels of p62/SQSTM1 
at 250ppc, 1000ppc, 2000ppc and 4000ppc; 1.21, 1.86, 3.28 and 2.72-fold increases 
compared to untreated control. In contrast, there were no changes when infected 
with 50ppc and 500ppc of AdE1A12S. The increase in the ratio of LC3B-II/LC3B-I in 
addition to the accumulation of p62/SQSTM1 indicate that AdE1A12S might impair 
autophagic-activity at 24h and 48h employing slightly different mechanism; 
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prevention of LC3B-II/I increases at 24h and prevention of p62 degradation at 48h 
(Fig. 34A). 
 
A) 
  
B) 
 
Figure 34. Differences in the ratios of LC3B-II to LC3B-I and expression of p62/SQSTM1 in 
PC-3 cells at 48h post-treatment with mitoxantrone and/or infection with the AdE1A12S 
virus. A) PC-3 cells treated with mitoxantrone at increasing concentrations, 50nM - 2000nM 
or infected with the AdE1A12S virus, at 50ppc - 4000ppc. Cells were also treated with 
staurosporine at 1nM and rapamycin 100nM as indicators of apoptotic and autophagic 
activity respectively. B) PC-3 cells treated with mitoxantrone for 48h at 250nM, 500nM, 
1000nM and 2000nM in combination with the AdE1A12S virus at 500ppc, 1000ppc and 
2000ppc. A-B) The intensity of the bands where quantified using Gene Tools version 4.01 
(Synoptics Ltd, Cambridge, UK). The variation in the ratio of LC3B-II to -I after normalizing the 
intensity of each band to the loading control (β-tubulin). Norm: indicates the fold change 
(FC) of each sample compared to untreated control, for LC3B indicates the ratio of LC3B II/I 
of each sample compared to the ratio of LC3B II/I of the untreated control.  Fold changes of 
untreated samples is 1.00. One experiment, blot representative of three repetitions.  
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LC3B-II to LC3B-I ratio compared to untreated samples (Fig. 34B), indicating a strong 
inhibition of autophagy initiation in response to mitoxantrone (3.19-fold increase for 
drug alone). Moreover, the treatment with 500nM mitoxantrone and infection with 
500ppc, 1000ppc and 2000ppc resulted in 2.46, 1.94 and 2.63-fold increases 
respectively, compared to untreated control, although, less than with mitoxantrone 
alone at this concentration (8.44-fold). The treatment with 1000nM mitoxantrone 
showed a more potent increase in LC3B-II to LC3B-I ratio when combined with 
AdE1A12S at 500ppc, 1000ppc and 2000ppc showing 7.93, 5.0 and 2.91-fold 
increases. Despite the increased ratios, the combination with the virus reduced, by 
half, the levels of LC3B-II induced by mitoxantrone alone (14.21-fold). The 
combination with 2000nM mitoxantrone and 500ppc, 1000ppc and 2000ppc showed 
3.98, 5.52 and 7.84-fold increases, respectively, when compared to untreated 
control, lower or similar ratios to those obtained by mitoxantrone alone (7.4-fold) 
(Fig. 34B). Interestingly, the combination of virus with 1000nM and 2000nM 
mitoxantrone induced different patterns in the ratio of LC3B-II to LC3B-I; treatment 
with 1000nM showed a trend towards decreased LC3B-II/LC3B-I ratios with 
increasing concentrations of the virus, whilst in the combination with 2000nM an 
increased trend was observed with increasing concentrations of the virus.  
The LC3B-II to LC3B-I ratios clearly demonstrated that at 48h, mitoxantrone induced 
the accumulation of LC3B-II, similarly to the results observed at 24h. The 
combination with the virus resulted in decreases in the ratios of LC3-II/I, indicating 
that the virus impairs mitoxantrone-induced autophagic activity; although, 
mitoxantrone is potent enough to partially overcome viral inhibition at higher drug 
doses also at the 48h time-point.  
The accumulation of the polyubiquitin-binding protein p62/SQSTM1 was also 
assessed in response to the combination treatments at 48h. Treatment with 250nM 
mitoxantrone in combination with 500ppc, 1000ppc and 2000ppc showed 2.30, 1.82 
and 3.79-fold increases respectively, in the expression of p62/SQSTM1 when 
compared to untreated control. Moreover, the treatment of PC-3 cells with 
mitoxantrone at 500nM in combination with 500ppc, 1000ppc and 2000ppc of the 
virus showed 4.96, 1.78 and 2.09-fold increases respectively, in the expression of 
p62/SQSTM1 when compared to untreated control. The combination of 1000nM 
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mitoxantrone with 1000ppc of the virus showed 1.90-fold increase when compared 
to untreated control. In contrast, mitoxantrone at 1000nM in combination with 
500ppc and 2000ppc decreased p62/SQSTM1 to 0.79- and 0.83-fold compared to 
untreated control. The treatment of PC-3 cells with 2000nM mitoxantrone in 
combination with 500ppc and 1000ppc of the virus showed a 1.82 and 2.07-fold 
increase in the expression of p62/SQSTM1 compared to untreated control. 
Moreover, a decrease in the expression of p62/SQSTM1 was observed when 2000nM 
mitoxantrone was combined with 2000ppc of the virus showing a 0.54 fold change 
compared to untreated control. The increased accumulation of p62/SQSTM1 in 
response to the combination treatments compared to mitoxantrone alone showed 
that at 48h, the virus might impair the mitoxantrone-induced autophagic 
activity/flux. In addition, despite the accumulation of autophagosomes indicated by 
the increased ratio of LC3B-II/I, contrary to the induction observed at 24h, these 
results indicate that mitoxantrone was unable to overcome the viral inhibition of 
autophagic flux at 48h at the majority of tested concentrations.  
3.5.3 Mitoxantrone inhibits p-Akt but not in combination with AdE1A12S in 
PC-3 cells at 24h. 
 
From the miRNA analysis we identified the protein kinase Akt as one of the most 
common targets (hsa-miR-23b, hsa-miR-128, hsa-miR-21 and hsa-miR-183; Tables 20 
and 22). The protein kinase Akt has been reported as a key regulatory factor of both 
autophagy and apoptosis.414-417 When Akt is upregulated and fully activated cell 
survival and proliferation was induced; Akt can be fully activated only by 
phosphorylation at Ser-473 by phosphoinositide-dependent kinase 2 (PDK2) of the 
mTORC2 inducing the activation of mTORC1 that blocks autophagy.414 Thus, we 
investigated the expression of phosphorylated-Akt (p-Akt) in response to the 
combination treatments.  
Cells were treated at increasing concentrations of mitoxantrone and infected with 
AdE1A12S for 24h, to determine changes in the phosphorylation at serine-473 on Akt 
(Fig. 35A). A dose-dependent decrease in p-Akt was observed in PC-3 cells treated for 
24h with increasing concentrations of mitoxantrone. The treatment with 1000nM 
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and 2000nM mitoxantrone resulted in 0.72 and 0.40-fold, respectively, when 
compared to untreated control (Fig. 35A). Infection with AdE1A12S at 50ppc and 
250ppc caused strong decreases in p-Akt resulting in 0.38 and 0.23-fold compared to 
untreated control. In contrast, increased doses of AdE1A12S at 500ppc, 1000ppc, 
2000ppc and 4000ppc increased p-Akt showing 1.26, 1.60, 2.34 and 2.97-fold 
changes, respectively, compared to untreated control. We observed that in cells 
treated for 24h with increasing concentrations of mitoxantrone there was a constant 
decrease in p-Akt while infection with AdE1A12S despite an initial inhibition of p-Akt 
at low doses, increasing concentrations strongly induced the levels of p-Akt.   
A) 
 
B) 
 
Figure 35. Changes in expression of phosphorylated Akt (Ser-473) and total Akt in PC-3 cells 
at 24h post-treatment with mitoxantrone and/or infection with the AdE1A12S virus. A) PC-
3 cells treated with mitoxantrone at increasing concentrations, 50nM - 2000nM or infected 
with the AdE1A12S virus, at 50ppc - 4000ppc. Cells were also treated with staurosporine at 
1nM and rapamycin 100nM as indicators of apoptotic and autophagic activity. B) PC-3 cells 
treated with mitoxantrone for 24h at 250nM, 500nM, 1000nM and 2000nM in combination 
with the AdE1A12S virus at 500ppc, 1000ppc and 2000ppc. A-B) The intensity of the bands 
where quantified using Gene Tools version 4.01 (Synoptics. Ltd, Cambridge, UK). Bands were 
normalized for p-Akt as the intensity of each band to Akt, and Akt to the loading control (KU-
70). Fold change of each sample after being compared to untreated control, were the change 
of the untreated samples is 1.00. One experiment, blot representative of three repetitions.  
kDa 
 
60 
 
 
60 
 
 
 
70 
 
 
kDa 
 
60 
 
 
60 
 
 
 
70 
 
 
161 
 
 
At 24h post-treatment we also assessed p-Akt in PC-3 cells treated in combination 
with mitoxantrone and infected with AdE1A12S. The combination of 250nM 
mitoxantrone with 1000ppc and 2000ppc of AdE1A12S showed slight reductions in p-
Akt; 0.88- and 0.83-fold changes, respectively. In contrast when treated with 
mitoxantrone at 500nM, 1000nM and 2000nM there were strong increases of p-Akt 
in combination with the virus at all doses compared to untreated samples. In 
summary, in contrast to the inhibition of p-Akt observed with mitoxantrone alone, all 
the combinations of AdE1A12S with mitoxantrone (except for some combinations 
with 250nM) induced strong increases in p-Akt at 24h post-treatment. These results 
indicate that AdE1A12S blocks mitoxantrone-induced inhibition of p-Akt promoting 
increases in p-Akt accumulation. The induction of p-Akt by the combination may 
contribute to the partial inhibition of autophagy initiation at this time point.  
3.5.4 Mitoxantrone potently inhibits p-Akt in combination with AdE1A12S at 
48h. 
 
Treatment with mitoxantrone at all concentrations induced decreases in the 
expression of p-Akt compared to untreated control at 48h (Fig. 36A). The treatment 
with 50nM and 2000nM mitoxantrone caused 0.74- and 0.83-fold, respectively, 
compared to untreated control. Moreover, the strongest decrease occurred with 
250nM and 1000nM mitoxantrone with 0.66 and 0.63-fold changes respectively, 
compared to untreated control. Despite that p-Akt levels were reduced by 
mitoxantrone both at 24 and 48h after treatment, the decreases were strongest after 
48h, indicating that mitoxantrone-dependent inhibition of p-Akt increases over time.  
 In contrast, infection with AdE1A12S increased the expression of p-Akt at 500ppc, 
1000ppc, 2000ppc and 4000ppc inducing 1.13-, 1.52-, 1.28- and 1.23-fold changes, 
compared to untreated control (Fig. 36A). Interestingly, the highest increases with 
the virus in p-Akt were when infected at 1000ppc, this may indicate that the 
induction of p-Akt by the virus is dose-dependent only to a certain threshold.  These 
results suggest that virus-induced p-Akt might be triggered at early stages and 
increase over time. We also investigated p-Akt in cells treated with mitoxantrone in 
combination with AdE1A12S and the drug at 48h post-treatment (Fig. 36B). 
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Treatment with 250nM mitoxantrone in combination with 500ppc and 1000ppc 
AdE1A12S resulted in 1.31 and 1.60-fold increases, compared to untreated control. 
These increases are slightly lower than observed for the same combinations at 24h 
(Fig. 35B).  
 
A) 
 
B) 
 
Figure 36. Changes in expression of the phosphorylated Akt (Ser-473) and total Akt in PC-3 
cells at 48h post-treatment with mitoxantrone and/or infection with the AdE1A12S virus. 
A) PC-3 cells treated with mitoxantrone at increasing concentrations, 50nM - 2000nM or 
infected with the AdE1A12S virus, at 50ppc - 4000ppc. Cells were also treated with 
staurosporine at 1nM and rapamycin 100nM as indicators of apoptotic and autophagic 
activity. B) PC-3 cells treated with mitoxantrone for 48h at 250nM, 500nM, 1000nM and 
2000nM in combination with the AdE1A12S virus at 500ppc, 1000ppc and 2000ppc. A-B) The 
intensity of the bands where quantified using Gene Tools version 4.01 (Synoptics Ltd, 
Cambridge, UK). A) Bands were normalized as the intensity of each band to the loading 
control (Actin). B) Bands were normalized for p-Akt as the intensity of each band to Akt, and 
Akt to the loading control (KU-70). Fold change of each sample after being compared to 
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untreated control, were the change of the untreated samples is 1.00. One experiment, blot 
representative of three repetitions.  
 
Treatment with 500nM mitoxantrone slightly induced p-Akt when combined with 
500ppc, 1000ppc and 2000ppc of the virus to 1.24, 1.26 and 1.26-fold respectively, 
compared to untreated control and was higher than with mitoxantrone alone (0.90-
fold decrease compared to control). When treated with 1000nM in combination with 
500ppc, 1000ppc and 2000ppc of virus, basal levels of p-Akt were re-established at 
0.93-, 0.96- and 0.95-fold changes. Moreover, with 2000nM mitoxantrone in 
combination with 500ppc, 1000ppc and 2000ppc of the virus, the strongest 
decreases in the levels of p-Akt were noted at 0.59, 0.38 and 0.37-fold respectively, 
when compared to untreated control. Thus, treatment with mitoxantrone abrogated 
virus-induced p-Akt in a dose-dependent manner at 48h post-treatment. However, 
although the p-Akt levels were lower in the combination-treated cells than in the 
AdE1A12S-infected cells, p-Akt levels were still higher than in cells treated with 
mitoxantrone alone. Furthermore, contrary the results from the 24h time-point in 
the combination-treated cells (p-Akt was induced; Fig. 35B), the combination 
treatments at 48h caused decreases in p-Akt compared to virus-only treated cells, 
suggesting that at this time point mitoxantrone-dependent decreases dominated. It 
is possible that, the virus-induced cell proliferative signalling through p-Akt to 
promote cell survival is impeded by mitoxantrone after >24h of treatment.          
 
3.5.5 Mitoxantrone in combination with AdE1A12S induces Bcl-2 in PC-3 cells at 
24h. 
 
The upregulation of the miRNAs hsa-miR-15/16 has been shown to target and inhibit 
Bcl-2 inducing pro-apoptotic signalling (Table 20). Moreover, the expression of Bcl-2 
acts as a pro-survival regulator by inhibiting apoptosis by direct binding to Bax. Bcl-2 
also blocks autophagy driven by the activation of Beclin-1, making Bcl-2 a key 
regulatory factor of both pathways.274,418 Therefore we assessed the expression of 
Bcl-2 to determine its role under chemosensitizing conditions. The expression of Bcl-
2 was assessed in cells treated at increasing concentrations of mitoxantrone (50nM-
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2000nM) for 24h (Fig. 37A). Treatment with 250nM mitoxantrone increased the 
expression of Bcl-2 1.30-fold compared to untreated control cells. In contrast, the 
expression of Bcl-2 was decreased in cells treated with 1000nM and 2000nM 
mitoxantrone; 0.80 and 0.77-fold respectively, compared to untreated control. 
Furthermore, increased concentrations of mitoxantrone decreased (except at 
250nM) Bcl-2expression. The expression of Bcl-2 was also assessed in response to 
AdE1A12S infection (Fig. 37A). Cells infected with 250ppc showed a slight decrease in 
Bcl-2 levels (0.86-fold) compared to untreated control. In contrast, the infection with 
500ppc, 1000ppc and 2000ppc slightly increased in Bcl-2 expression compared to 
untreated control. Moreover, infection with 4000ppc caused a 1.60-fold increase, the 
largest difference compared to untreated control (Fig. 37A). Taken together, Bcl-2 
expression showed a trend towards dose-dependent decreases with mitoxantrone 
and a trend towards increased levels with increasing doses of virus at this time point.   
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Figure 37. Changes in expression of Bcl-2 in PC-3 cells at 24h post-treatment with 
mitoxantrone and/or infection with the AdE1A12S virus. A) PC-3 cells treated with 
mitoxantrone at increasing concentrations, 50nM - 2000nM or infected with the AdE1A12S 
virus, at 50ppc - 4000ppc. Cells were also treated with staurosporine at 1nM and rapamycin 
100nM as indicators of apoptotic and autophagic activity. B) PC-3 cells treated with 
mitoxantrone for 24h at 250nM, 500nM, 1000nM and 2000nM in combination with the 
AdE1A12S virus at 500ppc, 1000ppc and 2000ppc. A-B) The intensity of the bands where 
quantified using Gene Tools version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were 
normalized as the intensity of each band to the loading control (β-Tubulin). Fold change of 
each sample after being compared to untreated control, where the change of the untreated 
samples is 1.00. Blot representative of three repetitions.  
The expression of Bcl-2 was also assessed by the treatments in combination. 
Unexpectedly, Bcl-2 expression was strongly increased when treated at all 
combinations (Fig. 37B). The strongest was shown with 2000nM mitoxantrone in 
combination with the virus at 500ppc, 1000ppc and 2000ppc showing 5.2-,  7.54- and 
9.81-fold increases, respectively, compared to untreated control. These results 
showed that mitoxantrone induced a dose-dependent increases in Bcl-2 expression 
in combination with AdE1A12S. Additionally, the levels of expression of Bcl-2 in the 
combinations were not impacted by virus doses. In summary, at this time point the 
combination treatments appear to, unexpectedly, induce an initial cell survival 
mechanism in contrast to the miRNA data but in agreement with the results 
observed with p-Akt at this time point. 
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3.5.6 The combination of mitoxantrone with AdE1A12S decreases the levels 
of Bcl-2 in PC-3 cells after 48h. 
 
The expression of Bcl-2 was assessed in cells treated with mitoxantrone or infected 
with AdE1A12S for 48h. Bcl-2 expression was increased by mitoxantrone at 50nM, 
250nM and 1000nM showing 1.15, 1.35 and 1.25-fold, respectively, compared to 
untreated control (Fig. 38A). Additionally, treatment with 1000nM and 2000nM 
mitoxantrone reduced Bcl-2 levels to 0.88-fold and 0.72-fold when compared to the 
untreated sample. Thus, low doses of mitoxantrone induced Bcl-2 expression, whilst 
high concentrations reduced Bcl-2 levels. Infection with AdE1A12S slightly induced 
Bcl-2 expression at 250ppc by 1.12-fold. In contrast, infection with 500ppc, 2000ppc 
and 4000ppc decreased Bcl-2 levels to 0.85, 0.74 and 0.64-fold, respectively, 
compared to untreated control. In summary, infection with AdE1A12S slightly 
decreased Bcl-2 levels 48h after infection and induced the expression after 24h of 
infection (Fig. 37 and 38). 
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Figure 38. Changes in expression of Bcl-2 in PC-3 cells at 48h post-treatment with 
mitoxantrone and/or infection with the AdE1A12S virus. A) PC-3 cells treated with 
mitoxantrone at increasing concentrations, 50nM - 2000nM or infected with the AdE1A12S 
virus, at 50ppc - 4000ppc. Cells were also treated with staurosporine at 1nM and rapamycin 
100nM as indicators of apoptotic and autophagic activity. B) PC-3 cells treated with 
mitoxantrone for 48h at 250nM, 500nM, 1000nM and 2000nM in combination with the 
AdE1A12S virus at 500ppc, 1000ppc and 2000ppc. A-B) The intensity of the bands where 
quantified using Gene Tools version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were 
normalized as the intensity of each band to the loading control (Actin). Fold change of each 
sample after being compared to untreated control, were the change of the untreated 
samples is 1.00.Blot representative of three repetitions.  
 
The expression of Bcl-2 was also assessed in cells treated in combination for 48h (Fig. 
38B). The combination of 250nM mitoxantrone with AdE1A12S at 500 and 1000ppc 
induced 2.02- and 1.27-fold increases, respectively, compared to untreated samples. 
In contrast, all other combinations decreased Bcl-2 expression, the largest decrease 
was observed with 2000nM mitoxantrone and 2000ppc; 0.18 fold. The combination 
of AdE1A12S and mitoxantrone, in contrast to the effects when added as single 
agents, reduced Bcl-2 levels in a dose-dependent manner at this time point (48h). 
Moreover, these results are in contrast with the increased Bcl-2 levels at 24h in 
response to the combination treatments (Fig. 37B-38B) but are in agreement with 
the miRNA data (has-miR-15/16; Table 19).   
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3.5.6.a. Summary of immunoblotting data in PC-3 cells infected with AdE1A12S 
and/or treated with mitoxantrone: 
• Infection with AdE1A12S represses the autophagy flux in PC-3 cells at both 24 
and 48h over a range of doses, while mitoxantrone induces the autophagy 
flux compared to basal levels.  
• Infection with AdE1A12S in combination with mitoxantrone greatly decreases 
mitoxantrone-induced autophagy flux at 24h and 48h compared to 
mitoxantrone alone and basal levels. 
• Infection with AdE1A12S induces p-Akt at 24h and 48h. In contrast, 
mitoxantrone inhibits p-Akt at both time points compared to untreated 
samples. 
• The combination treatments increase the levels of p-Akt at 24h however, at 
48h the combination treatments decreased the levels of p-Akt compared to 
basal levels and each single agent treatment. 
• The combinations of AdE1A12S and mitoxantrone increase the levels of Bcl-2 
at 24h. In contrast, at 48h the combinations induce strong dose-dependent 
inhibition of Bcl-2 compare to basal levels. 
 
3.5.7 Ad∆∆ impairs mitoxantrone-induced autophagy in PC-3 cells at 48h.  
 
We previously demonstrated that the oncolytic adenoviral mutant Ad∆∆  potentiates 
apoptotic cell death induced by drugs, including mitoxantrone and docetaxel, by 
selectively targeting tumours with deregulated cell cycle and apoptosis pathways.118 
Therefore, the replicating mutant Ad∆∆ could provide us, within a replicating 
context, with more insights of the mechanisms causing viral-induced sensitization of 
PCa cells to chemotherapeutic drugs, and if these were similar to the observed 
changes in protein expression levels in response to E1A12S combinations with drugs.  
To this end we assessed changes in expression of LC3B and p62 in PC-3 cells treated 
with the replication-selective Ad∆∆ oncolytic mutant with and without 
mitoxantrone, for 48h (Fig. 39A). Treatment with mitoxantrone verified our previous 
observations that increasing concentrations of mitoxantrone (250nM, 500nM, 
1000nM and 2000nM) induced higher ratios of LC3B-II to LC3B-I at 48h post-
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treatment. Infection with Ad∆∆ did not result in changes in the LC3B-II/I ratios at 
50ppc, 250ppc and 500ppc; a slight increase of 1.22 was observed in cells infected 
with 1000ppc. 
Interestingly, p62/SQSTM1 levels increased to 2.08- and 2.30-fold when infected with 
250ppc and 500ppc of Ad∆∆, respectively, compared to untreated control. In 
contrast, slight decreases (0.87 and 0.78-fold) were observed at 50 and 1000ppc. As 
expected and previously shown (Section 3.5.5), mitoxantrone caused decreases in 
the expression of p62/SQSTM1 with 250nM, 500nM, 1000nM and 2000nM; 0.59-, 
0.44-, 0.56- and 0.20-fold changes respectively.  
 
 A) 
  
B) 
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Figure 39. Differences in the ratio of LC3B-II to LC3B-I and expression of p62/SQSTM1 in PC-
3 cells at 48h post-treatment with mitoxantrone and/or infection with the Ad∆∆ virus. A) 
PC-3 cells treated with mitoxantrone at increasing concentrations, 250nM - 2000nM or 
infected with the Ad∆∆ virus, at 50ppc - 1000ppc and treated in combination with 2000nM 
mitoxantrone with Ad∆∆ at 1000ppc. Cells were also treated with staurosporine at 1nM and 
rapamycin 100nM as indicators of apoptotic and autophagic activity. B) PC-3 cells treated 
with mitoxantrone for 48h at 250nM, 500nM, 1000nM in combination with the Ad∆∆ virus 
at 50ppc, 250ppc, 500ppc and 1000ppc; 2000nM in combination with the Ad∆∆ virus at 
250ppc and 500ppc. A-B) The intensity of the bands where quantified using Gene Tools 
version 4.01 (Synoptics Ltd, Cambridge, UK). The variation in the ratio of LC3B-II to -I after 
normalizing the intensity of each band to the loading control (β-tubulin/PCNA). Norm: 
indicates the fold change (FC) of each sample compared to untreated control, for LC3B 
indicates the ratio of LC3B II/I of each sample compared to the ratio of LC3B II/I of the 
untreated control. Fold changes of untreated samples is 1.00. Blot representative of three 
repetitions.  
 
In cells treated with 250nM mitoxantrone, the combination with Ad∆∆ at 500ppc 
induced a 1.35-fold increase in the ratio of LC3B-II/I, compared to untreated control 
while lower viral doses prevented the mitoxantrone-induced increases and higher 
doses did not seem to have an effect (Fig 39B). Treatment with 500nM mitoxantrone 
increased the ratio of LC3B-II/I only in combination with 50ppc and 250ppc to 1.40- 
and 1.42-fold, respectively, compared to untreated samples but these ratios were 
lower than with mitoxantrone alone. At higher viral doses there was a clear dose 
dependent decrease in the mitoxantrone-induced LC3II/I ratios down to basal levels. 
Cells treated with 1000nM mitoxantrone and infected with Ad∆∆ at 250ppc and 
500ppc induced 2.89-, and 2.43-fold increases, respectively, compared to untreated 
control and were also higher than with mitoxantrone alone (1.92-fold). In contrast, 
when 1000nM mitoxantrone was combined with 1000ppc the drug-induced LC3II/I 
ratio was maintained at the same level.  Treatment with 2000nM mitoxantrone 
increased the ratio of LC3B-II to LC3B-I inducing 6.75, 3.09 and 3.94-fold, 
respectively, compared to untreated control. In summary, mitoxantrone (as 
previously observed in Section 3.5.2 with AdE1A12S) induced the accumulation of 
LC3B-II levels, whilst Ad∆∆ counteracted mitoxantrone-induced accumulation at high 
viral doses.   
In cells treated with 250nM mitoxantrone in combination with Ad∆∆ at 500ppc and 
1000ppc decreased the levels of p62/SQSTM1 to 0.43 and 0.43-fold, respectively, 
compared to the untreated control. Cells treated with 500nM mitoxantrone in 
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combination with Ad∆∆ at 500ppc and 1000ppc showed 1.57- and 3.40-fold 
increases of p62/SQSTM1 compared to untreated control. In addition, the 
treatments with mitoxantrone at 1000nM and 2000nM reduced the levels of 
p62/SQSTM1 (except for 1000nM mitoxantrone with Ad∆∆ at 500ppc and 1000ppc). 
These results suggest that Ad∆∆ in combination-treated cells prevented the 
mitoxantrone-dependent p62/SQSTM1 degradation. However, this Ad∆∆-induced 
effect appeared to be limited to a certain dose-range of mitoxantrone (Fig. 39B). In 
summary, as observed previously, mitoxantrone induces autophagy activity/flux, 
while Ad∆∆ potently inhibits autophagy flux similar to AdE1A12 but only at certain 
doses of mitoxantrone in PC-3 cells after 48h. Perhaps the observed differences 
between the viruses are a reflection of Ad∆∆ replication that may generate new viral 
particles at this time point and induce high levels of cell killing masking potential anti-
autophagic activities.      
3.5.8 Ad∆∆ induced activation of Akt is downregulated in combination with 
high doses of mitoxantrone in PC-3 cells at 48h. 
 
Phosphorylation of Akt in cells infected with Ad∆∆ at 50ppc, 250ppc, 500ppc and 
1000ppc resulted in 0.65, 0.78, 1.25 and 1.37-fold changes, respectively after 48h, 
compared with the untreated control, and appeared to be dose-dependent (Fig. 
41A). These findings were similar to those in AdE1A12S infected cells (Section 3.5.3). 
The levels of p-Akt decreased in cells treated with mitoxantrone at 1000nM and 
2000nM to 0.08- and 0.15-fold, compared to untreated control. The reduction in p-
Akt levels with high concentrations of mitoxantrone was consistent with previous 
findings (sections 3.5.3 and 3.5.4). The levels of p-Akt were increased in cells treated 
with 250nM mitoxantrone in combination with Ad∆∆ virus at 50ppc, 250ppc, 500ppc 
and 1000ppc to 1.20-, 1.73-, 1.54- and 1.27-fold, respectively, compared to 
untreated control and were higher than either agent alone (Fig. 41A-B). Treatment 
with 500nM mitoxantrone in combination with Ad∆∆ at 250ppc and 500ppc showed 
1.77- and 1.29-fold increases, of p-Akt compared to untreated control and were 
higher than either agent alone. In contrast, treatment with 1000nM and 2000nM 
mitoxantrone at all combinations with Ad∆∆ strongly reduced the levels of p-Akt 
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compared to untreated cells. While the reduction of p-Akt was independent on the 
virus dose, the p-Akt levels were still higher than with mitoxantrone alone. In 
summary, increasing doses of mitoxantrone impaired Ad∆∆-induced increases in p-
Akt levels, similarly to mitoxantrone in combination with AdE1A12S at 48h. The 
inhibition of p-Akt by mitoxantrone might contribute to mitoxantrone-induced 
autophagy activity in agreement with previous results of the autophagic markers at 
high concentrations of mitoxantrone (Fig. 40)  
 
A) 
 
B) 
 
Figure 40. Changes in expression of the phosphorylated Akt (Ser-473) and total Akt in PC-3 
cells at 48h post-treatment with mitoxantrone and/or infection with the Ad∆∆ virus. A) PC-
3 cells treated with mitoxantrone at increasing concentrations, 250nM - 2000nM or infected 
with the Ad∆∆ virus, at 50ppc - 1000ppc. Cells were also treated with staurosporine at 1nM 
and rapamycin 100nM as indicators of apoptotic and autophagic activity. B) PC-3 cells 
treated with mitoxantrone for 48h at 250nM, 500nM 1000nM and 2000nM in combination 
with the Ad∆∆ virus at 50ppc, 250ppc, 500ppc and 1000ppc. A-B) The intensity of the bands 
where quantified using Gene Tools version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were 
normalized for p-Akt as the intensity of each band to Akt, and Akt to the loading control (KU-
70). Fold change of each sample after being compared to untreated control, were the change 
of the untreated samples is 1.00. One experiment, blot representative of three repetitions 
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3.5.9 Bcl-2 is induced by mitoxantrone in combination with Ad∆∆ inPC-3 cells 
after 48h of treatment. 
 
PC-3 cells infected with Ad∆∆ at 50ppc, 250ppc, 500ppc and 1000ppc showed slight 
decreased expression of Bcl-2 at 0.86-, 0.85-, 0.84- and 0.73-fold respectively, 
compared to untreated control. In contrast, treatment with mitoxantrone at 250nM, 
500nM, 1000nM and 2000nM induced 1.87-, 1.88-, 1.85- and 1.26-fold increases, 
respectively, compared to untreated control. However, as shown in previous results 
(Section 3.5.6), high concentrations of mitoxantrone (2000nM) reduced Bcl-2 
expression compared to the lowest concentration (250nM). In summary, infection 
with Ad∆∆ decreased the expression of Bcl-2, but was not dose-dependent. 
Additionally, mitoxantrone induced Bcl-2 expression at all concentrations, 
nonetheless, high concentrations of mitoxantrone decreased Bcl-2 expression. 
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Figure 41. Changes in expression of Bcl-2 in PC-3 cells at 48h post-treatment with 
mitoxantrone and/or infection with the Ad∆∆ virus. A) PC-3 cells treated with mitoxantrone 
at increasing concentrations, 50nM - 2000nM or infected with the Ad∆∆ virus, at 50ppc - 
1000ppc. Cells were also treated with staurosporine at 1nM and rapamycin 100nM as 
indicators of apoptotic and autophagic activity. B) PC-3 cells treated with mitoxantrone for 
48h at 250nM, 500nM, 1000nM and 2000nM in combination with the Ad∆∆ virus at 50ppc, 
250ppc, 500ppc and 1000ppc. A-B) The intensity of the bands where quantified using Gene 
Tools version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were normalized as the intensity of 
each band to the loading control (PCNA). Fold change of each sample after being compared 
to untreated control, were the change of the untreated samples is 1.00. Blot representative 
of three repetitions.  
 
Surprisingly, Bcl-2 was increased in cells simultaneously treated with 250nM, 500nM, 
1000nM and 2000nM mitoxantrone and infected with Ad∆∆ virus at all 
combinations. The increase corresponded to the increased concentrations of 
mitoxantrone. In summary, elevated Bcl-2 expression was mitoxantrone-dependent 
at all concentrations in combination with Ad∆∆ in contrast to the findings with 
mitoxantrone and AdE1A12S at the 48h time point. These differences between 
viruses might again be explained by the potent replication of the Ad∆∆ mutant which 
could generate a significant amount of new viral particles resulting in high local doses 
of virus.   
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3.5.9.a  Summary of immunoblotting data in PC-3 cells infected with Ad∆∆ and/or 
treated with mitoxantrone: 
 
• In PC-3 cells infected with Ad∆∆ autophagy flux is not affect while in 
combination with low doses of mitoxantrone (250nM and 500nM) Ad∆∆ 
prevented mitoxantrone-induced autophagy flux and brought LC3I/II ratios 
back to basal (or below) levels.  
• Infection with Ad∆∆ induces a dose-dependent increase in p-Akt levels while 
the combination with mitoxantrone inhibits p-Akt increases similar to the 
observations with AdE1A12S and brings levels back to basal. 
• The levels of Bcl-2 are increased in response to the combination treatments 
with mitoxantrone and Ad∆∆ compared to the untreated control and either 
single agent. However, the Bcl-2 response appears to be caused mainly 
mitoxantrone. 
 
3.5.10 Ad5wt-mediated inhibition of autophagy is blocked by high doses of 
mitoxantrone in PC-3 cells at 48h.  
 
To explore whether Ad5wt infected cells caused similar changes and interacted in 
similar fashion with mitoxantrone as Ad∆∆, the expression levels of LC3B-II/I and 
p62/SQSTM1 were determined 48h after treatment. These studies would enable us 
to identify whether the gene-deletions in Ad∆∆ would cause a different response 
than that induced by the intact Ad5wt virus. For example, it was reported that the 
E1B19K protein may induce autophagy through interactions with Beclin-1.348 To 
assess LC3B-II to LC3B-I ratio, cells were infected for 48h with increasing 
concentrations of Ad5wt. Infection with Ad5wt strongly decreased the ratio of LC3B-
II to LC3B-I at 50ppc and 250ppc showing 0.38- and 0.37-fold changes, respectively, 
compared to untreated control. Moreover, Ad5wt-infections at 500ppc and 1000ppc 
resulted in 0.65- and 0.78-fold decreases, respectively, compared to untreated 
control. In addition, mitoxantrone increased the ratio of LC3B-II to LC3B-I in 
agreement with my previous results (Sections 3.5.1, 3.5.2 and 3.5.7). In summary, in 
PC-3 cells Ad5wt clearly reduced LC3B-II to LC3B-I ratios in contrast to the results 
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with the AdE1A12S non-replicating mutant that caused slight increases but in 
agreement with the decreases observed in Ad∆∆-infected cells (Fig. 39). Infection 
with Ad5wt at 250ppc induced a 1.12-fold increase in the levels of p62/SQSTM1 
compared to untreated control, whereas 500ppc and 1000ppc increased the levels of 
p62/SQSTM1 to 1.35 and 2.35-fold, respectively. Thus, Ad5wt increased the levels of 
p62/SQSTM1 in a dose-dependent manner. These results, suggest that the Ad5wt, 
similar to the Ad∆∆ and AdE1A12S mutants, can impair autophagic flux. In contrast, 
decreased levels of p62/SQSTM1 were observed in cells treated with mitoxantrone at 
500nM, 1000nM and 2000nM, showing 0.31-, 0.04- and 0.17-fold changes 
respectively. These results indicate as previously shown, that mitoxantrone induced 
dose-dependent autophagic flux. 
 
A) 
 
B) 
 
Figure 42. Differences in the ratio of LC3B-II to LC3B-I and expression of p62/SQSTM1 in PC-
3 cells at 48h post-treatment with mitoxantrone and/or infection with the Ad5wt virus. A) 
PC-3 cells treated with mitoxantrone at increasing concentrations, 50nM - 2000nM or 
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infected with the Ad5wt virus, at 50ppc - 1000ppc. Cells were also treated with 
staurosporine at 1nM and rapamycin 100nM as indicators of apoptotic and autophagic 
activity. B) PC-3 cells treated with mitoxantrone for 48h at 250nM, 500nM, 1000nM and 
2000nM in combination with the Ad5wt virus at 50ppc, 250ppc, 500ppc and 1000ppc. A-B) 
The intensity of the bands where quantified using Gene Tools version 4.01 (Synoptics Ltd, 
Cambridge, UK). The variation in the ratio of LC3B-II to I after normalizing the intensity of 
each band to the loading control (PCNA). Norm: indicates the fold change (FC) of each 
sample compared to untreated control, for LC3B indicates the ratio of LC3B II/I of each 
sample compared to the ratio of LC3B II/I of the untreated control. Fold changes of 
untreated samples is 1.00.Blot representative of three repetitions.  
 
Cells treated with mitoxantrone in combination with Ad5wt increased the ratio of 
LC3B-II to LC3B-I at all combinations compared to untreated controls. Treatment with 
250nM mitoxantrone in combination with Ad5wt at 50ppc, 250ppc, 500ppc and 
1000ppc resulted in 3.34-, 1.36-, 1.21- and 1.25-fold increases, respectively, LC3B-II 
to LC3B-I ratios compared to untreated control. However, compared to 
mitoxantrone-treatment alone this was a dose-dependent decrease in the LC3B-II/I 
ratios. Mitoxantrone at 500nM in combination with Ad5wt at 50ppc, 250ppc, 500ppc 
and 1000ppc showed 1.23-, 2.03-, 4.95- and 2.61-fold increases, respectively, in  
LC3B-II to LC3B-I ratio compared to untreated control, but except for the two highest 
virus doses these ratios were lower than with mitoxantrone alone (Fig. 42). Cells 
treated with 1000nM mitoxantrone in combination with Ad5wt induced 5.75-, 3.78-, 
6.76- and 8.67-fold increases, respectively, in LC3B-II to LC3B-I ratios compared to 
untreated control. Finally, mitoxantrone at 2000nM in combination with Ad5wt at 
50ppc, 250ppc, 500ppc and 1000ppc showed 3.01-, 11.34- and 25.56-fold increases, 
respectively, compared to untreated control (Fig. 42). These results suggest that 
Ad5wt was unable to supress mitoxantrone-induced accumulation of LC3B-II except 
at low doses of mitoxantrone (250nM). The levels of p62/SQSTM1 in cells treated 
with 250nM mitoxantrone in combination with Ad5wt 50ppc, 250ppc, 500ppc and 
1000ppc caused 1.88-, 1.70-, 1.78- and 3.74-fold increases, respectively, compared to 
untreated control and were higher than with drug alone. Moreover, cells treated 
with 500nM mitoxantrone in combination with Ad5wt at 50ppc, 250ppc, 500ppc and 
1000ppc (4.61-, 3.07-, 1.25- and 1.66-fold increases, respectively), strongly increased 
the levels of p62/SQSTM1 compared to untreated control and drug alone (Fig. 42). 
Cells treated with 1000nM mitoxantrone in combination with Ad5wt at 50ppc 
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induced a 1.41-fold increase in p62/SQSTM1 levels compared to untreated control. 
However, the levels of p62/SQSTM1 were reduced at 1000nM of mitoxantrone in 
combination with Ad5wt at 250ppc, 500ppc and 1000ppc causing 0.86-, 0.68- and 
0.46-fold changes, respectively, compared to untreated control but were still higher 
than with drug alone. The levels of p62/SQSTM1 potently decreased in cells treated 
with 2000nM mitoxantrone in combination with Ad5wt at 250ppc, 500ppc and 
1000ppc showing 0.48-, 0.54- and 0.02-fold decreases, respectively, compared to 
untreated control. Taken together, mitoxantrone in combination with Ad5wt caused 
accumulation of LC3B-II in proportion to LC3B-I, accompanied by decreased levels of 
p62/SQSTM1 indicating autophagic activity. Although, Ad5wt attenuated the 
mitoxantrone-induced increases in LC3-II/I and decreases in p62/SQSTM1, the virus 
did not completely block the mitoxantrone-dependent autophagy induction. 
However, in the combination-treated cells autophagy activity was only observed at 
high doses of mitoxantrone (1000nM and 2000nM) and not at lower doses, where 
the response to Ad5wt dominated and autophagy was impaired. 
 
3.5.11 Both mitoxantrone and Ad5wt can reduce Bcl-2 expression but not in 
combination in PC-3 cells at48h. 
 
PC-3 cells Infected with Ad5wt at 50ppc, 250ppc, 500ppc and 1000ppc decreased the 
expression of Bcl-2 to 0.85-, 0.62-, 0.40- and 0.49-fold respectively, compared to 
untreated control. In addition, treatment with mitoxantrone at 250nM, 500nM, 
1000nM and 2000nM decreased the expression of Bcl-2 to 0.73-, 0.63-, 0.73- and 
0.56-fold compared to untreated control. In summary, the infection with increasing 
concentrations of Ad5wt decreased Bcl-2 expression in a dose-dependent manner. 
Moreover, mitoxantrone reduced the levels of Bcl-2 at all concentrations.  
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A) 
  
B) 
 
Figure 43. Changes in expression of Bcl-2 in PC-3 cells at 48h post-treatment with 
mitoxantrone and/or infection with the Ad5wt virus. A) PC-3 cells treated with 
mitoxantrone at increasing concentrations, 50nM - 2000nM or infected with the Ad5wt 
virus, at 50ppc - 1000ppc. Cells were also treated with staurosporine at 1nM and rapamycin 
100nM as indicators of apoptotic and autophagic activity. B) PC-3 cells treated with 
mitoxantrone for 48h at 250nM, 500nM and 1000nM in combination with the Ad5wt virus at 
50ppc, 250ppc, 500ppc and 1000ppc. A-B) The intensity of the bands where quantified using 
Gene Tools version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were normalized as the 
intensity of each band to the loading control (β-Tubulin). Fold change of each sample after 
being compared to untreated control, were the change of the untreated samples is 1.00. Blot 
representative of three repetitions.  
 
Cells treated with 250nMmitoxantrone in combination with Ad5wt at 50ppc induced 
a 1.25-fold increase in Bcl-2 expression, compared to untreated control.  In contrast 
the combination of 250nM with 500ppc decreased the expression of Bcl-2 by 0.80-
fold, compared to untreated control (Fig. 43). Cells treated with 500nM 
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mitoxantrone in combination with Ad5wt at 50ppc, 250ppc, 500ppc and 1000ppc 
induced 1.23-, 1.50-, 1.25- and 1.93-fold increases, respectively, in the expression of 
Bcl-2 compared to untreated control (Fig. 43). Treatment of cells with 1000nM 
mitoxantrone in combination with Ad5wt at 250ppc, 500ppc and 1000ppc resulted in 
1.20-, 1.41- and 1.31-fold increases in Bcl-2 expression, respectively, compared to 
untreated control. In summary, unexpectedly and in contrast to AdE1A12S and 
similarly to Ad∆∆, the combination of mitoxantrone with Ad5wt re-establishes and in 
some combinations increased Bcl-2 expression despite the inhibitory activity of both 
agents when administered alone. 
 
3.5.11.a. Summary of immun0blotting data in PC-3 cells infected with Ad5wt 
and/or treated with mitoxantrone: 
 
• Infection with Ad5wt inhibits autophagy flux alone and in certain 
combinations with mitoxantrone (250nM and 500nM), compared to the 
untreated control and mitoxantrone alone. 
• Infection with Ad5wt inhibits increases in Bcl-2 levels at all concentrations 
similar to mitoxantrone. 
• The combination of Ad5wt and mitoxantrone, in contrast to either single 
agent, increases Bcl-2 levels. 
 
3.5.12 Summary of immunoblotting data in PC-3 cells 
 
In summary, at the 24h time-point, increasing concentrations of mitoxantrone 
induced autophagy flux observed by the increases in the ratios of LC3B-II/LC3B-I 
indicating the accumulation of autophagosomes and by the reduction in 
p62/SQSTM1 levels that are indicative of p62-degradation. In contrast, infection with 
AdE1A12S maintained basal levels of LC3B-II while p62/SQSTM1-degradation 
appeared to be promoted. The combination treatments resulted in the promotion of 
mitoxantrone-dependent autophagy activity, while AdE1A12S counteracted this 
activity resulting in attenuation of autophagy. The blockage of autophagy by the virus 
seemed to be overcome by increasing concentrations of the drug. 
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At the 48h time-point, more potent induction of mitoxantrone-induced autophagy 
flux was observed, determined as increased LC3B-II/I ratios in a dose-dependent 
manner and reduced levels of p62/SQSTM1. In contrast, AdE1A12S impaired 
autophagy flux shown by the decreased ratios of LC3B-II/I and increased levels of 
p62/SQSTM1. The combinations of mitoxantrone and AdE1A12S also resulted in 
increased LC3B-II/I ratios but p62/SQSTM1 was accumulated suggesting that the 
virus impairs mitoxantrone-induced autophagy flux and that mitoxantrone was 
unable to overcome the viral inhibition.  
The infection of PC-3 cells at 48h with Ad∆∆ did not induce changes in the ratio of 
LC3B-II/I. However, Ad∆∆ in combination with mitoxantrone, downregulated the 
levels of LC3B-II/I, although complete suppression to basal levels was not achieved. 
In addition, Ad∆∆ increased the expression of p62/SQSTM1 and in combination with 
mitoxantrone the virus effect dominated and prevented the mitoxantrone-induced 
decreases in p62/SQSTM1 (at certain doses). Ad5wt reduced the LC3B-II to LC3B-I 
ratios, in a dose-dependent manner and increased p62/SQSTM1 levels. In summary, 
mitoxantrone induced autophagy flux, while AdE1A12S, Ad∆∆ and Ad5wt potently 
inhibited drug-induced autophagy flux but only at certain doses of mitoxantrone at 
the 48h time-point. Ad5wt and Ad∆∆ might have contributed to increased cell killing 
especially at higher viral doses inhibiting autophagy activity and promoting cell 
proliferation enabling viral replication. These findings seem to verify some of our 
results from the miRNA analysis, indicating that in PC-3 cells treatment with 
mitoxantrone down-regulates the oncomiRs and autophagy inhibitors hsa-miR-17-92, 
hsa-miR-93/106b/25, hsa-miR-183-96-182 and hsa-miR-21, and consequently, 
mitoxantrone would be expected to promote autophagy-related events. In addition, 
AdE1A12S induced upregulation of these miRNAs and would be expected to impair 
autophagy-related events.  
 
The expression of p-Akt in PC-3 cells treated for 24h with mitoxantrone was 
decreased. The infection with AdE1A12S inhibited p-Akt at low doses, although, at 
higher doses the virus strongly induced the levels of p-Akt. Moreover, the 
combination of AdE1A12S with mitoxantrone strongly increased p-Akt. These results 
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suggest that mitoxantrone was unable to overcome the induction of p-Akt by 
AdE1A12S. Furthermore, the blockage of mitoxantrone seemed to potentiate p-Akt 
contributing to reduce the autophagic activity and possibly promote cell 
proliferation.  
At 48h the treatment with mitoxantrone inhibited p-Akt although, to a lesser extent 
than at 24h. Additionally infection with AdE1A12S increased the levels of p-Akt. 
However, the combination of AdE1A12S with increasing concentrations of 
mitoxantrone reduced p-Akt. The inhibition of p-Akt by the combination might 
contribute to the initial increase in autophagy activity as observed with increased 
levels of LC3B-II, however, the accumulation of LC3B-II and p62/SQSTM1 are 
indicative of impaired autophagy flux and may contribute to increased cell killing. 
Furthermore, the increase in hsa-miR-128 and the downregulation of p-Akt seemed 
to correlate with mitoxantrone-dependent abrogation of p-Akt that might lead to 
increased apoptosis. The infection with Ad∆∆ induced a dose-dependent increase of 
p-Akt. Moreover, mitoxantrone in combination with Ad∆∆  impaired the Ad∆∆-
induced increases of p-Akt, similarly to mitoxantrone in combination with AdE1A12S. 
The protein levels of Bcl-2 resulted in slight increases at 24h in PC-3 cells infected 
with AdE1A12S, while basal levels were observed in response to mitoxantrone. The 
combination treatments increased the levels of Bcl-2, as observed with p-Akt at this 
time point. The combination of mitoxantrone and AdE1A12S may induce cell 
proliferation, more likely driven by the virus. In contrast, at 48h the levels of Bcl-2 
were abrogated by the combination suggesting that, at this time point as observed 
with p-Akt, the combination treatments might induce cell killing and mitoxantrone 
might overcome the virus response. 
At 48h the results from the combination of mitoxantrone with AdE1A12S suggest 
that the upregulation of hsa-miR-15/16 contribute to the decreased levels of Bcl-2. 
Moreover, PC-3 cells infected for 48h with Ad∆∆ and Ad5wt in combination with 
mitoxantrone resulted in increased levels of Bcl-2, with the more potent responses in 
combination with Ad∆∆. The increased expression of Bcl-2 might be induced in 
response to the ability of both Ad∆∆ and Ad5wt to replicate and strongly promote 
cell proliferation.  
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3.5.13 AdE1A12S strongly inhibits autophagic activity in 22Rv1 cells at 48h  
 
We also assessed autophagic activity in response to the treatments alone or in 
combination in 22Rv1 cells at 48h post-treatment. 22Rv1 cells were treated for 48h 
with increasing concentrations of mitoxantrone and AdE1A12S alone and in 
combination. In 22Rv1 cells, the selected concentrations of viruses (10ppc - 1000ppc) 
and mitoxantrone (5nM - 500nM) were adjusted according to viral and drug 
concentrations that killed less than 20% of cells, and also including doses above that 
range. Treatment of 22Rv1 cells with mitoxantrone at 5nM and 25nM induced slight 
changes in the ratio of LC3B-II to LC3B-I compared to untreated control, whilst no 
change were observed with 50nM and 250nM mitoxantrone. Moreover, cells treated 
with 500nM mitoxantrone induced a 1.24-fold increase, in the ratio of LC3B-II to 
LC3B-I compared to untreated control. These results showing that mitoxantrone 
might promote autophagy only at very high cytotoxic concentrations, are in contrast 
to the strong increases in the ratio of LC3B-II to LC3B-I observed in PC-3 cells, 
suggesting that the differences between PC-3 cells and 22Rv1 cells are most likely 
due to the different genetic backgrounds in these cells (Table 6).  
Treatment of 22Rv1 cells with 5nM and 25nM mitoxantrone decreased the levels of 
p62/SQSTM1 to 0.81 and 0.72-fold, respectively, compared to untreated control. In 
addition, treatment with mitoxantrone at 50nM, 250nM and 500nM decreased the 
levels of p62/SQSTM1 to 0.84, 0.73 and 0.76-fold, respectively, compared to 
untreated control. In contrast to PC-3 cells where increasing concentrations of 
mitoxantrone induced dose-dependent decreases in the levels p62/SQSTM1, in 
22Rv1 cells, mitoxantrone decreased p62/SQSTM1 independently of the dose. Taken 
together, in 22Rv1 cells mitoxantrone seemed to induce autophagic flux, although, 
only at high doses of mitoxantrone, similar to the findings in PC3 cells (Section 3.5.2). 
Infection of cells with AdE1A12S at 10ppc increased the ratio of LC3B-II to LC3B-I 
inducing a 1.26-fold change compared to untreated control. No changes were 
observed with AdE1A12S at 25ppc and 50ppc (Fig. 44). In contrast, decreased ratios 
of LC3B-II to LC3B-I were observed in cells infected with AdE1A12S at 250ppc, 500ppc 
and 1000ppc to 0.79, 0.78 and 0.61-fold, respectively, compared to untreated control 
(Fig. 44). In summary, in 22Rv1 cells increasing doses of AdE1A12S reduced the ratios 
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of LC3B-II/-I in a dose-dependent manner. Thus, infection with AdE1A12S in 22Rv1 
cells decreases LC3B-II accumulation blocking autophagy. 
Infection of 22Rv1 cells with the AdE1A12S virus showed almost no changes in the 
levels of p62/SQSTM1 at 10ppc and 25ppc compared to untreated control. Increased 
doses of AdE1A12S decreased the levels of p62/SQSTM1 to 0.79, 0.85, 0.85; 0.64 at 
50ppc, 250ppc, 500ppc and 1000ppc, respectively, compared to untreated control 
(Fig. 44). Interestingly, AdE1A12S reduced the levels of p62/SQSTM1 in contrast to 
the virus activity in PC-3 cells, indicating a different mechanism of p62/SQSTM1 
regulation. However, similar to the findings in PC-3 cells, AdE1A12S did not appear to 
induce autophagic flux. 
 
A)  
 
 B) 
 
 
Figure 44. Differences in the ratio of LC3B-II to LC3B-I and expression of p62/SQSTM1 in 
22Rv1 cells at 48h post-treatment with mitoxantrone and/or infection with the AdE1A12S 
virus. A) 22Rv1 cells treated with mitoxantrone at increasing concentrations, 5nM - 500nM 
or infected with the Ad5wt virus, at 10ppc - 1000ppc. Cells were also treated with 
staurosporine at 1nM and rapamycin 100nM as indicators of apoptotic and autophagic 
activity. B) 22Rv1 cells treated with mitoxantrone for 48h at 5nM, 25nM, 50nM and 250nM 
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in combination with the AdE1A12S virus at 25ppc, 50ppc and 250ppc; 500nM in combination 
with the AdE1A12S virus at 50ppc, 250ppc and 500ppc . A-B) The intensity of the bands 
where quantified using Gene Tools version 4.01 (Synoptics Ltd, Cambridge, UK). The variation 
in the ratio of LC3B-II to I after normalizing the intensity of each band to the loading control 
(β-tubulin). Norm: indicates the fold change of each sample compared to untreated control, 
for LC3B indicates the ratio of LC3B II/I of each sample compared to the ratio of LC3B II/I of 
the untreated control.  Fold changes of untreated samples is 1.00. Blot representative of 
three repetitions.  
  
In 22Rv1 cells treated for 48h with 5nM mitoxantrone in combination with Ad12SE1A 
no changes in the ratios of LC3B-II to LC3B-I were observed compared to untreated 
control and mitoxantrone alone. Moreover, treatment with 25nM mitoxantrone in 
combination with AdE1A12S at 25ppc and 250ppc slightly increased the ratios to 1.27 
and 1.14-fold, respectively, compared to untreated control. 22Rv1 cells treated with 
50nM mitoxantrone in combination with AdE1A12S at 25ppc and 250ppc slightly 
increased the ratio of LC3B-II to LC3B-I compared to untreated control. Cells treated 
with 250nM mitoxantrone in combination with AdE1A12S at 50ppc and 250ppc 
increased the ratio of LC3B-II to LC3B-I to 1.63 and 1.59–fold, respectively compared 
to untreated control. The combination of 500nM mitoxantrone with AdE1A12S at 
250ppc and 500ppc decreased the ratio of LC3B-II to LC3B-I to 0.60 and 0.40-fold, 
respectively, compared to untreated control. No changes were observed in 
combination with 50ppc. At all combinations (except at 500nM) LC3B-II/I ratios were 
increased compared to mitoxantrone alone, suggesting that at these doses the 
combination stimulates the accumulation of LC3-II. These results indicate that in 
22Rv1 cells, AdE1A12S may abrogate the accumulation of LC3B-II at higher doses 
only; furthermore, mitoxantrone appeared to partly induce autophagy in 22Rv1 cells. 
The levels of p62/SQSTM1 in 22Rv1 cells were decreased in response to the 
treatment with 5nM mitoxantrone at all combinations with AdE1A12S to 0.78-, 0.81- 
and 0.69-fold, compared to untreated control but, remained similar to the levels 
observed with mitoxantrone alone at this concentration. Moreover, treatment with 
25nM mitoxantrone and infected with 25ppc of the virus induced a 1.22-fold 
increase, of p62/SQSTM1 compared to untreated control, however, the levels of 
p62/SQSTM1 increased compared to mitoxantrone alone. No other combinations 
increased the levels of p62. In addition, cells treated with 50nM mitoxantrone in 
combination with AdE1A12S at 50ppc and 250ppc decreased the levels of 
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p62/SQSTM1 0.78- and 0.56-fold, respectively, compared to untreated control. 
Moreover, cells treated with 250nM mitoxantrone in combination with Ad12S at 
25ppc, 50ppc, and 250ppc decreased the levels of p62/SQSTM1 to 0.56-, 0.45- and 
0.42-fold, respectively, compared to untreated control. Additionally, 500nM 
mitoxantrone in combination with AdE1A12S at 50ppc, 250ppc and 500ppc 
decreased the levels of p62/SQSTM1to 0.47, 0.28 and 0.20-fold, respectively, 
compared to untreated control. Furthermore, the combinations at increasing 
concentrations of mitoxantrone promoted stronger decreases in the levels of 
p62/SQSTM1 than mitoxantrone alone.   
In summary, the treatment with increasing concentrations of mitoxantrone 
decreased the expression of p62/SQSTM1 in 22Rv1 cells. In addition, from these 
results it was not clear if autophagy was induced or might have only been induced by 
certain combinations. Although, autophagy was not induced at low and high 
combinations, indicating that at low concentrations the viral-activity might have 
been more potent than mitoxantrone, whilst at high concentrations of mitoxantrone 
LC3B-II and p62/SQSTM1 decreases might be the effects of increased cell death.    
3.5.14 AdE1A12S potently induces p-Akt in 22Rv1 cells 48h after infection. 
 
Expression of p-Akt (Ser-473) in 22Rv1 cells was assessed in response to increasing 
doses of mitoxantrone; p-Akt was not induced at any concentrations of drugs (5nM – 
500nM). In contrast, there was a strong induction of p-Akt with increasing doses of 
AdE1A12S. The strongest increases were seen at 50ppc, 250ppc, 500ppc and 
1000ppc showing 55.31-, 190.56-, 283.56- and 427.03-fold, respectively, compared 
to untreated samples. Basal levels of p-Akt were below the limit of detection (Fig. 
45). 
In addition, 5nM mitoxantrone increased p-Akt in cells infected with AdE1A12S at 
25ppc, 50ppc and 250ppc inducing 49.16, 427.58 and 609.61-fold increases, 
respectively, compared to untreated control and were higher than with virus alone. 
Treatment with 25nM mitoxantrone in combination with 25ppc, 50ppc and 250ppc 
induced 148.01, 1873.09 and 292.40-fold increases of p-Akt, respectively, compared 
to untreated control. Cells treated with 50nM mitoxantrone in combination with 
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AdE1A12S at 25ppc, 50ppc and 250ppc induced 292.40, 585.07 and 746.90-fold 
increases, respectively, in the levels of p-Akt compared to untreated control. The 
treatment with 250nM mitoxantrone in combination with 25ppc, 50ppc and 250ppc 
showed 165.38, 298.97 and 618.33-fold increases in p-Akt expression compared to 
untreated control. The levels of p-Akt in cells treated with 500nM mitoxantrone in 
combination with AdE1A12S at 50ppc, 250ppc and 500ppc increased in 63.61, 164.77 
and 120.04-fold, respectively, compared to untreated control. The great increases in 
the expression levels of p-Akt were normalised to almost non-detectable levels of p-
Akt at the basal level (control cells).   
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Figure 45. Changes in expression of the phosphorylated Akt in 22Rv1 cells at 48h post-
treatment with mitoxantrone and/or infection with the AdE1A12S virus. A) 22Rv1 cells 
treated with mitoxantrone at increasing concentrations, 5nM - 500nM or infected with the 
AdE1A12S virus, at 10ppc - 1000ppc. Cells were also treated with staurosporine at 1nM and 
rapamycin 100nM as indicators of apoptotic and autophagic activity. B) 22Rv1 cells treated 
with mitoxantrone for 48h at 5nM, 25nM, 50nM, and 250nM in combination with the 
AdE1A12S virus at 25ppc, 50ppc and 250ppc; 500nM in combination with the AdE1A12S 
virus at 50ppc, 250ppc and 500ppc. A-B) The intensity of the bands where quantified using 
Gene Tools version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were normalized as the 
intensity of each band to the loading control (β-Tubulin). Fold change of each sample after 
being compared to untreated control, were the change of the untreated samples is 1.00. Blot 
representative of three repetitions 
 
The combination treatments increased the levels of p-Akt at all combinations 
compared to untreated control and mitoxantrone alone. Moreover, viral-induced 
increases in p-Akt levels were potentiated by some combinations with mitoxantrone. 
These findings are in contrast to those in PC-3 cells where p-Akt was decreased by 
the combinations. These results suggest that in 22Rv1 cells mitoxantrone might not 
cause Akt phosphorylation at ser-473 at the 48h time-point, although, it might 
deregulate other factors enabling AdE1A12S to potently induce p-Akt.  
 
3.5.15 Mitoxantrone attenuates the AdE1A12S-dependent inhibition of Bcl-2 
in 22Rv1 cells. 
 
Bcl-2 expression slightly increased in 22Rv1 cells treated with 5nM mitoxantrone, 
inducing a 1.16-fold increase, compared to untreated control. Moreover, with 25nM 
almost no change was observed compared to untreated control. In addition, 
mitoxantrone at 50nM, 250nM and 500nM decreased Bcl-2 levels to 0.82, 0.73 and 
0.69-fold, respectively, compared to untreated control (Fig. 46A). Infection with 
AdE1A12S at 10ppc, 25ppc, 50ppc, 250ppc, 500ppc and 1000ppc decreased Bcl-2 
expression to 0.32, 0.33, 0.35, 0.31 and 0.25-fold, respectively, compared to 
untreated control (Fig. 46A).  
In summary, increasing concentrations of mitoxantrone induced dose-dependent 
decreases in Bcl-2 expression in 22Rv1 cells at 48h. Furthermore, infection with 
AdE1A12S strongly reduced Bcl-2 expression independently of the viral dosage. 
Interestingly, these results, showed that Bcl-2 in 22Rv1 cells is highly sensitive to 
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AdE1A12S infection, in contrast to PC-3 cells where only high concentrations of both 
mitoxantrone and AdE1A12S decreased Bcl-2 expression. 
 
A) 
 
B) 
 
 
 
 
 
 
 
 
 
Figure 46. Changes in expression of Bcl-2 in 22Rv1 cells at 48h post-treatment with 
mitoxantrone and/or infection with the AdE1A12S virus. A) 22Rv1 cells treated with 
mitoxantrone at increasing concentrations, 50nM - 2000nM or infected with the AdE1A12S 
virus, at 50ppc - 1000ppc. Cells were also treated with staurosporine at 1nM and rapamycin 
100nM as indicators of apoptotic and autophagic activity. B) 22Rv1 cells treated with 
mitoxantrone for 48h at 5nM, 25nM, 50nM and 250nM in combination with the AdE1A12S 
virus at 25ppc, 50ppc and 250ppc; 500nM in combination with the AdE1A12S virus at 50ppc, 
250ppc and 500ppc. A-B) The intensity of the bands where quantified using Gene Tools 
version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were normalized as the intensity of each 
band to the loading control (β-Tubulin). Fold change of each sample after being compared to 
untreated control, were the change of the untreated samples is 1.00. Blot representative of 
three repetitions.  
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While the 22Rv1 cells were highly sensitive to AdE1A12S dependent downregulation 
of Bcl-2, in combination with 5nM mitoxantrone basal levels of Bcl-2 were re-
established. Moreover, Bcl-2 expression in cells treated with 25nM mitoxantrone in 
combination with AdE1A12S at 50ppc induced a slight increase of 1.34-fold, 
compared to untreated control (Fig. 46B). The combination of 25nM with 25ppc 
maintained basal levels of Bcl-2, whereas AdE1A12S at 250ppc slightly reduced the 
levels of Bcl-2. However, the virus in combination with 25nM showed slight increases 
compared to mitoxantrone and to the virus alone at similar doses (Fig. 46B). The 
expression of Bcl-2 decreased in cells treated with 50nM mitoxantrone and 
AdE1A12S at 25ppc, 50ppc and 250ppc to 0.73-, 0.76- and 0.59-fold, respectively, 
compared to untreated control. Moreover, the combination when compared to 
mitoxantrone alone showed similar levels of Bcl-2 except at the highest viral dose, 
however, these combinations had increased Bcl-2 levels when compared to 
AdE1A12S alone.  Furthermore, 250nM mitoxantrone in combination with AdE1A12S 
at 25ppc, 50ppc and 250ppc decreased Bcl-2 expression to 0.55-, 0.27- and 0.52-fold, 
respectively, compared to untreated control (Fig. 46B); the levels of Bcl-2 with the 
combination were increased (except at 50ppc) compared to AdE1A12S alone. The 
levels of Bcl-2 with 500nM mitoxantrone in combination with AdE1A12S at 50ppc 
and 250ppc decreased to 0.34- and 0.67-fold respectively, compared to untreated 
control (Fig. 46B), the 500nM mitoxantrone in combination with 500ppc regain basal 
levels; these combinations showed increasing trend compared to the virus alone at 
those doses. In summary, mitoxantrone abrogates the AdE1A12S-dependent 
reduction in Bcl-2 levels only at the lower drug doses; in contrast, high doses of 
mitoxantrone may contribute to Bcl-2 downregulation through cell-death induction.  
 
3.5.15.a. Summary of immunoblotting data in 22Rv1 cells infected with AdE1A12S 
and/or treated with: 
 
• In 22Rv1 cells infection with AdE1A12S inhibits autophagy flux. In addition, 
only high doses of mitoxantrone (500nM) induce autophagy slightly. 
However, the combination of AdE1A12S with mitoxantrone impairs 
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autophagy flux at low and high doses of mitoxantrone (500nM) compared to 
untreated control and mitoxantrone alone.  
• Treatment with mitoxantrone does not induced p-Akt, while AdE1A12S 
strongly induces higher levels of p-Akt compared to untreated control. The 
combination of AdE1A12S with mitoxantrone further potentiates the 
increases in p-Akt levels compared to single agents.   
• Both mitoxantrone and AdE1A12S decreases the levels of Bcl-2 at all 
concentrations. Bcl-2 expression is increased in response to the combination 
of both treatments compared to single agent treatment. However, despite 
that the levels of Bcl-2 are higher the expression levels are still predominantly 
lower than basal levels.  
3.5.16 Ad∆∆ potently inhibits autophagy-activity in 22Rv1 cells. 
 
The response to infection with the Ad∆∆ virus was assessed in parallel to the 
infection with AdE1A12S. Levels of the autophagic marker LC3B-II were determined 
in cells infected with Ad∆∆ at 10ppc, 25ppc, 50ppc, 250ppc, 500ppc and 1000ppc 
showing 0.74-, 0.48-, 0.31-, 0.39-, 0.31- and 0.25-fold decreases, respectively, in the 
ratio of LC3B-II/LC3B-I compared to untreated samples (Fig. 47A). The expression of 
p62/SQSTM1 decreased with increasing concentrations of Ad∆∆ at 10ppc, 25ppc, 
50ppc, 250ppc, 500ppc and 1000ppc to 0.78-, 0.88-, 0.71-, 0.77-, 0.43- and 0.26-fold, 
respectively, compared to untreated control (Fig.47A). In summary, in 22Rv1 cells 
Ad∆∆  potently impaired autophagy activity similarly to AdE1A12S as indicated by 
the decreased levels of LC3B-II/I ratios. However, p62/SQSTM1 levels were also 
decreased, similarly to the effects in PC-3 cells; it is likely that the apparent 
degradation of p62 is caused by increased cell death in response to the virus and/or 
viral replication since accumulation of autophagosomes did not occur. 
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A) 
  
B) 
 
Figure 47. Differences in the ratio of LC3B-II to LC3B-I and expression of p62/SQSTM1 in 
22Rv1 cells at 48h post-treatment with mitoxantrone and/or infection with the Ad∆∆ 
virus. A) 22Rv1 cells treated with mitoxantrone at increasing concentrations, 5nM - 500nM 
or infected with the Ad∆∆ virus, at 10ppc - 1000ppc. Cells were also treated with 
staurosporine at 1nM and rapamycin 100nM as indicators of apoptotic and autophagic 
activity. A/B) 22Rv1 cells treated with mitoxantrone for 48h at 5nM, 25nM, 50nM, 250nM 
and 500nM in combination with the Ad∆∆ virus at 25ppc, 50ppc and 250ppc.  A-B) The 
intensity of the bands where quantified using Gene Tools version 4.01 (Synoptics Ltd, 
Cambridge, UK). The variation in the ratio of LC3B-II to -I after normalizing the intensity of 
each band to the loading control (β-tubulin). Norm: indicates the fold change of each sample 
compared to untreated control, for LC3B indicates the ratio of LC3B II/I of each sample 
compared to the ratio of LC3B II/I of the untreated control.  Fold changes of untreated 
samples is 1.00. One experiment, blot representative of three repetitions.  
 
The combination of 5nM mitoxantrone with Ad∆∆ at 25ppc, 50ppc and 250ppc 
decreased the ratio of LC3B-II to LC3B-I to 0.44-, 0.48- and 0.40-fold, respectively, 
compared to untreated control (Fig. 47A), the combination ratios were also 
decreased when compared to mitoxantrone alone but remained similar to Ad∆∆ at 
those doses. Moreover, treatment with 25nM mitoxantrone in combination with 
Ad∆∆ at 25 ppc, 50 ppc and 250ppc caused 0.69-, 0.61- and 0.48-fold decreases, 
respectively, in LC3B-II to LC3B-I ratios compared to untreated control (Fig. 47A), the 
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LC3B-II to LC3B-I ratios were also decreased when compared to mitoxantrone alone, 
but were increased compared to Ad∆∆ at those doses. The treatment of 22Rv1 cells 
with 50nM mitoxantrone also decreased the ratios of LC3B-II to LC3B-I in 
combination with Ad∆∆ at 25ppc, 50ppc and 250ppc to 0.55-, 0.40- and 0.32-fold, 
respectively compared to untreated control and also to mitoxantrone alone (Fig. 47 
A-B) Additionally, 250nM mitoxantrone combined with Ad∆∆ at 25ppc, 50ppc, and 
250ppc decreased the ratio of LC3B-II/I to 0.40-, 0.42- and 0.39-fold, respectively, 
compared to untreated control and mitoxantrone alone (Fig. 47 A-B). Finally, cells 
treated with 500nM mitoxantrone in combination with Ad∆∆ at 25ppc, 50ppc and 
250ppc caused 0.49-, 0.59- and 0.31-fold decreases, indicating a decrease in the ratio 
of LC3B-II to LC3B-I compared to untreated control and mitoxantrone alone (Fig. 47 
A-B). In summary, all combinations in 22Rv1 cells decreased the accumulation of 
LC3B-II in respect to LC3B-I. Decreased accumulation of LC3B-II in response to Ad∆∆ 
was dose-independent. Interestingly, Ad∆∆-dependent inhibition of LC3B-II 
accumulation was stronger than the inhibition induced by AdE1A12S in this cell line. 
The decreased p62/SQSTM1 levels in combination-treated cells were dependent on 
the viral dose; increasing doses of Ad∆∆ caused decreasing levels of p62/SQSTM1 
(Fig. 47A-B). Cells treated with 5nM mitoxantrone in combination with Ad∆∆ at 
50ppc and 250ppc showed decreased levels of p62/SQSTM1, 0.80- and 0.69-fold, 
respectively, when compare to untreated control (Fig. 47), only small variations were 
observed compared to mitoxantrone alone at 5nM, while, the changes induced by 
the combination were similar to those observed with Ad∆∆ at similar doses. 
Moreover, the treatment with mitoxantrone at 25nM and infection with Ad∆∆ at 
25ppc, 50ppc and 250ppc decreased the levels to 0.69-, 0.61- and 0.48-fold, 
respectively, compared to untreated control and when compared to mitoxantrone 
and Ad∆∆ alone (Fig. 47A-B).  In combination with 50nM mitoxantrone and Ad∆∆ at 
50ppc p62/SQSTM1 levels decreased to 0.81-fold, but not with 250ppc that caused a 
1.25-fold increase and 25ppc that caused no change, compared to untreated control, 
however, the levels of p62/SQSTM1 were increased compared to Ad∆∆ and 
mitoxantrone at 50nM (Fig. 47A-B). Cells treated with mitoxantrone at 250nM also 
showed decreased levels of p62/SQSTM1 in combination with Ad∆∆ at 50ppc and 
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250ppc at 0.29- and 0.19-fold, respectively, compared to untreated control and 
mitoxantrone and Ad∆∆. No change was observed in combination with 25ppc 
compared to untreated control; however, the levels of p62/SQSTM1 were increased 
compared to both mitoxantrone and Ad∆∆ (Fig. 47A-B). Furthermore, cells treated 
with 500nM mitoxantrone had decreased levels of p62/SQSTM1 in combination with 
Ad∆∆-infection at 25ppc, 50ppc and 250ppc (0.43-, 0.31- and 0.21-fold respectively), 
compared to untreated control, mitoxantrone at 500nM and Ad∆∆ alone at those 
doses. Overall, the combination of both agents decreased the levels of p62/SQSTM1. 
Taken together, mitoxantrone slightly induced autophagy flux, while the oncolytic 
mutant Ad∆∆ attenuated drug-induced autophagosome formation (decreased LC3B-
II/I ratios) in all combinations. This attenuation of autophagy-related activities was 
more potent with Ad∆∆ than with AdE1A12S. 
 
3.5.17 Activation of Akt is strongly induced by Ad∆∆ and is further increased 
in combination with mitoxantrone in 22Rv1 cells. 
 
The levels of p-Akt in response to Ad∆∆ were assessed in 22Rv1 cells after infection 
with 10ppc, 25ppc, 50ppc, 250ppc 500ppc and 1000ppc (Fig. 48A). Increases of 15.6-, 
37.4-, 32.3-, 58.8-, 47.3- and 22.4-fold respectively, were observed when compared 
to untreated control. Interestingly, induction of p-Akt was less with 1000ppc 
compared to 250ppc and 500ppc.   
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Figure 48. Changes in expression of the phosphorylated Akt in 22Rv1 cells at 48h post-
treatment with mitoxantrone and/or infection with the Ad∆∆ virus. A) 22Rv1 cells treated 
with mitoxantrone at increasing concentrations, 5nM - 500nM or infected with the Ad∆∆ 
virus, at 10ppc - 1000ppc. Cells were also treated with staurosporine at 1nM and rapamycin 
100nM as indicators of apoptotic and autophagic activity. B) 22Rv1 cells treated with 
mitoxantrone for 48h at 5nM, 25nM, 50nM, 250nM and 500nM in combination with the 
Ad∆∆ virus at 25ppc, 50ppc and 250ppc.  A-B) The intensity of the bands where quantified 
using Gene Tools version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were normalized as the 
intensity of each band to the loading control (β-Tubulin). Fold change of each sample after 
being compared to untreated control, were the change of the untreated samples is 1.00.Blot 
representative of three repetitions 
 
Although, Ad∆∆ increased p-Akt levels it appeared to be less potent than AdE1A12S 
in activating p-Akt (Fig. 48A-B). The combination of Ad∆∆ with mitoxantrone strongly 
enhanced p-Akt at all combinations compared to the virus alone, indicating that, 
despite that mitoxantrone does not induce p-Akt, the drug plays a role in 
potentiating Ad∆∆-induced p-Akt similar to the findings in PC-3 cells. 
3.5.18 Ad∆∆ and Mitoxantrone downregulated Bcl-2 both alone and in 
combination in 22Rv1 cells. 
 
22Rv1 cells infected with Ad∆∆ at 10ppc, 25ppc, 50ppc, 250ppc, 500ppc and 
1000ppc showed decreased levels of Bcl-2; 0.80-, 0.84-, 0.68-, 0.57-, 0.47- and 0.20-
fold, respectively, compared to untreated control (Fig. 49A). In addition, infection 
with Ad∆∆ resulted in a dose-dependent decrease in the expression of Bcl-2 in 
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response to increasing concentrations of the virus. Mitoxantrone also decreased Bcl-
2 levels (Fig. 49A).  
 A) 
 
 
 
 
 
 
 
 
 
B) 
 
Figure 49. Changes in expression of Bcl-2 in 22Rv1 cells at 48h post-treatment with 
mitoxantrone and/or infection with the Ad∆∆ virus. A) 22Rv1 cells treated with 
mitoxantrone at increasing concentrations, 5nM - 500nM or infected with the Ad∆∆ virus, at 
10ppc - 1000ppc. Cells were also treated with staurosporine at 1nM and rapamycin 100nM 
as indicators of apoptotic and autophagic activity. B) 22Rv1 cells treated with mitoxantrone 
for 48h at 5nM, 25nM, 50nM, 250nM and 500nM in combination with the Ad∆∆ virus at 
25ppc, 50ppc and 250ppc and additionally, with mitoxantrone with 500nM in combination 
with 50ppc, 250ppc. A-B) The intensity of the bands where quantified using Gene Tools 
version 4.01 (Synoptics Ltd, Cambridge, UK). Bands were normalized as the intensity of each 
band to the loading control (β-Tubulin). Fold change of each sample after being compared to 
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untreated control, were the change of the untreated samples is 1.00. Blot representative of 
three repetitions 
 
Expression of Bcl-2 was decreased in cells treated with 5nM mitoxantrone in 
combination with Ad∆∆ at 25ppc, 50ppc and 250ppc to 0.67-, 0.65- and 0.64-fold, 
respectively, compared to untreated control  and when compared to mitoxantrone 
alone (Fig. 49A-B). Cells treated with 25nM mitoxantrone in combination with Ad∆∆ 
at 25ppc, 50ppc and 250ppc showed 0.35-, 0.68- and 0.48-fold decreases, 
respectively, compared to untreated control, mitoxantrone alone and when 
compared to Ad∆∆ at those doses (Fig. 49A-B). Moreover, the expression of Bcl-2 
also decreased in cells treated with 50nM mitoxantrone in combination with Ad∆∆ at 
25ppc and 250ppc showing 0.73- and 0.48-fold changes, respectively, compared to 
untreated control, and also compared to mitoxantrone alone (Fig. 49A-B). No 
changes were observed in combination with 50ppc. Furthermore, Ad∆∆ at 25ppc, 
50ppc and 250ppc combined with 250nM mitoxantrone decreased Bcl-2 levels to 
0.52-, 0.42- and 0.24-fold, respectively, compared to untreated control, the values 
were decreased also when compared to Ad∆∆ at those concentrations and to 
mitoxantrone alone (Fig. 49A-B). Finally, cells treated in combination with 500nM 
mitoxantrone and Ad∆∆ at 25ppc, 50ppc and 250ppc decreased Bcl-2 levels to 0.37-, 
0.32- and 0.42-fold, respectively, compared to untreated control (Fig. 49B). The 
combination at 500nM strongly decreased the levels of Bcl-2 when compared to 
mitoxantrone alone and Ad∆∆ at similar doses. Overall, the expression of Bcl-2 was 
inhibited both by each agent alone and by the combination treatments. Taken 
together, both mitoxantrone and Ad∆∆ contributed to downregulation of Bcl-2 levels 
that is likely to play a significant role in driving cell death in these cells.  
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3.5.18.a. Summary of immunoblotting data in 22Rv1 cells infected with Ad∆∆ 
and/or treated with mitoxantrone: 
 
• Infection with Ad∆∆ potently inhibits autophagy flux both alone and in 
combination with mitoxantrone compared to untreated control.  
• The treatment with mitoxantrone alone does not cause changes in the 
expression levels of p-Akt. In contrast, infection with Ad∆∆ strongly increases 
the expression of p-Akt both alone and in combination with mitoxantrone 
compared to untreated control and mitoxantrone alone. 
• Cells treated with mitoxantrone and/or infected with Ad∆∆ show decreased 
levels of Bcl-2 under all conditions compared to untreated control. 
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4. Discussion 
 
4.1 The role of the adenoviral early E1A proteins in combination 
treatments with cytotoxic drugs. 
 
This work was aimed at identifying E1A regions involved in the sensitization of 
prostate cancer cells to chemotherapeutic drugs and to elucidate the mechanisms 
involved in the synergistic enhancement of cancer cell killing. The identification of 
cellular factors that may be responsible for sensitizing the cells could further enable 
targeting of these cellular pathways by novel drug combinations to improve current 
therapies for prostate cancer. In summary, through this work we found that the small 
adenoviral E1A12S protein was sufficient to sensitize both human and murine 
prostate cancer cells to mitoxantrone. Furthermore, the non-replicating mutants 
AdE1A12S, AdE1A1102 and AdE1A1108, potently sensitized all tested human PCa cell 
lines (PC-3, 22Rv1 and DU145) to chemotherapeutic drugs while AdE1A1104 did not. 
To explore different cellular functions that could uncover the underlying mechanisms 
of this sensitization, and to give more insight into previous studies on virus-drug 
interactions causing synergistic cell killing,95 we investigated changes in the 
expression of cell cycle regulators. We observed that mitoxantrone induced cyclins A 
and B in PC-3 cells but not in 22Rv1 cells. In addition, the AdE1A12S and AdE1A1102 
viral mutant enhanced mitoxantrone-induced p21 mRNA expression in PC-3 cells but 
not in 22Rv1 cells. We also demonstrated potent synergistic cell killing with 
mitoxantrone and mutants with intact E1A p300-binding regions in both PC-3 and 
22Rv1 cells. The interaction of mitoxantrone with the replicating mutant dl1102 
(intact p300-binding) resulted in synergy in both 22Rv1 and PC-3 cells. Furthermore, 
the replicating adenoviral mutants did not enhance cell killing in combination with 
mitoxantrone in normal human cells, and the dl1102 mutant potently reduced 
tumour growth in combination with docetaxel in PC-3 xenografts in vivo. These 
results demonstrate that binding of AdE1A12S to p300 is essential for the synergistic 
sensitisation of prostate cancer cells to mitoxantrone and docetaxel, showing high 
efficacy and potency in PCa cell killing but being safe to normal tissue. However, 
these results did not generate in depth mechanistic data and further studies were 
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necessary to investigate the cellular factors that were involved in the 
chemosensitization. To better address what cellular pathways might be involved in 
the sensitization, we employed an extensive miRNA array screen attempting to 
identify a broader network of potential factors responsible for the sensitization in 
PCa cells. We first analysed the combination of AdE1A12S with mitoxantrone under 
synergistic conditions in PC-3 cells and compared to the sum of each single agent 
treatment. The PC-3 cells were selected because of the high resistance to both virus 
and drugs when administered as single agents and the potent synergistic cell killing 
when combined. The miRNA data indicated that pathways regulating cell cycle 
progression, cell proliferation, survival and death played major roles in the 
synergistic cell killing. Key factors in these pathways were verified as regulated both 
by the non-replicating AdE1A12S and the replicating Ad∆∆ and Ad5wt viruses in 
combination with mitoxantrone over time. Interestingly, mitoxantrone induced 
autophagic flux in both PC-3 and 22Rv1 cells while this induction was prevented in a 
dose-dependent manner by all viruses and appeared to contribute to the increased 
cell death.    
Our previous results95 demonstrated that the combinations of mitoxantrone and all 
tested AdE1A12S mutants (except AdE1A1104) induced changes in cell cycle 
progression, by increasing the G2/M cell population. In PC-3 cells, the expression of 
cyclins A and B was induced by mitoxantrone and did not change in combination with 
any of the AdE1A12S mutants. Both cyclins A and B are highly expressed during the 
G2/M phase419,420 and mitoxantrone can induce cell cycle arrest in the G2/M phase 
because of its DNA-damaging effects.421 Therefore, increased G2/M phase in PC-3 
cells and upregulation of cyclins A and B was likely caused by mitoxantrone alone, 
since the viral mutants had minor effects alone and showed similar changes as cells 
infected with AdGFP. However, the variations in the cell cycle profile in response to 
the combination of mitoxantrone and the different AdE1A12S mutants,95 specifically 
AdE1A1104, suggest that E1A-binding to cellular factors contribute to the increase in 
the G2/M population in the presence of drug. E1A promotes cell proliferation by 
releasing pRb-bound E2F1.83 It has also been shown that pRb and CBP/p300 have 
common binding sites on E2F1; while E2F1-binding to pRb represses E2F1-mediated 
transcriptional activation, E2F1-binding to CBP/p300 stabilizes and stimulates its 
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activation.386 The lack of a CBP/p300 binding to the AdE1A1104 mutant might 
diminish the role of E1A in cell cycle regulation, perhaps by the inability of this 
mutant E1A to mediate CBP/p300 interaction with E2F1 and at the same time E1A 
sequestering pRb. In contrast, the formation of the complex E1A-CBP/p300 (e.g. in 
AdE1A1102) might enable the binding and transcriptional activation of E2F1, 
promoting cell cycle.422 We expected that these mechanisms would be reflected in 
the levels of cyclin expression. However, the expression patterns of cyclins A, B, E 
and D in PC-3 and 22Rv1 cells did not give further insights of the cell cycle regulatory 
mechanisms and the potential roles in chemosensitization in these cells. Even though 
changes in expression levels were observed, the implication of these changes were 
less clear and further investigation is required such as determination of the degree of 
activation (phosphorylation/dephosphorylation) of Cdk1 and Cdk2 proteins.423  
The role of p21 in G1-arrest is well established, however, overexpression of p21 has 
also been reported to induce G2/M arrest in both p53-dependent and p53-
independent pathways.386 Therefore, we assessed the expression of this regulatory 
protein. However, the expression of p21 could not be detected in PC-3 cells by 
immunoblotting. Previous reports showed that p21 was expressed at low levels in 
PC-3 cells and was also suggested to be AR-regulated in prostate cancer cells.424 
Next, we investigated the expression of p21 mRNA in PC-3 cells. In cells infected with 
AdE1A12S alone, no effects on cell cycle regulators were detected by 
immunoblotting analysis. It was previously reported that both E1A13S and E1A12S 
(to a lesser degree) could induce cell cycle progression, and inhibit p21 expression by 
direct binding.425 In contrast, mitoxantrone alone induced the expression of p21 
mRNA through a p53-independent pathway in PC-3 cells (p53-/-, AR-/-). Surprisingly, 
the combination of mitoxantrone and AdE1A1102 or AdE1A12S further increased 
p21 mRNA levels in PC-3 cells. Although p21 mRNA levels do not necessarily translate 
into protein expression, it is plausible that G2/M arrest might be induced through a 
p53-independent pathway in PC-3 cells in which p21 may contribute even if only as a 
minor player.426,427 Furthermore, the upregulation of p21 mRNA by the AdE1A12S 
mutants has also been reported recently in A549 cancer cells, although these cells 
express wild type p53.428 It has also been demonstrated that p21 is p53-dependent 
and that activation of AR can promote this activation, an observation that was 
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previously reported for LNCaP cells (p53+AR+).424 However, whether the induction of 
p21 by AdE1A1102 and AdE1A12S in combination with mitoxantrone contributes to 
cell sensitization remain unclear; therefore, further investigations will be necessary 
to conclusively interpret our observations in PC-3 cells.   
In contrast, 22Rv1 cells infected with the AdE1A12S mutants showed increased 
expression of cyclin A and B, and similar increases were observed in response to 
AdGFP infection. The apparent non-specific virus-induced effects on cyclin expression 
suggest that E1A-independent viral mechanisms may also regulate cell cycle 
progression in 22Rv1 cells. However, in 22Rv1 cells treated with mitoxantrone the 
expression of cyclin A and B was decreased, which is in contrast to the effects 
observed in PC-3 cells. Moreover, cyclin D did not change in response to any of the 
non-replicating viral mutants or to mitoxantrone in either PC-3 or 22Rv1 cells. Cyclin 
E was induced by viral infection similar to both cyclins A and B. In 22Rv1 cells, the 
upregulation of cyclins A, B and E suggests a drive for cell cycle progression; 
nonetheless, the combination with mitoxantrone subsequently induced the 
downregulation of these proteins, an indication of cell cycle arrest possibly in a p53- 
and p21-dependent manner. It has been established that mitoxantrone can activate 
p53 in turn contributing to both cyclin A and B degradation which is facilitated by the 
upregulation of p21. The p21-dependent degradation of cyclin B is essential for G2/M 
arrest in response to DNA-damaging agents including mitoxantrone, which causes 
double strand breaks.392 Despite an increase in the levels of p21 mRNA in PC-3 cells, 
the corresponding p21 protein expression could not be detected in these cells, 
possibly because of the absence of p53 as a main regulator of p21. In a p53-
independent context E2F1 can regulate p21 at a transcriptional level stimulating the 
p21-promoter, however, in the presence of p53 it has been reported that p21 
expression is strongly enhanced by a combined interaction of p53 with E2F1.429,430 
Therefore, in 22Rv1 cells the presence of p53 is likely to strongly contribute to the 
stimulation of p21 to regulate the increase in the G2/M cell population.386,426,431,432 
These data are complemented by the activation of p53 (data not shown) by 
mitoxantrone, although, phospho-p53 was also induced by AdE1A1102 and was not 
reflected in increased expression of p21. Nevertheless, the contribution of active 
phospho-p53 to G2/M arrest in 22Rv1 cells is evident. In summary, the responses to 
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the DNA-damaging drug mitoxantrone suggest that the regulation of the G2/M 
regulatory cyclins is dependent on the genetic background of the cells. 
Another factor that could favour a DNA-damage response induced by mitoxantrone 
in 22Rv1 cells is the increased expression of topoisomerase II (data not shown), 
which is consistent with previously published data showing that E1A induces an 
increase in topoisomerase-II mRNA expression and protein synthesis.131,433 This 
upregulation seems to increase the sensitivity of the cells to cytotoxic drugs targeting 
topoisomerase II.433 The exact mechanism by which E1A up-regulates topoisomerase 
II is mainly unknown but it would be expected that E1A interacts with the 
transcription machinery to enhance topoisomerase levels and facilitate cellular 
protein synthesis and S-phase entry, to ultimately enable viral replication. However, 
the downregulation of topoisomerase II with mitoxantrone is consistent with 
previous reports showing that mitoxantrone inhibits topoisomerase II by inducing 
DNA-strand breaks and targets the enzyme for degradation.67  
 
A G2/M arrest or delay of tumour cells frequently causes apoptotic cell death and 
the caspase effectors caspase-3 and caspase-7 may be activated. We have shown in 
22Rv1 cells that the AdE1A12S-mutants induced sensitization of PCa cells in 
combination with mitoxantrone was reduced by a pan-caspase inhibitor.95 Therefore, 
to verify the activity of caspase-3 and caspase-7 (data not shown) key effector 
caspases, we assessed the expression of caspase-3 and 7 in response to the 
combined treatments in PC-3 cells. However, I was unable to detect activation and 
expression of caspase 3 and 7, and could therefore not show the activity of caspases 
as part of the apoptotic response, however, cells treated with staurosporin induced 
the activation of caspase 3 while  caspase 7 was not detected.   
In order to determine if the differences in the sensitization to chemotherapeutic 
drugs and cell cycle progression in the PC-3 and 22Rv1 cells were due to sensitivity to 
infection alone, we attempted to use matched ovarian cancer cell lines; sensitive 
(Skov3) and less sensitive (Skov3ip1) to viral infection.371-373 Previous reports 
demonstrated that Skov3 cells were more sensitive to viral infection than 
Skov3ip1.372 However, in my dose-response infectivity assays I found that Skov3ip1 
were less sensitive than Skov3. Nevertheless, cytotoxicity was not significantly 
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different between the two cell lines and was in stark contrast to previously published 
data.371 It is possible that the similar responsiveness to virus and combination 
treatments was due to the absence in both Skov3 and Skov3ip cells of common cell 
death regulatory mechanisms such as p53 (not expressed in both cell lines) although, 
this does not explain the contradiction with the published data. While further testing 
of these cell lines using STR-profiling demonstrated that both cell lines were indeed 
Skov3, there was no marker for the reported sensitive versus insensitive cell line. In 
our study the regulatory mechanisms in these cells might be essential in the 
induction of sensitization to the combination of the drug and the viruses. Thus, we 
concluded that Skov3ip1 and Skov3 cells could not be used as a tool to investigate 
differences in chemosensitization in different cell lines (PC-3 and 22Rv1). The aim 
was to elucidate whether these differences were due to sensitivity to infection 
and/or additional mechanisms, and consequently other matched cell lines would be 
required but were not available at the time. 
 
We previously demonstrated that the interactions of AdE1A12S with both 
mitoxantrone and docetaxel synergistically enhanced cell killing in PCa cells.95 In 
order to determine the synergistic interactions in which E1A-deletion mutants 
(AdE1A-replicating and non-replicating) could best sensitize cells and enhance cell 
killing in combination with mitoxantrone, I set up synergy assays to determine 
combination indexes (CI). The results from the studies showed strong synergism 
between mitoxantrone in combination with AdE1A12S, AdE1A1102 and dl1102, but 
not with mutants with the E1A p300-binding region deleted in PC-3 cells. In 22Rv1 
cells the combination of dl1102 with mitoxantrone showed the strongest synergy. 
The sensitization and synergy studies suggested that dl1102 was a strong candidate 
for consideration when improving current vectors, being the most potent and having 
the strongest synergistic effects in combination with drugs in both cell lines. These 
findings are in agreement with previous results where the dl1102 virus induced more 
sensitization in cells in response to chemotherapeutic drugs than other viral 
mutants.95 These and previous results, contributed to our conclusion that the E1A-
p300 binding region (amino acids ∆26-35) was essential for the sensitization of 
prostate cancer cells to mitoxantrone but not the E1A-p400 binding region (∆48-60). 
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However, there is controversy in the literature about the role in drug-sensitization 
for the p300 and p400 binding sites on E1A.76,96,100 Both regions have been reported 
to be responsible for sensitizing cancer cells to cytotoxic agents dependent on cell 
line. Our data strongly support the E1A-p300 binding region as essential for the 
sensitization of prostate cancer cells in combination with the currently used clinical 
cytotoxic drugs for prostate cancer patients; mitoxantrone and docetaxel. However, 
the mechanisms behind the synergistic interactions remain unclear and further 
studies will be designed to address these observations in future projects.  
In order to generate more selective and potent oncolytic viruses, it was important to 
determine the selectivity of replication and the potency of the E1A deleted mutants 
in normal cells. To investigate the safety in normal cells, NHBE and PrEC cells where 
used to determine replication and virus-mediated sensitivity to chemotherapeutic 
drugs. The results showed that the replicating AdE1A oncolytic mutants dl1102 and 
dl1104 replicated to a significantly lesser degree than Ad5wt in NHBE cells while the 
mutants replicated as potently as wild type virus in prostate cancer cells. 
Importantly, the mutants did not sensitize normal cells (NHBE and PrEC cells) to 
mitoxantrone as previously observed for tumour-selective viruses in combination 
with other cytotoxic drugs.131 In contrast, Ad5wt caused more than additive cell 
death in combination with mitoxantrone in both NHBE and PrEC cell. As previously 
shown the replication-selective oncolytic Ad∆∆ did not enhance cell killing in 
combination with mitoxantrone in the normal cells.118 The results demonstrated that 
dl1102, dl1104 and Ad∆∆ had low cytotoxicity to normal cells. The dl1102 were as 
potent, safe and efficient as Ad∆∆ in the PCa cells, in contrast, the dl1104 was less 
effective.  
Furthermore, using an in vivo murine model with PC-3 xenografts (athymic mice), 
dl1102 in combination with docetaxel was significantly more potent than a similar 
combination with dl1104; prolonged time to tumour progression and reduced 
tumour growth were significantly higher when dl1102 was combined with docetaxel 
than with either agent alone. In addition, cell death might be induced through 
apoptosis, as previously shown for AdE1A1102 but remain to be determined in 
additional studies.  
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Our results show evidence of apoptotic cell death however, it is not completely clear 
which mechanisms are interacting and are being regulated to increase the apoptotic 
death in response to the combination treatments. Therefore, the identification of the 
mechanisms involved in the E1A-induced sensitization of prostate cancer cells to 
chemotherapeutic drugs remain elusive.95 Among the main problems that are 
hindering the identification of virus-induced sensitization of PCa cells to 
chemotherapeutic drugs triggering cell death mechanisms are the binding of a 
plethora of cellular factors to overlapping binding regions within the E1A-protein 
with the majority having redundant functions.83,84 Most of these factors are involved 
in regulation of cell death/survival and cell cycle pathways. Furthermore, to elucidate 
the mechanisms and pathways involved in synergistic cell killing, an extensive in 
depth study in each cell line would be required. Therefore, we employed a miRNA 
array screening that would enable us to identify a broader network of possible 
mechanisms involved in the sensitization of the PCa cells. We focused on the miRNA 
analysis in PC-3 cells because of the insensitivity of these cells to each single agents 
and the significantly synergistic enhancement of cell killing when virus and drug were 
combined. We postulated that the expression of miRNAs may be affected either by 
chemotherapeutic drugs and/or expression of E1A12S and that the combination-
treated cells would induce a different pattern of miRNA expression.  
Interestingly, most of the miRNAs that were upregulated in response to combination 
of AdE1A12S and mitoxantrone have been reported as downregulated in PCa, 
(including the miRNAs, hsa-let-7a/b/c/d/e/f/g, hsa-miR-125a-5p, hsa-miR-125b, hsa-
miR-128, hsa-miR-15b, hsa-miR-16, hsa-miR-23a, hsa-miR-23b and hsa-miR-
27a).374,389-398 These miRNAs have been established as tumour suppressors 
contributing to apoptosis by increasing or inhibiting the expression of their 
respective target genes such as p53, caspase-3 and Bcl-2, or regulating the 
autophagy pathway through the PI3K/AKT/mTOR pathway.192,195-199 In contrast, most 
of the miRNAs that were downregulated in our study were oncomiRs including hsa-
miR-93/106b/25, hsa-miR-17-18a, -19a/b, -20a, and miR-92a. Thus, when tumour 
suppressor miRNAs are upregulated cell death is promoted and inversely, 
downregulation of oncomiRs also promotes cell death and inhibition of 
proliferation.203,228,374,389-398 Some miRNAs were reported to be part of the same 
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clusters and to be jointly regulated, either by the same promoter and/or the same 
transcription factors.231,235-239,388-390 Specific miRNA clusters have been implicated in 
both tumour suppression and tumour progression. In our study we identified the 
following miRNA clusters and families; the let-7 family including hsa-let-7d, hsa-let-
7e, hsa-let-7f and hsa-let-7g; the hsa-miR-23 cluster including hsa-miR-23, -10, -24, -
26, -27 and -30; the cluster 17-92 encoding hsa-miR-17-18a, -19a/b, -20a, and miR-
92a; and hsa-miR-183-96-182 cluster including hsa-miR-15/16, hsa-miR-221/222, 
hsa-miR-93/106b/25, hsa-miR-let-7c/125b-1/99a and hsa-miR-100/7a/125b-2. In 
summary, the miRNA analysis predicted a role for regulatory factors implicated in cell 
death and survival pathways, such as autophagy and apoptosis signalling that were 
further investigated.   
 
4.2 The role of Autophagy in the synergistic cell killing 
 
In addition to the miRNA analysis, previous works in our team (Adam V, unpublished 
data and Thesis434) have shown that both mitoxantrone and docetaxel increased the 
expression levels of LC3B-II, an indicator of autophagy activation. It was also shown 
that the replication–selective Ad∆∆ mutant could prevent these drug-induced 
increases in LC3B-II/I ratios. 
Several miRNAs have been associated with functions in autophagy flux, and have 
important roles in autophagy regulation.352,353,355 The relevant miRNAs related to 
autophagy that we identified in our screen were the clusters hsa-miR-17-92, hsa-
miR-93/106b/25, hsa-miR-183-96-182 and hsa-miR-21 considered as oncomiRs and 
hsa-miR-128 as a tumour suppressor (Tables 20 and 22). 
The oncogenic clusters hsa-miR-17, -20, -93, -106, hsa-miR-21 and hsa-miR-183 were 
demonstrated to negatively regulate autophagy flux by targeting 
p62/SQSTM1.352,353,355 In addition, the hsa-miR-106a targets ULK1 and LC3B.314,315,317 
The hsa-miR-17-92 and Akt forms a positive-feedback loop and hsa-miR-21 were 
shown to inhibit PTEN enabling the activation of mTOR and consequently blocking 
autophagy.390,410 Moreover, Akt has been described as a putative target for hsa-miR-
183.353,355,435,436 In our study, the clusters were induced by AdE1A12S-infection and 
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were supressed by treatment with mitoxantrone. The combination of AdE1A12S with 
mitoxantrone resulted in inhibition of these miRNA clusters. We hypothesised that 
though these changes in miRNA levels AdE1A12S might inhibit autophagy flux while 
mitoxantrone would induce both autophagy initiation and completion as previously 
reported for this drug in selected cell lines.437 To verify our findings and investigate 
the overall effects on autophagy when virus and mitoxantrone were combined, we 
determine the levels of expression of the autophagy markers LC3B-II and 
p62/SQSTM1 in PC-3 and 22Rv1 cells. 
In PC3 cells after 24h of treatment, increasing concentrations of mitoxantrone 
induced autophagy flux determined as increased LC3B-II/LC3B-I ratios and reduced 
levels of p62/SQSTM1 indicating that autophagosomes accumulated followed by 
p62/SQSTM1 degradation. In contrast, infection with AdE1A12S maintained basal 
levels of LC3B-II, although AdE1A12S also seemed to contribute to the degradation of 
p62/SQSTM1. These data suggest that AdE1A12S might prevent drug-induced 
autophagy flux. The blockage of autophagy by the AdE1A12S seemed to be overcome 
by increasing concentrations of the drug. 
In PC3 cells the treatment with mitoxantrone for 48h induced higher levels of 
autophagy-flux than at 24h, observed as increased in LC3B-II/I ratios in a dose-
dependent manner indicating accumulation of autophagosomes, in a dose-
dependent manner and reduced levels of p62/SQSTM1. In contrast, the AdE1A12S 
virus impaired autophagy flux seen as decreased LC3B-II/I ratio and increased levels 
of p62/SQSTM1. However, the combinations of mitoxantrone and AdE1A12S, despite 
the increased ratio of LC3B-II/I, also induced the accumulation of p62/SQSTM1 
suggesting that the virus impaired mitoxantrone-induced autophagy flux and that 
mitoxantrone was unable to overcome the viral inhibition of autophagy flux. When 
PC-3 cells were infected with Ad∆∆ for 48h there were no changes in LC3B-II/I ratios. 
Moreover, Ad∆∆ in combination with mitoxantrone decreased the drug-induced 
increases in LC3B-II/I ratios. In addition, Ad∆∆ increased the expression of 
p62/SQSTM1 and in combination with mitoxantrone the virus prevented the 
mitoxantrone-dependent decreases in p62/SQSTM1, although only at certain doses. 
Ad5wt reduced the LC3B-II to LC3B-I ratios, in a dose-dependent manner and 
increased the levels of p62/SQSTM1. In summary, mitoxantrone appeared to induce 
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complete autophagy flux, while AdE1A12S, Ad∆∆ and Ad5wt potently inhibited the 
flux but only at certain doses in combination with mitoxantrone in PC-3 cells. The 
effects were more noticeable after 48h of treatment although, a trend was already 
observed after 24h. The replicative properties of Ad5wt and Ad∆∆ might also have 
influenced the degree of autophagy activity by generating high cellular levels of virus 
through amplification resulting in more acute induction of cell death. The inhibition 
of autophagy by Ad5wt and Ad∆∆ could serve as a mechanism used to block virus 
elimination, and allow completion of viral virus entry and replication in infected 
cells.438 However, it has also been reported that adenovirus (wild type and a ∆CR2-
deleted mutant) can induce autophagy and promote viral replication and oncolysis in 
glioma and lung cancer cell lines.344,347 In another reports, the same viruses were 
demonstrated to promote cell survival in both glioma and ovarian cancer cell 
lines.345,349 Moreover, previous reports have shown that autophagy-induction blocks 
virus infection and replication in sympathetic neurons and mouse embryonic 
fibroblasts.438 In contrast, influenza-A virus and human immunodeficiency virus-1 
HIV-1 (HSV-1) inhibit autophagy by blocking Beclin-1 or autophagosome formation in 
U937 and CD4+ T-cells respectively.439,440 Our results clearly demonstrate that the 
virus and E1A12S prevent or attenuated complete autophagic flux in PCa cells. The 
AdE1A12S might inhibit autophagy to promote only cell proliferation; since, the lack 
of a trans-activating domain does not allow the virus to replicate. Furthermore, the 
inhibition of autophagy and promotion of cell proliferative pathways might enable 
viral replication of Ad5wt and the oncolytic Ad∆∆, although only at certain doses of 
mitoxantrone. The differences between pro- or anti-autophagy responses in different 
models might indicate that the outcome is virus and cell type dependent. 
Our preliminary results were in agreement with our findings from the miRNA 
analysis, indicating that in PC-3 cells the treatment with mitoxantrone 
downregulated the oncomiRs and autophagy inhibitors hsa-miR-17-92, hsa-miR-
93/106b/25, hsa-miR-183-96-182 and hsa-miR-21. Thus, mitoxantrone promoted the 
induction of autophagy flux. In contrast, AdE1A12S induced upregulation of these 
miRNAs and likely impaired autophagy initiation and/or flux.  
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In 22Rv1 cells, mitoxantrone induced the accumulation of LC3-II only at high 
cytotoxic concentrations after 48h, accompanied by decreased p62/SQSTM1 levels. 
Thus, only the highest concentrations of mitoxantrone (still below the EC30 values), 
might induce autophagy in these cells in contrast to findings in PC-3 cells where even 
low doses of drug induced autophagy. When infected with AdE1A12S a slight dose-
dependent decrease in LC3B-II/I ratios and also in the p62/SQSTM1 levels suggest 
that autophagy activity was likely prevented with no autophagosome formation. It is 
possible that the decreases in p62/SQSTM1 levels were caused by potent apoptosis-
induction in these cells in response to AdE1A12S-expression. Previous reports 
demonstrated that p62/SQSTM1 is also degraded by caspases and non-autophagy 
ubiquitination events targeting p62/SQSTM1 to the proteasome.320 The combination 
of AdE1A12S with mitoxantrone resulted in attenuation of mitoxantrone-induced 
autophagy at certain combination-ratios. However, the attenuation was less potent 
than in PC-3 cells and will require further investigations to generate conclusive data. 
Infection of 22Rv1 cells with the replicating Ad∆∆ resulted in strong depletion of 
p62/SQSTM1 and decreases in LC3B-II/I ratios. Thus, both viruses seemed to induce a 
stronger response than mitoxantrone potently preventing autophagy. A possible 
mechanism for the viral attenuation of autophagy is the strong activation of Akt both 
in response to the viruses alone and in combination, which would result in activation 
of mTOR and inhibition of autophagy.  
Again, results from these preliminary protein expression studies appeared to be in 
agreement with our findings from the miRNA analysis, indicating that in PC-3 cells 
the treatment with mitoxantrone downregulated the oncomiRs and autophagy 
inhibitors hsa-miR-17-92, hsa-miR-93/106b/25, hsa-miR-183-96-182 and hsa-miR-21 
resulting in increased autophagy flux. In contrast, AdE1A12S induced upregulation of 
these miRNAs. Moreover, the combination of all viruses with mitoxantrone 
decreased the drug-induced autophagy flux although, at increasing concentrations of 
mitoxantrone the drug-induced effects dominated. It is likely that viral replication in 
cells infected with Ad5wt or Ad∆∆ could mask the effects on autophagy once the 
viral amplification reached a certain level, rather causing cell lysis and death than 
inhibition of autophagy survival mechanisms. Despite the differences in gene 
expression and viral replication, both AdE1A12S and Ad∆∆ had similar effects in 
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combination with mitoxantrone, suggesting that E1A might play an important role in 
these mechanisms. Another miRNA that was identified to target the autophagy and 
the apoptotic pathways is the tumour suppressor hsa-miR-128; when overexpressed 
it inhibits PCa cell invasion.400 In addition, the overexpression of hsa-miR-128 was 
shown to inhibit p-Akt leading to activation and increase in the acetylated and 
normal forms of FOXO3a enabling the transcription of target genes that contribute to 
the induction of apoptosis.441 The hsa-miR-128 was shown to induce apoptosis 
through both p53-dependent and -independent pathways by direct regulation of p53 
upregulated modulator of apoptosis (PUMA).441 Furthermore, the activation of 
FOXO3a promotes apoptosis by inhibiting the oncomir hsa-miR-21 that abrogates 
FasL translation.407 In our study, hsa-miR-128 and hsa-miR-21 were up- and 
downregulated respectively in response to the combination treatments, suggesting 
that this regulatory pathway might contribute to cell killing. Therefore, the targets 
for hsa-miR-128 seemed to be relevant for analysis. We first analysed the expression 
of p-Akt in PC-3 cells treated for 24h with mitoxantrone; a dose-dependent decrease 
in p-Akt was observed. Infection with AdE1A12S inhibited p-Akt at low 
concentrations, and at higher concentrations basal levels of p-Akt were retained or 
increased. In contrast, the combination of AdE1A12S with mitoxantrone strongly 
increased p-Akt. These results suggest that AdE1A12S blocks the mitoxantrone-
mediated inhibition of p-Akt and promotes p-Akt activation. In spite of mitoxantrone-
mediated attenuation of p-Akt when administered alone, in combination with 
AdE1A12S, mitoxantrone seemed to potentiate the activation of p-Akt. At 48h p-Akt 
was still inhibited by mitoxantrone although to a lesser degree than after 24h, 
indicating that mitoxantrone-mediated inhibition might be strongest early after 
treatment and subsequently decline. The infection with AdE1A12S for 48h greatly 
increased the levels of p-Akt, suggesting that virus-induced p-Akt might be triggered 
at early stages and increase over time. The combination of AdE1A12S and 
mitoxantrone increased the levels of p-Akt at low concentrations of mitoxantrone 
however, the effect was not dose-dependent and at higher concentrations of 
mitoxantrone the activation was less obvious. These results, suggest that the potency 
of AdE1A12S to increase the levels of p-Akt decrease over time, being abrogated over 
time but only at high concentrations of mitoxantrone. The infection with Ad∆∆ also 
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induced a dose-dependent increase in p-Akt levels. Moreover, similarly to AdE1A12S, 
Ad∆∆ in combination with low doses of mitoxantrone increased the levels of p-Akt, 
and with increasing doses of mitoxantrone the Ad∆∆-dependent increases of p-Akt 
were impaired. 
In 22Rv1 cells no basal levels of p-Akt were detected and the treatment with 
mitoxantrone did not cause any detectable change. However, infection with 
AdE1A12S induced a strong dose-dependent increase in p-Akt. In addition, the 
combination of AdE1A12S with mitoxantrone increased the levels of p-Akt at all 
combinations compared to untreated control. Moreover, virus-induced increases in 
p-Akt were potentiated in combination with mitoxantrone, as observed in PC-3 cells 
at 24h. However, in PC-3 cells at 48h only AdE1A12S in combination with low doses 
of mitoxantrone increased the levels of p-Akt, whereas in 22Rv1 the levels of p-Akt 
were increased with all combination ratios. These results suggest that in both PC-3 
and 22Rv1 cells mitoxantrone does not cause phosphorylation of Akt at ser-473 
although the drug might cause deregulation of other factors enabling AdE1A12S to 
potently induce p-Akt. Furthermore, infection with Ad∆∆ also increased p-Akt levels, 
although, Ad∆∆ was not as potent as AdE1A12S. The combination of Ad∆∆ with 
mitoxantrone strongly enhanced p-Akt at all combinations compared to the virus 
alone, indicating that, despite that mitoxantrone did not induce p-Akt the drug could 
potentiate Ad∆∆-dependent increases in p-Akt. Thus, the increased hsa-miR-128 
expression and the downregulation of p-Akt seemed to correlate when cells were 
treated with mitoxantrone. Taken together, Akt is a known negative regulator of 
autophagy by inducing the activation of mTOR. Therefore, the induction of p-Akt 
would result in the inhibition of autophagy.265,301 Moreover, previous reports have 
shown that adenovirus induce the Akt/mTOR pathway in glioma cells.349 In 
agreement with the literature, we demonstrated that all tested adenoviruses 
(AdE1A12S, Ad∆∆) induced p-Akt. As expected the induction of p-Akt with all viruses 
alone and in combination (except at high drug doses) correlates with the inhibition of 
autophagy flux markers. However, despite that Botta and colleagues349 showed that 
adenovirus can induce Akt/mTOR-pathway in agreement with our results, they also 
reported the induction of autophagy in glioma cell lines. These contrasting results 
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might be due to the genetical background of the cell lines. Nonetheless, other 
reports showed that adenovirus-5 vectors (with E1 and E3 regions deleted) promotes 
cell survival mechanisms by activating the PI3K/Akt/mTOR signalling pathway and 
that re-stimulation of this pathway may have saturating effects, sensitizing HT-29 
cells colon carcinoma cells to TNF.442 It was suggested that virus-induced cell survival 
mechanism might be counterproductive undermining the cells capacity to overcome 
the cytotoxic stimulus.442 In our study, similar results in PCa cells with the 
combinations at low doses of mitoxantrone make plausible that this mechanism 
might also contribute to increased cell killing. However, the oncolytic adenovirus 
used in our study strongly induced cell killing and might be unable to saturate the 
mechanism before inducing cell death. Nevertheless, this mechanism might be a 
relevant alternative to be explored under our chemosensitizing conditions. 
Furthermore, p-Akt induces FOXO3a phosphorylation blocking its activation and 
translocation to the nucleus. In contrast, hsa-miR-128 inhibits p-Akt-dependent 
phosphorylation of FOXO3a and inhibits the deacetylase sirtuin-1 (SIRT-1), promotes 
FOXO3a acetylation and enables FOXO3a to translocate to the nucleus.441 Therefore, 
if the regulatory mechanism driven by hsa-miR-128 correlates with mitoxantrone-
dependent attenuation (or no effects) of p-Akt this could lead to the induction of 
acetylated FOXO3a and increase total levels of FOXO3a leading to increased 
apoptosis.441 In melanoma, the transcription factor FOXO3 inhibits cell migration by 
downregulating hsa-miR-182, in contrast FOXO3 is impaired when the hsa-miR-182 is 
overexpressed.408 Additionally, the levels of FOXO3a and hsa-miR-182 are inversely 
correlated, in our results hsa-miR-182 was inhibited by the combination, thus 
inhibition of hsa-miR-182 might favoured FOXO3a expression. Another highly 
expressed miRNA in cancer progression is the hsa-miR-21; its overexpression has 
been shown to induce cell proliferation in response to androgen-stimulus in PCa. In 
contrast, the inhibition of hsa-miR-21 facilitates the induction of apoptosis triggered 
by FOXO3a by repressing hsa-miR-21.406,407 Therefore, we assessed the expression of 
FOXO3a, and found that AdE1A12S induced p-Akt 24h after infection as expected,441 
whilst FOXO3a was downregulated by the virus (Fig. 55A). However, the 
downregulation of p-Akt in response to mitoxantrone did not cause the expected 
increase in total FOXO3a and in contrast showed a trend towards decreasing levels of 
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FOXO3a. The combination of virus and mitoxantrone did not cause detectable 
changes in the expression of FOXO3a. It is known that the inhibition of FOXO3a by p-
Akt promotes the translocation of FOXO3a to the cytoplasm where it accumulates 
and is retained by the protein 14.3.3 through direct binding.443 To determine the 
involvement of 14.3.3 in response to the treatments we assessed the levels of 
expression of 14.3.3. We observed that at the 24h and 48h time-points the virus 
increased the levels of 14.3.3 while mitoxantrone decreased the levels both alone an 
in combination with virus (Fig. 55-56). Although, further verification is necessary, the 
increased expression of 14.3.3 induced by the virus could be due to the accumulation 
of FOXO3a in response to Akt phosphorylation. However, it is known that 14.3.3 is a 
carrier protein that translocates phosphorylated proteins from the nucleus to the 
cytoplasm, the exact function in regard to virus and mitoxantrone treatments in our 
study remain unclear. After 48h of treatment FOXO3a expression was not affected by 
mitoxantrone. Surprisingly, at high viral doses the levels of FOXO3a were elevated 
(Fig. 56). The combination of mitoxantrone with AdE1A12S did not affect the 
expression of FOXO3a at any combination. These preliminary results suggest that 
FOXO3a at this time point might not be essential in the mechanism of cell death 
induced by the combination treatments or that FOXO3a or its role might not be an 
important factor under these conditions, although more conclusive experiments are 
required. However, these mechanisms (FOXO3a, 14.3.3 and p-Akt) regulated through 
hsa-miR-128 might contribute to autophagy and apoptosis; it remains unclear and 
would require more experiments to validate the involvement of hsa-miR-128. 
 
4.3 Autophagy-apoptosis cross-talk 
 
Numerous reports have demonstrated the presence of complex cellular networks 
that support cross-talk between autophagy and apoptosis.265,298,444 Our previous 
findings indicate that the mechanisms of cell death in response to the combination 
treatments strongly promoted apoptosis. However, the results were not conclusive 
and as demonstrated in this thesis autophagy also was found to play a role in the cell 
death/survival mechanisms. As a result of the combination treatments, we observed 
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that many upregulated miRNAs coincidentally are reported to be tumour-
suppressors and important regulators of the apoptotic pathways. In contrast most 
downregulated miRNAs are considered as oncomiRs.  The cluster miR-106b-25 has 
been shown to be oncogenic in prostate cancer.445 The hsa-miR-106b-25 cluster 
promotes cell proliferation and tumour progression by targeting and inhibiting PTEN, 
E2F1 and p21/WAF1.212,226,404,446,447 It was reported in PCa cells, overexpression of 
hsa-miR-106b induced radiation-therapy resistance, promoting cell-cycle progression 
and cell proliferation.445 The hsa-miR-106b-25 cluster inhibits Bim and E2F1-induced 
apoptosis.445 Moreover, overexpression of the hsa-miR-106b-25 and hsa-miR-17-92 
clusters have been shown to regulate TGFβ signalling by preventing cell cycle arrest 
and apoptosis in gastrointestinal cells.405 Another example is the amplification of the 
hsa-miR-17 cluster that is associated with malignant lymphomas.288 The hsa-miR-17-
92 cluster can also inhibit apoptosis via the inhibition of PTEN through the hsa-miR-
19 component, inducing tumour progression.410  
Overexpression of hsa-miR-1246 a target of the p53 family (H1299 cells), was shown 
to induce apoptosis by targeting and downregulating DYRK1A (Down-syndrome 
marker) in U2OS cells.374  The overexpression of hsa-miR-23b has been shown to 
target Src kinase and Akt, decreasing tumour growth in nude mice.393 In an 
orthotopic xenograft murine model of hepatocellular carcinoma the inhibition of hsa-
miR-191 reduced tumour size while in vitro cell proliferation was inhibited and 
apoptosis was induced.409 Overexpression of the hsa-miR-23a/27a/24-2 cluster has 
been shown to trigger endoplasmic reticulum stress (ER stress) inducing apoptosis in 
HEK293T cells.389 Moreover, cell proliferation induced by Myc is regulated through 
the repression of hsa-miR-23a and hsa- miR-23b.401 In contrast, in renal cancer the 
reduction of hsa-miR-23b was associated with increased expression of PTEN, 
although a reduction of PI3K and total Akt was also observed.399 In A549 cells, 
downregulation of hsa-miR-24 has been shown to inhibit cell growth.288 The hsa-miR-
221/222 have been demonstrated to target and inhibit the tumour suppressor p27, 
inducing cell proliferation in PC-3 cells, while knock-down of hsa-miR-221/222 
increased clonogenicity.291 In addition, overexpression of hsa-miR-221/222 and the 
downregulation of hsa-miR-23b/27b are considered as markers for a poor prognosis 
in metastatic castrate-resistant PCa.384 
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Members of the let-7 family are known to cause tumour suppression, their 
downregulation or deletion has been associated with breast, lung, ovarian and 
prostate cancer.222,396 The downregulation of let-7 promotes cell proliferation and 
increased clonogenicity contributing to tumour progression, and let-7 has been 
shown to be downregulated by Myc.448 In contrast, overexpression of let-7 induces 
cell cycle arrest at the G1/S-phase by inhibition of E2F2, CCND2, and Enhancer of 
Zeste homolog 2 (EZH2). Additionally, the let-7 family was reported to induce tumour 
suppression by inhibiting cell proliferation in PCa models both in vivo and in 
vitro.395,449  Let-7 is known to target Myc, E2F2, CCND2 and Lin-28, and the 
downregulation of let-7 results in tumour progression while overexpression 
correlates with the downregulation of Myc, E2F2, CCND2 and Lin-28 resulting in 
tumour suppression of PCa. In our study, all the let-7 family members were 
upregulated (except let-7i), in response to the combination treatments, which would 
indicate that Myc, E2F2, CCND2 and Lin-28 are be important regulatory factors that 
play a role in the synergistically enhanced cell killing in response to the combination 
treatments. Further investigations to determine changes in the expression levels of 
these factors would be an interesting aspect of the project to pursue in future work.      
Additionally, it is important to point out that hsa-let-7c is part of the hsa-miR-
99a/let7c/125b cluster, which has been shown to regulate AR expression through the 
inhibition of Myc.34 However, hsa-miR-99a was not verified as differentially regulated 
in our second study. The hsa-miR-99a/let7c/125b cluster has also been shown to be 
downregulated in the presence of androgens. In contrast, in the absence of 
androgens and AR-activation the cluster is induced resulting in decreased cell 
proliferation.450,451 The hsa-miR-125b has been shown to target and down-regulate 
Mcl-1, Bcl-w and interleukin (IL)-6R reducing the mitochondrial membrane potential 
and inducing pro-caspase-3 cleavage, resulting in apoptosis, mainly by the inhibiting 
of members of the Bcl-2 family.391 In PCa cells (PC-3) it was shown that hsa-miR-125b 
contributes to tumour progression by downregulating p14ARF and inducing cell 
proliferation.452 However, changes in expression levels of the entire cluster in 
response to cytotoxic agents were not explored in the same study. In our study hsa-
miR-125b was upregulated in response to the combination treatment in addition to 
let-7c and let-7a. Thus, the contribution of hsa-miR-125b and let-7c might be a 
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consequence of the entire cluster rather than the sole expression of one miRNA. 
Nonetheless, the expression of one miRNA could also be determinant for the 
expression of the cluster. In summary, in our study the Let-7 family and the hsa-miR-
99a/let7c/125b cluster might contribute to cell killing although mainly in response to 
mitoxantrone rather than AdE1A12S. 
The hsa-miR-15/16 cluster, which is frequently downregulated in PCa,225 is a tumour 
suppressor cluster that contributes to apoptosis by targeting and downregulating Bcl-
2, CCND1 and WNT3A in PCa thereby inhibiting cell survival and proliferation. 
Interestingly, Myc induces the downregulation of this cluster.397,453,454 In our study, 
we found that Bcl-2 levels were slightly increased in PC-3 cells infected with 
AdE1A12S for 24h and this increase was enhanced in combination with 
mitoxantrone. In contrast after 48h the levels of Bcl-2 were decreased by the 
combination. Our results suggest that the upregulation of the let-7 family contributes 
to the induction of the hsa-miR-15/16 cluster through inhibition of Myc. The increase 
in hsa-miR-15a/16 followed by the decrease in the levels of Bcl-2 might be further 
regulated by mitoxantrone-induced DNA-damage response that targets E2F1, which 
is also a direct regulator of hsa-miR-15a/16. Taken together, this indicates that in the 
absence of viral replication the response might be strongly regulated by 
mitoxantrone.455,456 In PC-3 cells infected with Ad∆∆ and Ad5wt, the combination 
treatments caused increased levels of Bcl-2, which was strongest with Ad∆∆. The 
increased expression of Bcl-2 might be because viral replication could potentially 
induce an anti-apoptotic response in the cells, at least at earlier time-points (<48h). 
However, in 22Rv1 cells the combinations of mitoxantrone with either AdE1A12S or 
Ad∆∆ caused a decrease in of Bcl-2 levels, indicating that the genetic background of 
the cell is also important. Moreover, previous reports have shown that the 
phosphorylation of Bcl-2 at ser-70 is necessary for full anti-apoptotic activity and that 
it requires multi-phosphorylation for the induction of autophagy, resulting in the 
release of Beclin-1 and thus inducing autophagy.457,458 However, PC-3 (24h) and 
22Rv1 (48h) cells infected with AdE1A12S did not show expression of phospho-Bcl-2 
(not shown), indicating no activation of the anti-apopototic response at any 
conditions, although more experiments are needed to conclusively elucidate these 
preliminary results. 
218 
 
In addition, hsa-miR-107 is part of a group of miRNAs located next to the hsa-miR-
15/16 gene cluster and was reported to be upregulated by p53 inhibiting HIF-1 in 
colon cancer cells, although, these findings have not been validated in PCa.225,459 The 
hsa-miR-107 also has high homology with hsa-miR-103 with differences only in one 
nucleotide.402 The expression of hsa-miR-103 has been reported as deregulated in 
PCa,385 however, in response to the combination treatments the expression 
remained downregulated. The contribution of both hsa-miR-107 and hsa-miR-103 to 
cell killing in this study, remain unclear and will require more studies to determine 
their role in response to the combination treatments.    
Nonetheless mitoxantrone is known to induce DNA double strand breaks that could 
trigger the DNA damage response, induce apoptosis and G2/M arrest. To explore 
whether DNA-damage was part of the mechanism and if mitoxantrone in 
combination with the virus increased this damage, we assessed the expression of p-
H2AX as a marker for DNA-damage repair response in PC-3 cells.460 While the 
infection with AdE1A12S did not activate p-H2AX under our conditions (24h), p-H2AX 
was induced by mitoxantrone (Fig. 55). Remarkably, the combination of 
mitoxantrone with AdE1A12S did not affect the activation of p-H2AX and maintained 
the mitoxantrone-dependent induction of p-H2AX demonstrating activation of the 
DNA-damage response. The induction of apoptosis by the DNA-damage response is 
mostly dependent on activation of p53 however induction of cell death in response 
to DNA-damage can also be caused by p73, a member of the p53-family.461,462 PC-3 
cells are p53-/- and consequently it was important to determine if p73 was involved in 
the apoptotic response to the combination treatments. Preliminary results in PC-3 
cells infected with AdE1A12S indicate that p73 expression was downregulated 
compared to basal levels (Fig. 56). Moreover, the combination of mitoxantrone with 
AdE1A12S seemed to decrease p73 levels (Fig. 56). Unfortunately, it was not possible 
to determine the exact role of mitoxantrone in the expression of p73 due to 
contradictory results, but it was clear that the virus reduced the levels of p73. 
Therefore, more conclusive results are needed to determine the role of p73 in 
response to the treatment combinations.  
Additionally, we identified hsa-miR-361-5p, hsa-miR-423-5p, hsa-miR-1826 and hsa-
miR-107 as upregulated in response to the combination treatments in our study. 
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These miRNAs are deregulated in different types of cancer, although none of them 
has been reported and validated in PCa. Similarly, there is limited information 
available in the literature regarding hsa-miR-1268 and hsa-miR-1275 and their role(s) 
is currently incompletely understood. It would therefore be important to determine 
their function in PCa since like other tumour suppressor miRNAs they were 
upregulated by the combination treatments. Importantly this work is to my 
knowledge the first to report on the involvement of these miRNAs in PCa. However, 
more studies are necessary to validate these initial data and to explore the functional 
implications. 
Taken together, my work presented in this thesis is to the best of my knowledge the 
first analysis in prostate cancer cells, which demonstrates that binding of AdE1A12S 
to p300 is essential for the sensitisation of prostate cancer cells to mitoxantrone and 
docetaxel. Our preliminary results indicate miRNA-driven regulation of cellular 
pathways in response to the combination of AdE1A12S and mitoxantrone. 
Furthermore, despite viral induction of cell survival mechanisms, the viruses might 
also contribute to cell killing complementing mitoxantrone-induced cell death (DNA-
damage response-dependent cell death), and favouring enhanced tumour-
suppressing signals where the inhibition of autophagy might play a complementing 
role. Further studies should be aimed at investigating in depth the specific interplay 
of these mechanisms to develop a better understanding of adenovirus-dependent 
enhancement of mitoxantrone-mediated apoptotic cell killing and identification of 
novel therapeutic targets or therapies.  
 
4.4 Summary of this thesis:  
 
• We demonstrate that the E1A-p300 binding region is essential for the 
synergistic sensitisation to cell killing in combination with the 
chemotherapeutics mitoxantrone and docetaxel in prostate cancer cell lines. 
• We show that the oncolytic mutants dl1102 and dl1104 potently contribute 
to prostate cancer cell killing both in vitro and in vivo. 
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• The oncolytic mutants dl1102 and dl1104 are replication-selective with 
minimal toxicity in two normal cell types.  
• Our results indicate that the combination of AdE1A12S and mitoxantrone 
regulates the expression of miRNAs by downregulating oncoMIRs and 
upregulating tumour suppressor miRNAs in PCa cells, ultimately affecting the 
regulation of several key pathways including apoptosis, cell proliferation and 
autophagy. 
• We show that the let-7 family, the hsa-miR-23 cluster (hsa-miR-23, -10, -24, -
26, -27 and -30), the 17-92 cluster (hsa-miR-17-18a, -19a/b, -20a, and miR-
92a) and the hsa-miR-183-96-182 cluster (hsa-miR-15/16, hsa-miR-221/222, 
hsa-miR-93/106b/25, hsa-miR-let-7c/125b-1/99a and hsa-miR-100/7a/125b-
2) are potentially involved in the miRNA-driven regulation of cell pathways 
(apoptosis, cell proliferation and autophagy) in response to the combination 
treatments. 
• Our data demonstrate that the changes in expression levels of selected 
miRNA-targets correlate with the changes in miRNA expression levels. 
• We show that while mitoxantrone induces autophagy flux, the viral mutants 
AdE1A12S, Ad∆∆ and Ad5wt inhibit the autophagy flux both alone and in 
combination with mitoxantrone in PC-3 and 22Rv1 cells. 
• All three viruses AdE1A12S, Ad∆∆ and Ad5wt induce increased expression of 
p-Akt promoting cell proliferation, while mitoxantrone inhibits this activity in 
PC-3 and 22Rv1 cells. 
• The observed changes in expression of Bcl-2 levels are likely dependent on 
the replicative properties and promotion of S-phase in response to the viruses 
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5. Future directions 
 
To further delineate the cellular mechanisms that are activated in response to the 
viruses and mitoxantrone both alone and in combination including apoptosis and 
autophagy that appear to be regulated by changes in miRNA processing, it will be 
important to determine how inhibition or activation of specific miRNAs occurs. For 
example, are there changes in activity of miRNAs-transcription factors or processing 
enzymes?.463,464 The miRNA-regulated pathways that were repressed or activated in 
our study in response to the different stimuli have been reported to be tightly 
regulated by transcription factors and miRNAs in a feed-forward loop interaction.465 
Of the miRNAs analysed in this study the majority were regulated by the 
transcription factors Myc and E2F1.463,466,467 Both Myc and E2F1 are key regulators of 
cell death and survival pathways in the absence of p53, and mutually regulated; both 
Myc and E2F1 can trigger cell survival or apoptosis depending on the stimulus (Fig. 
50). Moreover, Myc is the main regulator of oncomiRs while E2F1 mostly regulates 
tumour suppressor miRNAs.468-471 E2F1 is a key factor in the DNA-damage response 
pathway promoting apoptosis and DNA-damage induced autophagy. The DNA-
damage response is mediated by ATM/ATR, inducing down-stream activation of E2F1 
(Fig. 50).472-476 Moreover, it has been reported that E2F1 induces cell death in a p53-
independent pathway in PCa cells (Fig. 50).477 Furthermore, E1A and specifically 
E1A12S have been reported to contribute to the activation and p300-mediated 
stabilization of E2F1 (Fig. 50).83,422  
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Figure 50. Potential cell death mechanisms involved in the synergistically increased 
cell killing in response to the combination treatments. The combination of 
mitoxantrone and AdE1A12S induces the activation of tumour suppressor miRNAs 
and the downregulation of oncomiRs. Despite mitoxantrone-induced cell death being 
partly opposed by AdE1A12S, there is an additional pro-apoptotic stimulus driven by 
E1A12S that contributes to tilting the balance towards enhanced cell killing, in which 
both apoptosis and autophagy are intimately linked. Based on the results in this 
thesis and previously published reports 83,203,228,288,353,355,390,395-
398,400,410,422,427,436,441,448,450,451,453,455,460,463-467,469-471,473-476,478,479. 
 
Taken together, these reports in addition to our previous results and the findings 
presented in this thesis suggest that E1A-dependent stabilization of E2F1 is a key 
factor in the E1A mediated sensitization of prostate cancer cells to the mitoxantrone-
induced DNA-damage response. Thus, it is important to determine the involvement 
of the miRNA-transcription factors E2F1 and Myc in the regulation of autophagy and 
DNA-damage induced apoptosis and autophagy in response to the combination 
treatments and also to validate the involvement of the identified miRNAs within 
these cross-talk pathways. Therefore, to address these issues our future plans are:   
 
• To assess the response of both E2F1 and Myc under chemosensitizing 
conditions. The expression of E2F1 will be verified in PC-3 cells infected with 
AdE1A12S, treated with mitoxantrone and both agents in combination by 
immunoblotting.  
• To test the expression of both E2F1 and Myc with the potent viruses Ad∆∆ 
and dl1102 to verify the regulation of E2F1 and Myc in response to these 
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viruses and to validate if AdE1A12S could be the sole core of the mechanism 
and if this could be extrapolated to the replicating viruses.  
• To determine the role of E2F1 and Myc in 22Rv1 cells and test if the inhibition 
of p53 in 22Rv1 cells changes the regulation of E2F1 to determine if the 
modulation of these transcription factors is a p53-dependent and/or -
independent response.  
• To verify the involvement of E2F1 in response to the combination treatments, 
which will further be used to confirm the regulation of downstream signalling 
of the DNA-damage response pathway. Specifically the BH3-family members 
BIM, PUMA and NOXA which are known to be pro-apoptotic targets of E2F1, 
will be explored for involvement in the response to the combination 
treatments under chemosensitizing conditions by downregulating each factor 
by siRNA targeting.480   
 
Our results suggest the downregulation of autophagy in response to the combination 
treatments however, the role and contribution of autophagy to cell death in 
response to the combination treatments remain unsolved. Therefore, verification of 
the role of autophagy in cell death will be necessary. Thus, it will be interesting to 
dissect the autophagy flux in response to the combination treatments in more detail.  
• To dissect dynamic autophagy-flux the use of known autophagy inhibitors 
would add more variables to our current model, while the use of siRNAs to 
down-regulate key markers of autophagy might be a better solution, by 
targeting of Beclin-1, Atg-7 and LC3B and measuring the sensitisation of cells 
in response to the combination treatments. The downregulation of Beclin-1, 
Atg-7 and LC3B will give us a better understanding if the autophagy flux is 
contributing to the enhanced cell killing in response to the combination 
treatments or if it is a side effect. Moreover, the silencing of Beclin-1, Atg-7 
and LC3B will enable us to determine if dynamic autophagy flux is essential 
for this response and how this can be optimized.  
In addition, the protein DRAM is known to be a link between apoptosis and 
autophagy.265,298,475,481 Therefore, we will need: 
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• To determine the role of DRAM in response to the treatments, and to 
determine if the downregulation of DRAM (siRNA) affects the sensitisation of 
prostate cancer cells induced by the combinations.  
 
Furthermore, we will verify the role of the tumour-suppressor miRNAs and oncomiRs 
identified in this study to determine their role in the chemosensitization of PCa cells 
and their regulatory mechanisms. These studies will enable us to validate our 
findings and to verify the role of miRNAs in response to the combination treatments. 
• To overexpress with miRNA mimics of the tumour-suppressor miRNAs 
including hsa-miR-125/99/let-7, hsa-miR-15/16, 128 and 100 and inhibition of 
oncomiRs (e.g. hsa-miR-17-92 and hsa-miR-106/93/25) in untreated cells and 
overexpression of oncomiRs under chemosensitizing conditions. These 
studies will enable us to verify their role in the regulation of their apoptotic 
and autophagy targets.  
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6. Appendix. 
 
6.1 AdE1A mutants characterization 
To determine that the viral mutants were functional and expressed appropriate 
gene-products, E1A protein expression was determined in the replicating and non-
replicating dl1102 and AdE1A1102, and dl1104 and AdE1A1104 viruses by 
immunoblotting.  
 
Figure 51. Comparative expression of E1A of replicating and non-replicating AdE1A12S 
mutants in PC-3 cells. The differential expression of E1A of each viral mutant due to the 
different deletions is evident in the pattern of expression. Each lane was loaded with 20µg of 
protein from cells untreated or infected at 100ppc with all viruses alone or in combination 
with 50nM mitoxantrone Immunoblot representative of three experiments. 
 
The deletions included in each virus are shown in Fig. 19, with AdE1A12S, dl1102 and 
AdE1A1102 being slightly larger than those of dl1104 and AdE1A1104. All mutants 
except dl1104 and AdE1A1104 showed the same size and similar expression pattern 
with several proteins expressed from ~35-45 KDa (Fig.51). However as previously 
reported 375 dl1104 and AdE1A1104 lacked the higher molecular weight proteins 
E1A 
dl1102 
- + 
AdE1A 1102 
- + 
dl1104 
- + 
AdE1A 1104 
- + 
Ad12S 
- + Mitoxantrone 
kDa 
55 
36 
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since they do not express exon 1 of the E1A gene. The addition of mitoxantrone did 
not affect E1A expression. 
 
Replicating dl1102, dl1104 (Fig. 52, A and B) and non-replicating (Fig. 52, C and D) 
viruses were characterized using the primer sets described in Table 4, to determine 
that correct deletions were present and that the viral genome was intact and 
corresponded to that of Ad5wt after amplification in the producer cell line HEK293.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         
  
A) dl1102 
 
B) dl1104 
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C) AdE1A 1102 
 
D) AdE1A 1104 
 
Figure 52. Characterization of viral replicating and non-replicating AdE1A12S mutants used 
in this project. Viral DNA was extracted to determine the gene size pattern for each set of 
primers (Table 4). DNA of Ad5wt and mutant viruses previously characterized were extracted 
and used as reference. Deletion indicates that primers were used for the specific region of 
the deletion, and as expected no DNA was amplified. The shifts in the bands compared to the 
Ad5wt virus were caused by the deletions within the genes in each mutant. Other mutants 
including dl922-947, dl1520, AdE1A1108, Ad∆∆ and AdGFP were produced in the course of 
other projects by team-members and already characterised aliquots were used in this thesis.  
 
As shown in figure 16 the different mutants (Replicating dl1102, dl1104 (A and B) and 
non-replicating (C and D) viruses showed different patterns compared to the 
corresponding regions in Ad5wt. 
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6.2 Dose-responses to viral mutants and mitoxantrone in PCa cells tp 
determine EC50 values and relative sensitivity using the MTS- viability 
assay. 
 
Due to differences in virus and drug batches compared to earlier analysis362 we 
conducted a broad screen of virus and drug dose-responses by cell viability assays 
(Fig 53). 
 
 
Figure 53. Representative illustration of dose-response assays for Ad5wt, AdE1A12S, Ad∆∆, 
AdGFP and mitoxantrone in PC-3 cells. The graphics indicate the percentages of cell death vs 
mitoxantrone concentrations (nM) or viral particle per cell (ppc). Data are representative of 
>5 experiments in triplicates.   
 
Dose-response assays were performed to determine viral and drug concentrations 
that killed less than 20% of cells in order to investigate key regulatory factors in 
response to mitoxantrone, viruses and the combinations under synergistic conditions 
using fixed doses. These dose-response viability assays were routinely performed 
throughout the thesis work to adjust the doses when necessary for the mechanistic 
studies. 
 
6.3 The combination of mitoxantrone and AdE1A12S at doses selected 
in the immunoblot assays enhances cell death.  
 
Previous results showed that the non-replicating AdE1A12S mutants (AdE1A12S, 
AdE1A1102 and AdE1A1108) increased the percentages of mitochondrial membrane 
depolarisation membrane as an indication of cell death by apoptosis.95 The 
combination of the viruses and mitoxantrone increased cell killing up to 30% after 
96h compared to drug alone.95 In contrast, the AdE1A1104 mutant was unable to 
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further increase the mitoxantrone-induced apoptosis and had similar effects as the 
control AdGFP.95 
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Figure 54. Induction of cell death by the non-replicating AdE1A12S mutant. PC-3 cells were 
analysed by tetramethylrhodamine uptake (TMRE assay) to measure the mitochondrial 
membrane potential depolarization and cell death in response to the combination 
treatments at selected doses. PC-3 cells were treated for 96h with 1000nM mitoxantrone 
alone or in combination, and infected with: A)the non-replicating AdE1A12S mutant at 
500ppc and 1000ppc, B)Ad∆∆ at 500ppc and 1000ppc and C)Ad5wt at 500ppc and 1000ppc. 
PC-3 cells were treated with rapamycin at 100nM, staurosporine at 1nM and zVAD-fmk at 
25µM as controls. The percentage of cell death was determined by measuring TMRE 
and DAPI uptake. Preliminary data, one experiment by duplicate. 
 
My preliminary results testing some of the doses used in the immunoblot screenage, 
showed that in PC-3 cells at 96h post-treatments, the non-replicating AdE1A12S virus 
at 500ppc and 1000ppc in combination with mitoxantrone at 1000nM increased the 
percentages of cells with mitochondrial-depolarised membrane, compared to 
mitoxantrone alone and showed to be as potent as the wild type virus (Fig. 54A and 
54C). However, this increase in cell death was slightly reduced by a pan-caspase 
inhibitor (Fig. 54A). Moreover, the combination with the replicating oncolytic virus 
Ad∆∆ strongly enhanced cell death with both 500ppc and 1000ppc doses, the 
combination of mitoxantrone with 1000ppc showed percentage of cell death above 
30% similarly to cells treated with staurosporine (Fig. 54B). Interestingly, treatment 
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with the caspase inhibitor did not seem to reduce cell death (Fig. 54B). Cells infected 
with Ad5wt showed increased cell death in combination compared to mitoxantrone 
alone (Fig. 54C), however, both viral doses (500ppc and 1000ppc) induced similar 
percentages of cell death (Fig. 54C). Furthermore, the percentages of cell death 
induced by Ad5wt were similar to those showed by the non-replicating AdE1A12S 
but were less than with the replicating Ad∆∆ (Fig. 54A-C). Thus, the differences in cell 
death were caused by the treatments in combination and not as the result of viral 
replication. Nonetheless, these results are preliminary and more experiments are 
needed, although, the results verified that the combination of mitoxantrone and the 
viruses at these doses sensitize cells and potentiate cell killing.  
 
6.4 Mitoxantrone in combination with the AdE1A12S virus triggers a 
DNA-damage response but fails to activate the FOXO3a-mediated 
regulatory mechanism.  
 
In our miRNA study we observed that a recurrent target of deregulated miRNAs was 
the transcription factor FOXO3a. FOXO3a  is a key regulator of the p-53-independent-
DNA-damage response which is negatively regulated by p-Akt.441 In addition, in PCa 
FOXO3a has been shown to induce apoptosis.406,407 Therefore, we assessed the 
expression of FOXO3a at 24h and 48h in PC-3 cells. The expression of FOXO3a at 24h 
after infection with AdE1A12S showed a trend towards decreased levels (Fig. 55A). 
The possible decreases in FOXO3a is in agreement with the findings that AdE1A12S 
induced phospho-Akt (Section 3.5.3) which in turn may inhibit FOXO3a as previously 
reported.441 Treatment with mitoxantrone did not significantly affect FOXO3a levels. 
I previously observed (Section 3.5.3) that mitoxantrone decreased phospho-Akt 
activation however, this was apparently not reflected in increased levels of FOXO3a 
(Fig. 55A). The combination of both agents maintained FOXO3a at basal levels except 
at high concentrations of mitoxantrone where the levels of FOXO3a with 1000nM 
were slightly increased and decreased with 2000nM, these results did not correlate 
with expected decreases in p-Akt levels at this time point. FOXO3a might not be an 
important factor under these conditions, although additional studies will be required 
to verify these preliminary findings.  
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A) 
 
B) 
 
 
Figure 55. Changes in expression of 14.3.3, FOXO3a and phospho-H2AX in PC-3 cells at 24h 
post-treatment with mitoxantrone and/or infection with the AdE1A12S virus. A) PC-3 cells 
treated with mitoxantrone at increasing concentrations, 50nM - 2000nM or infected with 
AdE1A12S,at 50ppc - 4000ppc. Cells were also treated with staurosporine at 1nM and 
rapamycin 100nM as indicators of apoptotic and autophagic activity. B) PC-3 cells treated 
with mitoxantrone for 24h at 250nM, 500nM, 1000nM and 2000nM in combination with the 
AdE1A12S virus at 500ppc, 1000ppc and 2000ppc and rapamycin 100nM, loading control KU-
70. A-B) Preliminary data, one experiment.  
  
 
It is known that the inhibition of FOXO3a by Akt promotes the translocation of 
FOXO3a to the cytoplasm, where it accumulates and is bound and retained by the 
protein 14.3.3.443 To determine the involvement of 14.3.3 in response to the 
treatment we assessed the levels of expression of 14.3.3, we observed that 14.3.3 
was strongly induced by the virus and to a lesser extent by mitoxantrone (Fig. 55). 
These results suggest an accumulation of 14.3.3. In contrast, the combination of 
AdE1A12S with mitoxantrone reduced the levels of 14.3.3 at increasing 
concentrations of virus (1000ppc and 2000ppc with 250nM and 500nM 
mitoxantrone) and was greatly reduced with all combinations at the higher doses 
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(1000nM and 2000nM) of mitoxantrone. In conclusion, these results are insufficient 
to elucidate the roles of p-Akt, FOXO3a or 14.3.3, in response to AdE1A12S, 
mitoxantrone or the combinations. These findings open an interesting area of 
investigation to identify novel cellular interactions by either E1A or DNA-damaging 
drugs. It is known that mitoxantrone induces a DNA-damage response which leads to 
apoptosis. Therefore, we assessed the activation of p-H2AX, a DNA-damage repair 
marker at 24h in PC-3 cells.460 As could be expected p-H2AX was activated by 
mitoxantrone even at low doses (50nM; Fig. 55A). In contrast, infection with 
AdE1A12S did not activate p-H2AX at any concentration. Interestingly, when 
mitoxantrone was combined with AdE1A12S the activity of p-H2AX at lower drug 
doses (250nM and 500nM) was similar to that of drug alone however, at the higher 
drug doses (1000nM and 2000nM) the expression of E1A12S in combination with 
mitoxantrone appeared to further activate p-H2AX (Fig. 55B). In conclusion, 
activation of the DNA-damage repair response is clearly involved in the 
synergistically enhanced apoptosis in response to the combinations. 
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Figure 56. Expression of 14.3.3, FOXO3a and p73 in PC-3 cells at 48h post-treatment with 
mitoxantrone and/or infection with the AdE1A12S virus. A) PC-3 cells treated with 
mitoxantrone at increasing concentrations, 50nM - 2000nM or infected with AdE1A12S at 
50ppc - 4000ppc. Cells were also treated with staurosporine at 1nM as indicators of 
apoptotic and autophagic activity. B) PC-3 cells treated with mitoxantrone for 48h at 250nM, 
500nM, 1000nM and 2000nM in combination with the AdE1A12S virus at 500ppc, 1000ppc 
and 2000ppc and rapamycin 100nM. Loading control Actin. Preliminary data, one 
experiment. 
 
We also assessed the expression of FOXO3a at 48h. FOXO3a expression-levels were 
not affected by mitoxantrone at any concentration while AdE1A12S increased the 
expression at all doses (Fig. 56A). However, when combined, no significant changes 
in FOXO3a levels were observed compared to basal (Fig. 56B) The levels of 14.3.3 
increased similarly at 48h as at the 24h time point in response to both AdE1A12S and 
mitoxantrone when administered alone (Fig. 55A-56A). In combination, the trend 
was similar to the 24h findings although the expression levels were more potently 
increased at all combinations.  
In addition, the lack of p53 in PC-3 cells made it interesting to determine the levels of 
other members of the p53-family that could be regulating the apoptotic pathway in 
response to the combination treatments. The induction of cell death in response to 
DNA-damage can also be induced by the p53-family member p73.461,462 Therefore, 
we investigated if p73 was involved in the apoptotic cell killing in response to the 
combination treatments. However, p73 levels were not detectable in PC3 cells after 
treatment with AdE1A12S, mitoxantrone or the combinations (Fig. 56). Only a faint 
signal was detectable in untreated and uninfected cells while rapamycin and 
staurosporine potently induced p73. These studies need further repetitions including 
loading with more protein lysates (~40µg/lane) and inclusion of loading controls such 
as β-actin or β-tubulin. 
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